Determinants of depressive symptom trajectories among older adults in community and treatment settings by Smagula, Stephen
 DETERMINANTS OF DEPRESSIVE SYMPTOM TRAJECTORIES AMONG OLDER 
ADULTS IN COMMUNITY AND TREATMENT SETTINGS 
 
 
 
 
 
 
 
 
 
 
by 
Stephen Fearns Smagula 
BS in Neuroscience, Lafayette College, 2009 
MS in Neuroscience and Education, Teachers College Columbia University, 2010 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2014 
 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
This dissertation was presented 
by 
Stephen Fearns Smagula 
It was defended on 
December 3rd, 2014 
and approved by 
Robert M. Boudreau, PhD, Assistant Professor, Department of Epidemiology, Graduate School of Public Health 
University of Pittsburgh  
Joyce T. Bromberger, PhD, Professor, Department of Epidemiology, Graduate School of Public Health; 
Department of Psychiatry, Western Psychiatric Institute and Clinic, School of Medicine 
University of Pittsburgh 
Anne B. Newman, MD, MPH, Professor and Chair, Department of Epidemiology, Graduate School of Public 
Health; Professor of Medicine and Clinical Translational Science Institute, School of Medicine; 
 Katherine M. Detre Endowed Chair of Population Health Sciences 
University of Pittsburgh 
Charles F. Reynolds, III, MD, Professor, Departments of Psychiatry, Western Psychiatric Institute and Clinic, 
and Clinical Translational Science Institute, School of Medicine; Department of Behavioral and Community 
Health Sciences, Graduate School of Public Health; University Medical Center Endowed Professor of 
Geriatric Psychiatry 
University of Pittsburgh 
Dissertation Advisor: Jane A. Cauley, DrPH, Professor and Vice-Chair of Research, Department 
of Epidemiology, Graduate School of Public Health 
University of Pittsburgh  
ii 
  
Copyright © by Stephen F. Smagula 
2014 
 iii 
ABSTRACT 
Sub-diagnostic depression, sleep, and circadian rest-activity rhythm (CAR) syndromes 
are common in late-life, but their characteristics, prevalence, and relations to future depression 
are unclear. We characterized commonly occurring sleep, CAR, and depressive sign/symptom 
patterns using a data-driven approach applied to a large population-based study of older men. We 
next examined relationships of these baseline syndromes with longitudinal change in depressive 
symptoms. Common (32.44%) probable depressive syndromes were characterized by 
somatic/apathy symptoms; two subset (5.74% and 8.45%) characterized by somatic/apathy 
symptoms also reported emotional-related impairment. Subjective complaints without 
objectively (actigraph) assessed disturbances characterized two distinct classes of men (totaling 
37.46%); a pattern of objective disturbance (including greater sleep fragmentation with probable 
prolonged sleep latency or short (<5 hour) sleep duration) occurred in both the presence (8.87%) 
and absence (8.51%) of subjective complaints. Only 32.18% appeared to be free of a non-
normative CAR parameter; 8 classes were distinguished by activity timing, levels, and the active 
period length. Baseline sleep and depression latent classes were not meaningfully associated with 
rates of change in depression severity. The rate of increase in depressive symptoms was higher 
for classes with later activity and for a class with dampened, earlier, and compressed activity 
combined. Future work should assess the modifiability of the identified markers of depressive 
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symptom increases through preventive interventions. Nevertheless, there remains a need to 
understand mechanisms of variability in pharmacological treatment response among older adults 
with major depressive disorder (MDD). We therefore assessed prognostic factors associated with 
distinct trajectories of depressive symptom change over 12-weeks of open-label MDD treatment 
(with Venlafaxine XR). Only 44.59% exhibited a clear response, and the clinical prognostic 
factors linked to unique patterns of non-response included: worse depressive severity, longer 
illness duration, higher levels of guilt, worse work/activity impairment, and worse list 
recognition performance. Overall, this work has public health relevance by providing a novel 
description of common sleep-wake/depressive syndromes in the community and distinct 
symptom trajectories found in response to pharmacologic treatment. There is a need to integrate 
the identified prognostic markers with neurobiological research towards a valid predictive 
science of depression pathogenesis, prevention, and treatment.   
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1.0  INTRODUCTION 
According to the World Health Organization, depressive disorders are the leading cause 
of disease burden in the developed world and the third leading cause globally [1]. The burden of 
mental illnesses, along with other non-communicable diseases, is expected to rise following the 
epidemiologic transition [2] which is now well underway around the globe. Major depressive 
disorder (MDD) entails functional impairment which often spans across settings causing 
significant interpersonal strain extending the burden of depression well beyond individual 
patients.  
On the societal level depression leads to substantial lost productivity and increased health 
care costs [3] totaling to an estimated 83.1 billion dollars in year 2000 for the United States alone 
[4].  When combined with common chronic diseases, depression reduces quality of life in a 
synergistic manner [5]. Because depressive disorders also increase mortality [6] and 
cardiovascular risk [7], preventing and/or effectively treating depression is an important public 
health priority with far reaching social and economic implications.  
For older adults, the public health imperative is not only pressing, it is also increasing. 
The global population aged 65 years or older is expected to double by 2040 [8]. In the United 
States, as the post-World War II (WWII) “baby boom” generation enters later life in 
unprecedented numbers, they carry with them higher rates of prior lifetime episodes of MDD [9]. 
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Because a history of MDD is a significant risk factor for future episodes [10], it is expected that 
the prevalence of MDD among older adults will rise in coming decades.  
Mental health problems are a strong risk factor for suicide completion [11], a problem 
that is especially pronounced among older men (see Center for Disease Control (CDC) statistics, 
Figure 1). Currently, a substantial portion (8-16%) of older adults suffer from clinically 
significant depressive syndromes [12]; and the geriatric mental health care system must be 
prepared to provide services for a growing population of older adults at risk for suicide. The 
burden of late-life depression is therefore an increasingly significant public health problem with 
already great costs including troubling, unacceptably high rates of suicide.  
Further, mood disturbances do not occur in isolation and are often accompanied by other 
health issues like cognitive impairment, sleep disturbances, and anxiety disorders. Sleep 
disturbances are extremely common in older adults with depressive symptoms; for example, in 
the Osteoporotic Fractures in Men Sleep Study (MrOS Sleep), over 74% of older adults with 
clinically significant depressive symptoms also report disturbed sleep. Sleep disturbances may 
actually increase the risk of developing depression (for an early report, see [13]). Cognitive 
impairment can entail or “mimic” a depressive syndrome, while MDD increases the risk of 
developing cognitive impairment [14]. Altogether, among older adults the importance of 
effectively preventing and/or treating depression extends well beyond the realm of mood alone 
and most generally includes the maintenance of mental health and quality of life.  
We begin by reviewing the history of psychiatric classification. Current measurement 
techniques and heterogeneity within late-life depression is then discussed. After addressing the 
prevalence and incidence of depression across the life-course, we briefly discuss risk relations in 
later life with a particular focus on the potentially central role of sleep-wakefulness patterns. We 
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conclude that a person-centered longitudinal approach is needed to understand the etiology and 
treatment of late-life depression.  
1.1.1 History of psychiatric classification 
Marking what might be considered the first official attempt to classify the burden of 
psychiatric conditions, in 1840 the U.S. census recorded the frequency of “idiocy/insanity” [15]. 
The 1880 census classification expanded to eight categories: mania, melancholia, monomania, 
paresis, dementia, dipsomania, and epilepsy. In 1917 the American Medico-Psychological 
Association and National Commission on Mental Hygiene developed a system of nomenclature 
for characterizing patients in mental hospitals.  
Around WWII, in a leap forward described previously by Wilson [16] and the American 
Psychiatric Association (APA) [15], psychiatry moved out of psychiatric hospitals and into an 
outpatient setting. Various mental conditions related to WWII (including trauma related stress 
syndromes) provided a concrete picture of mental illness within the context of what Karl 
Menninger called the “personality-environment” struggle [17]. This psychodynamic and 
psychosocial framework did not clearly demarcate mental health from illness: exposed to severe 
trauma or an otherwise noxious environment, mental illness could emerge in anyone. Psychic 
conflict was the source of mental disease and the cause of disintegrating interpersonal and social 
contexts. The job of the psychiatrist was to thus formulate how an individual’s psychosocial 
history and current circumstances led to the presenting symptoms. As put by Karl Menninger, 
“what is behind the symptom?”  
Following contemporary psychoanalytic thinking, in 1952 the Diagnostic and Statistical 
Manual: Mental Disorders (DSM-I) was published. The DSM-I expanded the concept of 
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neuroticism and also included psychotic, somatization, and character disorders. This DSM 
version prominently referred to “reactions,” as in Adolf Meyer’s formulation of mental disorders 
as personal response to psychosocial circumstances. In an update published in 1968 (the DSM-II) 
the term “reactions” was removed although nomenclature remained both theoretical and 
descriptive. This set of diagnostic guidelines included vignettes illustrative of possible clinical 
presentations, but avoided precise disorder definitions because it was thought that symptoms 
were merely overt, indirect manifestations of the underlying causal conflicts [16].  
Throughout the 1970’s the imminent implications of psychiatry’s newfound place within 
the public’s view were being borne out. At least two mounting problems threatened the 
established psychiatric enterprise. Ideas that psychiatry arbitrarily distinguished between well-
being and illness spread alongside social and cultural change. Critics argued that psychiatry was 
pathologizing normal human emotions and individual differences. Public protests urged the 
removal of homosexuality which was included in the DSM until 1973 [18].  
Meanwhile within the field, simultaneous technological advancements, a growing 
emphasis on biological mechanisms, and a scarcity of research funding motivated psychiatrists to 
embrace a more reliable, explicit classification schema within a remedicalized framework. Using 
early DSM versions, agreement between psychiatrist’s diagnoses of the same patient was only 
slightly better than chance [16]. National Institute for Mental Health funding decreased by 5% a 
year between 1965-1972. Improving psychiatric classification could also provide scaffolding 
from which to investigate the causal biological aspects within the now dominate biopsychosocial 
model. The DSM-III was therefore developed with an emphasis on assessment and diagnosis. 
Personified in the 1976 resignation of a psychoanalyst from the DSM-III task force, the once 
dominant psychoanalytic paradigm had fallen out of favor. 
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Empirical studies were conducted to support disorder classifications schemes, which 
were formed into explicit diagnostic criteria in the 1980 publication of DSM-III. This version 
shifted away from any particular theoretical framework and included specific lists of observable 
criteria for each of an expanding disorder set. As new evidence emerged and issues with the 
DSM-III became clear, updates were published in 1994 (the DSM-IV) and 2000 (the DSM-IV-
Text Revision).  
Psychoanalytic thinking formed the basis from which psychiatry evolved into the modern 
era. This psychodynamic tradition sought to understand the person’s psychosocial history and 
context in order to formulate then resolve the individual patient’s psychologically seeded 
dysfunction. To date, reliable systems of psychiatric classification have resulted in several 
national and community-based research studies that vastly increased our understanding of the 
burden and etiology of mental disease. This storied history of psychiatric classification forms the 
basis of the vast and ever-advancing knowledge base from which to understand the 
biopsychosocial causes of mental disease. Future endeavors to examine the burden and causes of 
mental illness will benefit from remembering the purpose of psychiatric classification in its 
historical context, as well once prominent theoretical dispositions which have now fallen to the 
wayside.  
1.1.2 Current classification system and etiological research 
The recent release of DSM-5 continued the incremental refinement of a descriptive 
medical classification system. From the re-medicalization of psychiatric classification in the 
DSM-III onward, the debate continued regarding how to account for both the continuous and 
categorical aspects of mental disorders. Critics still argue against discrete and absolute 
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distinctions between mental health and illness; although DSM-type systems are necessary for 
clinical practice and research, alone, they may be insufficient towards understanding the causal 
origins of mental illness.   
Indeed, depressive syndromes are much more common than MDD among older adults 
[12], however the clinical significance of these syndromes is not clearly agreed upon. Modern 
thinking places mental traits on a continuum while still recognizing that beyond a certain 
threshold (of severity, duration, or impairment), true and burdensome pathology deserves clinical 
attention. The recent emphasis on explicit, atheoretical classification has led to an increase in the 
reliability of psychiatric diagnoses. However the search for the causal origins of mental illness 
also requires a high level of diagnostic validity.  
In other words, etiologically useful phenotypes are those that relate homogeneously to a 
central disease process and/or a common causal mechanism. While the DSM-5 as well as prior 
versions included a system for coding severity within disorders, established nosology allows for 
within-disorder heterogeneity above and beyond a function of severity. Any of 227 possible 
combinations of symptoms may lead to an MDD diagnosis [19]. For the same reasons that 
research seeking to identify the causes of the flu would be hindered by misclassifying a hangover 
as influenza, it is necessary for psychiatric outcome classifications to be highly specific.  
Three MDD symptoms (Table 1) are actually compound psychophysiological indicators: 
appetite/weight disturbance, sleep disturbance, and psychomotor disturbance. Sleep disturbance 
is included as one of the nine MDD symptoms, but endorsement of this single sleep symptom 
encompasses conditions (insomnia or hypersomnia) that result from separate causal processes. 
On the other hand, multiple disorders or aspects of disorders can co-occur. For example, sleep 
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disturbances and depression often co-occur among older adults (i.e. [20]), and this suggests a 
shared dysfunction and a common causal mechanism for study.  
In 2011, the National Institute of Mental Health presented the Research Domains of 
Criteria (RDOC) framework designed to advance etiological research by cutting across 
diagnostic categories and targeting core dysfunctions. By doing so, it may be possible to focus 
research on the common etiological mechanisms which lead to specific mental dysfunction. 
Although the DSM-5 and RDOC now exist, currently available evidence is mostly based on the 
DSM-IV-TR and prior versions. 
In summary, the etiological picture developed using the reliable system of DSM 
classification has limits. Existing challenges are readily apparent in the study of late-life 
depression. Sub-diagnostic depressive syndromes are very common among older adults, but it is 
unclear whether these represent a separate or simply less severe version of the same phenotype; 
uncertainty follows regarding which causal pathways to target in preventative interventions. 
Thus, research examining the range of related symptoms, within and across disorders, is needed 
to refine our description of common late-life depressive phenotypes (regardless of diagnostic 
criteria) as well as their causal origins.  
1.1.3 Measurement of Depression in Aging Research 
Diagnostic instruments: In large-scale research, clinical judgment is rarely employed for 
the purposes of diagnosis because it is usually unreliable or cost-prohibitive. Two main fully- 
structured instruments are used instead to operationalize DSM nomenclature in research: the 
Diagnostic Interview Schedule (DIS) [21] and the Composite International Diagnostic Interview 
(CIDI) [22]. The Structured Clinical Interview for DSM (SCID), a semi-structured instrument, is 
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also available but can only be administered by individuals with clinical training [23]. These 
instruments are considered gold-standards in psychiatric epidemiologic research, and continue to 
be updated in step with revisions to official nomenclature. Test re-test reliability has been 
demonstrated to be higher in both the DIS and CIDI compared to semi-structured clinician 
interviews [24]. 
Fully-structured and computerized, the DIS and CIDI can be administered by lay-people 
to render a diagnosis of past month, past year, or lifetime mental health disorders.  One study 
showed that the CIDI was a valid diagnostic instrument for research in a medically ill population 
[25]. The DIS was demonstrated to have similar sensitivity and specificity (compared to a 
clinical diagnosis) between medically ill older and younger adults [26]. Although limited 
research has compared the performance of these structured instruments by age, a recent study 
raises questions regarding the validity of these structured instruments for use in older adults [27] 
(discussed in Section 1.1.2).  
Symptom Scales: Depending on the purpose and aims of a study, the overall cost of 
administering structured diagnostic instruments may exceed the added value. This is especially 
true when there is an interest in overall mental well-being, requiring multiple aspects of mental 
health to be assessed. Indeed, researchers may be interested in symptom patterns rather than 
clinical diagnoses. Many instruments are available to measure depressive symptomology in 
general population-based or community research, and these symptom scales have also been 
developed for screening purposes.  
The Montgomery-Åsberg Depression Rating Scale (MADRS) was developed specifically 
to detect changes within individuals over time. One report provides evidence that the MADRS is 
more sensitive to change than the Beck Depression Inventory (BDI) [28], although another study 
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found no difference [29]. The sensitivity of other scale’s to change has been examined less often. 
Although most scales have been developed to be used for screening purposes in the general 
population, the Geriatric Depression Scale (GDS) [30] was developed specifically for older 
adults.  
The criterion validity of many instruments (compared with an MDD diagnosis) has been 
examined in community, clinic, and nursing home settings (Table 2). Because most validation 
studies were conducted in separate samples and often using different threshold values, direct 
comparisons of sensitivity/specificity are unwarranted. Generally these studies have shown better 
sensitivity than specificity. These scales can be said to measure the level of depressive 
symptomology, however they do not systematically determine several key diagnostic 
requirements, namely: illness duration, whether the episode occurs secondary to another cause 
(i.e. physical illness), and whether the symptomology is associated with significant functional 
impairment.  
A limited evidence base directly compares the performance of these screens. In a study of 
older primary care patients [31] using SCID-determined MDD as the “gold-standard,” the Center 
for Epidemiological Studies Depression Scale – 20 (CES-D 20) and both GDS versions 
demonstrated similar, acceptable sensitivity and specificity (CES-D 20: 92% sensitivity, 87% 
specificity; GDS-30: 100% sensitivity, 84% specificity; GDS-15: 92% sensitivity, 81% 
specificity). This study found that the GDS was associated with minor depressive disorder while 
the CES-D was not, although both scales lost considerable accuracy screening for less than major  
depression. As these authors point out, the GDS’s “yes/no” response format may add to ease-of-
use compared to the likert-style CES-D response options.   
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A recent systematic review of instruments for screening older adults in hospitals 
concluded that only the GDS scales have been sufficiently validated in this setting [32]. Among 
older adults recovering from a stroke, the GDS had higher sensitivity while the CES-D had 
higher specificity (CES-D 20: 56% sensitivity, 91% specificity; GDS-30: 88% sensitivity, 64% 
specificity) [33]. In patients with Parkinson’s disease, a study comparing nine self-report scales 
to a psychiatric interview demonstrated a range of sensitivity (66-85%) and specificity (60-88%) 
for detecting MDD [34]; although most other scales also performed acceptably, of the scales 
examined, the authors concluded that the GDS-30 was the most efficient due to “brevity, 
favorable psychometric properties, and a lack of copyright protection”.  
Arguably the most important health condition affecting depression scale performance is 
cognitive impairment. Many validation studies exclude participants with cognitive impairment. 
In a nursing home setting, the sensitivity/specific of the GDS-30 was 63/83%, however when 
excluding participants with cognitive impairment sensitivity/specificity was 84/91%.  
The Cornell Scale for Depression in Dementia (CSDD) was purposely designed to 
preserve screening validity in older adults with cognitive impairment [35].  In one study the 
CSDD outperformed the GDS-30 and GDS-15 compared with clinician diagnosis in both 
demented and non-demented participants [36]. The specificity of the GDS-30 was shown to be 
low (38%) among patients with dementia, although in the same participants the GDS-15 yielded 
adequate specificity (85%) [37]. Another study showed that the GDS-15 did not retain validity in 
the presence of cognitive impairment [38]. However, in patients with mild cognitive impairment 
(MCI) the GDS-30 performed adequately compared to the CSDD [39], and among patients 
without dementia the MADRS has been shown to be preferable [40].  
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The GDS-30 may not be a reliable screening tool compared to the CSDD in the presence 
of Alzheimer’s disease (AD) [39]. In patients with AD, the BDI yielded low sensitivity and 
moderate specificity [41]. The CSDD, however, requires a proxy informant which is not always 
feasible and performance comparisons may therefore one-sidedly reflect methodological (as 
opposed to questionnaire) driven differences. Dementias may affect scale sensitivity by causing 
symptom under-reporting, while scale specificity can also be negatively impacted since cognitive 
impairment mimics mood disturbance; the ontogeny of late-life depression may differ in the 
presence of cognitive impairment. Proxy informants may be required to assess the burden and 
course of mood disturbances when occurring alongside cognitive impairment. Future research is 
needed to both clarify and optimize the validity of screening instruments in patients with 
cognitive impairment.  
In addition, other factors may affect the performance of these screens. Papassotiropoulos 
and colleagues [42] showed that false positives using the CES-D were more common for 
participants living in an old age residence or with family members (compared to those living 
with a spouse). Mottram et al. [43] demonstrated that sensitivity/specificity of both the MADRS 
and HAM-D was acceptably invariant across gender and age groups. Another study found that 
CES-D 20 false positives were no more likely among participants with physical illness, cognitive 
decline, or anxiety symptoms [44].  
Despite finding a range of sensitivity/specificity within and across instruments, current 
evidence demonstrates that it is possible to screen for MDD among cognitively intact older 
adults with a high degree of sensitivity. Further research is needed to assess the validity of 
measurement in the presence of factors, like cognitive impairment, which may bias participant 
responses and threaten overall interpretability. Questionnaire development should target scale 
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specificity in order to provide clinical context when assessing depression symptoms in 
epidemiologic studies of older adults. Adding simple questions may improve scale validity, for 
example, assessing the duration and the severity of emotionally attributable functional 
impairment. Instruments measuring common depression symptoms are important tools which 
make assessing the burden and etiology of mood feasible in a wide variety of research settings.  
1.2 DESCRIPTIVE EPIDEMIOLOGY 
1.2.1 Prevalence of depression and aging 
Using a data-driven approach applied to nationally representative data (the 
Epidemiological Catchment Area (ECA) Study), Mezuk & Kendler [45] identified four-classes 
of participants: (1) non-depressed (83.2%), (2) those with mild depression (11.6%), (3) severe 
depression (1.9%), as well as a (4) despondent (3.2%) group. Among the despondent group, the 
probability of endorsing most symptoms was intermediate between the mild and severe 
depression group, with a few exceptions: the despondent and severe groups had similar 
probabilities of endorsing suicide items; however, compared with mild and severe depression 
groups, despondent participants had a lower probability of neurovegetative symptoms.  
The authors reported the prevalence of LCA derived sub-groups by age groups. It is 
important to note that adults 65+ in the ECA study were born during or before 1920, and the 
latent structure of depression may differ among more recent cohorts of older adults. Findings 
show the prevalence of the severe depression sub-group was inversely associated with age; 
prevalence estimates within each age group were: 2.3% for 18-29 year olds; 2.0% for 30-44 year 
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olds; 2.0% for 45-64 year olds; and 1.3% for ≥65 year olds. The mild depression sub-group 
(which may or may not meet diagnostic criteria for MDD) followed something like an upside-
down “U-shape” with age; the prevalence for this sub-group per age group were 6.9% for 18-29 
year olds; 12.2% for 30-44 year olds; 11.7% for 45-64 year olds; and 9.7% for ≥65 years old.  
The prevalence of the despondent group by age appeared to follow a “J-shaped” curve 
(18-29 years: 7.5%; 30-44 years: 1.8%; 45-64 years: 1.1%; ≥65 years: 2.0%). Among the group 
of adults who were ≥65 years old, the despondent class was more prevalent than the severely 
depressed class. These authors note that longitudinal research is needed to directly examine 
transitions across latent states over time. Finding differences in patterns of sub-type expression 
across the life course begs the question of whether survival bias might lead to highly selected 
samples of older adults. Indeed, participants aged ≥65 in this study were 60.1% women 
indicating that survival did affect sampling.  
Nationally representative samples have consistently found a lower prevalence of MDD 
among older adults (Table 3). One major limitation is that nationally representative samples have 
reported on older adults as a single age group (65+). Characterizing all adults 65+ as a single 
group may hinder our understanding of the life course of depression, as the prevalence of 
depression may vary by age post-65 years (i.e. comparing adults 65-69 vs. 70-74; see discussion 
of age effects below).  
Prominent late-life depression researchers Drs. Celia Hybels and Dan Blazer noted in a 
review paper (citing their own prior review) that “most epidemiologists agree the contribution of 
methodological and sampling bias…is small” [46]. Before discussing the possibility of true age 
and cohort effects, we first consider how selection and measurement bias may result in perceived 
differences in MDD prevalence across the lifespan. Dr. Blazer suggests that the accumulated 
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evidence regarding selection bias and differential symptom endorsement is not substantial 
(Personal Communication, 11/14/2013). However in addition to differential symptom 
endorsement within scales by age, evidence suggests that variation in measurement methodology 
can lead to substantial differences in prevalence estimates for older adults [27, 47] .  
With regard to selection bias, Dr. Blazer stated that only about 4% of older adults live in 
institutional settings and that this proportion is decreasing. Nevertheless, if the prevalence of 
MDD among elders living in institutional settings is very high, this will lead to a non-trivial 
increase (for example, 25% with MDD among 4% institutionalized older adults could lead to a 
1% increase in the overall prevalence estimate). Finally, Dr. Blazer also expressed that “we do 
not believe that survival bias is a factor except with the more severe depression,” however recent 
evidence suggests that the depression-survival association is not restricted to severe cases [6]. 
We briefly review these potential explanations for observed differences in MDD prevalence 
across the lifespan.   
Selection Bias: Differential survival may lead to sampling bias. Indeed, in a meta-
analysis of 25 community-based studies the pooled relative risk of dying in depressed subjects 
was 1.81 times that of non-depressed participants [48]. A more recent study in a nationally 
representative sample found that the elevated mortality risk associated with depressive symptoms 
was accounted for by physical health problems [6]. Regardless of whether MDD contributes to 
mortality independent of other known risk factors, if people with or prone to depression are 
characteristically more sick and likely to die earlier, they are less proportionally likely to survive 
to be included in study samples.  
Another source of selection bias pertains to planned or de facto exclusion of medically 
ill/institutionalized individuals. The NESARC and NCS-R did not include adults living in an 
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institutional setting. In addition, compared to younger age-groups, on average, older adults suffer 
from a higher burden of disease and disability and may be thus disproportionately predisposed 
towards non-participation. The same older adults who are sicker and potentially less likely to 
participant in studies are more likely to have MDD.  
The prevalence of MDD increases from the community to primary care settings, and 
prevalence further rises in an inpatient setting [49]. Current depression is prevalent among 6.5% 
of older adults in primary care [50], exceeding the average prevalence of current or past year 
MDD for all age groups in national studies included in Table 3 [9, 51, 52]. In hospitals, the 
prevalence of MDD among older adults was found to be 11.5% in one study [53], and ranging 
(depending on the hospital) from 14.2 to a startling 44.5% in another study [54]. In nursing 
homes, which again are not typically included in epidemiological samples, the prevalence of 
MDD among older adults is consistently three-four times higher than in a community setting 
(8.1-12.4% [55, 56]). Therefore, the older adults most susceptible to MDD may also be the least 
likely to participate in community-based studies.  
Measurement Bias: Older adults may fail to recall earlier depressive episodes, thereby 
lowering lifetime prevalence estimates. Another explanation for differences in prevalence rates 
by age may be that depression is expressed differently across the lifespan. If this were the case, 
depression might be equally prevalent in older adults, however it may not be captured using 
standard criteria and instruments. Particular depression symptoms are in fact reported more or 
less often depending on age. In the ECA study, the prevalence of almost every depression 
symptom significantly differed across age groups. For example, 12.0% of adults ≥65 years of age 
reported insomnia symptoms while 9.6% of the youngest adults reported these symptoms; 5.2% 
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of the youngest adults reported hypersomnia compared to 1.6% of older adults [57]. Older adults 
with MDD tend to have fewer crying spells than younger depressed adults [58]. 
Patients with late-onset depression may be more likely to have weight loss and 
gastrointestinal symptoms than early onset patients [59], and regardless of disease onset, 
differences in symptom expression are found when comparing adults <44 to adults >65 [60]. 
Older patients are less likely to report sadness, a cardinal symptom of diagnosable MDD (>60 
vs.18-59[58, 61], >65 vs. <65 [61]). Somatic symptoms which are common in older adults may 
not attributed to physical rather than mental disease; one small study showed that respondents 
55-75 years old were more likely than respondents aged 25-40 to attribute their symptoms to a 
physical illness, thus excluding them from meeting MDD criteria [62]. However, a re-analysis of 
the ECA study which allowed symptoms with physical attributions to be counted as psychiatric 
symptoms demonstrated that subsequent prevalence increases were consistent across all age 
groups [63]; that is, removing the physical attribution exclusion for symptoms did not result in a 
disproportionate increase in prevalence among older adults. Because this single study was 
conducted using data from the ECA study in which older adults (>65) were born before 1920, 
future studies are needed among more recent cohorts to determine the extent to which older 
adults would qualify for MDD if it were not for the physical illness exclusion.  
In addition to differences in symptom expression and physical attributions, differential 
measurement error may bias prevalence estimates. In the CIDI, participants must endorse a 
screening item to enter the depression module, either: “In the past 12 months, have you had two 
weeks or longer when nearly every day you felt sad, empty, or depressed for most of the day?” or 
“In the last 12 months, have you had two weeks or longer when you lost interested in most things 
like work, hobbies and other things you usually enjoyed?” As pointed out by Karlsson et al. [64], 
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semi-structured interviews allow for more liberal diagnostic decision making than the structured 
instruments which find that MDD prevalence is lower among older adults. These authors 
demonstrated that altering the criterion of “depressed mood all of the day” to “depressed mood 
most of the day” or “depressed mood half of the day” changed prevalence estimates from 4.67 to 
9.23 and 11.29%, respectively.  
O’Connor & Parslow examined this potential source of age-related measurement bias by 
assessing concordance in reporting depression between the CIDI and a more simple measure of 
mood disturbance [27]. While the prevalence of CIDI-based MDD fell sharply with aging, 
simpler questions probing mood disturbance were mostly age-invariant. Importantly, the level of 
inconsistency between simple and complex questions about depression rose within subjects 
sharply beginning at ages 55-64. These authors conclude that older adults may have difficulty 
processing complex questions and default to non-endorsement. This finding suggests that the 
measurement error may substantially and differentially influence prevalence estimates by age.   
Age Effects: In the Longitudinal Aging Study Amsterdam, the prevalence of MD 
increased from 1.3% among adults ages 55-59, to 2.7% among adults 80-85 [65]. In the 
Cardiovascular Health Study, the prevalence of depressive symptoms increased with age among 
men and women >65 years of age [66]. In the Baltimore Longitudinal Study of Aging, 
depressive symptoms appeared to peak in young adulthood, decrease across middle adulthood, 
before increasing again in later life [67]. A recent meta-analysis demonstrated that increasing age 
is associated with increased risk for mood disturbance across all age groups spanning from 60-
85, however the risk of depression did not increase with age after 85 years [68].  
The same positive association between age and depressive symptoms was observed in the 
Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE) study. 
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However, when adjusting for socio-demographic and health factors this pattern reversed so that it 
appeared that age was inversely associated with depressive symptom levels [69]. It is important 
to remember that, to the individual and population, the burden of depression is nonetheless real 
(when it is attributed to disease and disability). Because physical health and other factors that 
account for the increase in depressive symptoms with age are thought to be modifiable, it is 
possible that by eliminating or minimizing such causes, many cases can be prevented.  
Cohort Effects: Cohort effects potentially explain age-related prevalence trends. 
Survivors of “hard” times including WWII and the Great Depression may have been healthier 
across their life, and/or may find living today to be relatively easy [46]. Yang [70] demonstrated 
that age-related declines in depressive symptom levels were more rapid for earlier cohorts.  
MDD later in life may be more common among the post-WWII “baby boom” generation; 
reporting for the NESARC study, Hasin et al. noted that the highest life-time prevalence had 
shifted from younger adults in earlier studies to middle aged adults by year 2000 [9]. Others have 
noted that late-life MDD is typically an exacerbation of chronic mood disturbance [65]; because 
a history of MDD is a strong risk factor for developing new MDD [10], the aging of the post-
WWII generation may mark the beginning of a new era where late-life MDD becomes more 
common. In summary, cohort effects appear robust and important, however other explanations 
for differences in prevalence rates are also viable. Potential selection biases as well as new 
information regarding age-differential measurement error indicate that cohort and age effects 
may not entirely explain the differences in MDD prevalence across the lifespan.  
 
It is critical to keep in mind that, regardless of the prevalence of MDD in later life, the 
prevalence of clinically significant depressive syndromes among community-dwelling older 
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adults is quite substantial (8-16% [12]) and may increase with age (see above). In a review of 34 
studies, Beekman et al. [71] noted that although MDD was relatively rare (1.8%) in older adults, 
minor depressive disorder was present in 9.8% of participants; all depressive syndromes 
combined to an alarming 13.5% prevalence among older adults. In primary care settings, 5.2% of 
study participants had minor depression and 9.9% had subsyndromal depression [50]. In a 
nursing home setting, 14.1% of older adults suffered from minor depression with an additional 
24% reporting clinically significant sub-clinical depressive symptoms [56]. Depressive 
syndromes are therefore quite common among older adults.   
1.2.2 Incidence of depression and aging 
MDD is a chronic disease and prior depressive episodes are a strong risk factor for future 
occurrences [10]. First onsets of MDD occurring in late-life are therefore may represent a 
variation from the typical disease phenotype. Late onset MDD is characterized, at least, by a 
prolonged latency period and possibly different etiological mechanisms. First-onset MDD in late 
life is relatively rare: the ECA study found that among adults ages 65+ new onset of MDD 
occurred at a rate of 1.25 per 100 person years [72].  
In the Netherlands Mental Health Survey and Incidence Study, no statistically significant 
differences in the incidence of MDD were found across age groups, although no adults aged 65+ 
were included [73]. Their data suggested that among men but not women, MDD incidence 
peaked in younger adult years. In a nursing home setting, MDD incidence was 13.6 per 100 
person years [74].  
It is generally recognized that among older adults the rate of incident clinically 
significant depressive syndromes is higher than that of MDD [46]. When including episodes of 
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clinically significant depressive symptoms, incidence rates more than double among community-
dwelling older adults [75]. In a systematic review, Buchtemann et al. [76] found that among 
older adults, the rate of incident depressive syndromes was 6.8/100 person years. In this review, 
incidence rates were generally higher in females than males, although associations of age and 
incidence were found to be inconsistent. In a primary care setting, one study found that the 
incidence of depressive symptoms was 3.54 per 100 person years for adults 75-79, while among 
adults 85+ years of age the incidence rate rose to 7.52 per 100 person years [77]. 
1.3 ANALYTIC EPIDEMIOLOGY 
1.3.1 Risk factors for late-life depression 
In a meta-analysis of risk factors for depression (disorders and syndromes) identified in 
community-based studies, the following have been associated with increased risk in multiple 
studies: female gender (pooled OR 1.4, 95% CI: 1.2-1.8), disability (pooled OR 2.5, 95% CI: 
1.6-4.8), new medical illness (pooled OR 2.1, 95% CI: 0.4-10.1), poor health status (pooled OR 
1.8, 95% CI: 0.5-12.8), prior depression (pooled OR 1.8, 95% CI: 1.1-7.1), recent bereavement 
(pooled OR 3.3, 95% CI: 1.7-4.9), and sleep disturbance (pooled OR 2.6, 95% CI: 1.9-3.7), [78]. 
In a primary care setting, risk factors include: mobility, vision, cognitive and memory 
impairment, as well as smoking [77]. In a nursing home setting, dementia has also been 
associated with increased risk, while using a hearing aid has been associated with relative 
resilience [74]. Perhaps the most broadly relevant factors are disability, disease (including 
cognitive impairment), and sleep disturbances.  
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The relationship between disability and depression is intuitive. Disability can lead to role 
changes thus serving as a significant stressor, although individual responses to new functional 
limitations range widely. Although depression is appropriately conceived of as a cause of 
disability and disease [1, 79], in fact disability is a main contributor to late-life depression [80]. 
One study demonstrated that over time, an increasing burden of disability was associated with 
increasing levels of depressive symptoms [81]; change in depression were also positively 
associated with change in disability, however less strongly so. In another study, disability was 
robustly associated with new onset depression, while the persistence of depression was predicted 
by social support rather than disablement [82].  
Social support is also thought to be an important factor in depression etiology. Recent 
research demonstrates that for women, a high need for affiliation was associated with depression 
risk, while among men different aspects of social support (not having a partner in the household 
or having a small social network) predicted depression onset [83]. Marriage may be protective 
for men, but a risk factor for women [82]. Personality factors have also been related to 
depression, for example environmental mastery, purpose in life and autonomy have been related 
to depressive symptoms among nursing home residents [84]. Another study showed that social 
support modifies the relationship of neuroticism and openness with depression [85]. Because 
most prior research is cross-sectional, future longitudinal research is required to evaluate the 
roles of personality and social support over time and as potential determinants of depression 
following incident health/life events. Although depression and personality were examined as 
predictors of health status in the Veterans Administration Normative Aging Study [86], no 
community or general population-based research has examined personality as a predictor of 
future depression.  
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Chronic pain and depression are also likely related. Chronic pain may worsen depression 
while depression may worsen chronic pain [87]. In the Baltimore ECA study sample, however, 
depression was associated with increased risk for incident back pain over long periods of time 
while pain was not related to future depression [88]. Future research is needed to clarify potential 
bi-directional relations between depression and pain.  
Other illnesses contribute to depression risk through a range of potential mechanisms. 
One of the most common and impactful health factor among older adults is cognitive 
impairment. There may be substantial etiological overlap between a portion of dementia and 
depression cases in late life. The “vascular hypothesis” of late-life depression suggests that 
cerebrovascular changes including white matter hyperintensities [89] cause depression; vascular 
causes of dementia have been recognized and catalogued for at least two decades [90].  
Cognitive decline can certainly serve as a stressor (i.e. disintegrating the social environment) 
leading to depression. At the same time, in meta-analysis, late-life depression has been 
associated with increased dementia risk [14]. It is unclear whether depression exerts a causal 
effect on dementia risk or if a single mechanism causes both depression and dementia.  
Another potential source of overlap between illness and depression in older adults 
involves the inflammatory response. In younger adults, administration of endotoxin raises levels 
of inflammatory markers and causes a “sickness-like” behavior characterized by low mood, 
tiredness, and social withdrawal [91, 92]. When treated with interferon-alpha, which also 
increases levels of inflammatory cytokines, patients are at an increased risk for developing 
depression [92, 93]. In an elucidating study using time-lagged predictors, levels of interleukin-6 
were found to predict subjective sleep disturbances which subsequently predicted levels of 
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depressive symptoms [93]. However this study examined younger adults in the process of 
treatment for hepatitis C, and these findings must be replicated in epidemiologic studies of aging.  
Five cross-sectional studies, including our own prior work, tested whether raised levels of 
inflammatory markers are associated depression in older adults [94-98]. Our research suggests 
that the relationship between inflammatory markers and depressive syndromes in older adults 
may differ depending on age [98]. In additionally, sleep characteristics may represent a residual 
confound in previously identified associations of inflammatory markers and depression. In a 
prospective study, Milaneschi et al. [99] demonstrated an elevated risk for developing clinically 
significant depressive symptoms in late-life on the basis of interleukins – 1 receptor agonist 
levels. Future longitudinal work is needed to replicate this finding and examine the role of sleep 
disturbances in these etiological pathways across the lifespan.  
1.3.2 The central role of sleep in late-life depression 
Sleep disturbances are a common symptom of depression. About 74% of men with 
clinically significant depressive symptoms in the MrOS Sleep Study also reported poor 
subjective sleep quality. Sleep problems in late-life depression can be heterogeneous, although 
more older adults report insomnia and daytime sleepiness complaints than hypersomnia [57]. 
Older adults with mood disturbance tend to have difficulty falling asleep, maintaining sleep, and 
report waking early in the morning without being able to return to rest [100]; insufficient sleep 
quantities and reports of non-restorative are also common among older adults with depression.  
Depression also correlates with altered sleep architecture. In laboratory based studies, 
depression has been consistently associated with an increased percentage of sleep time spent in 
rapid-eye movement (REM) sleep (i.e. see [101]). In the first epidemiological investigation of 
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these relationships among older adults, we found that depressed mood was instead associated 
with a lesser percentage of time spent in REM sleep [102]. This finding suggests that the 
relationship between mood and depression may be modified by age, and future research is 
needed to clarify the nature of these associations across the lifespan. REM sleep deprivation 
contributes to a reduction in hippocampal neurogenesis in rats [103], and in humans recent data 
suggests that disrupted slow-wave sleep may be related to prefrontal atrophy and hippocampal-
dependent memory [104], altogether suggesting that sleep architecture may reflect a process 
central relevant to both mood and cognition.  
At least since an early report by Ford and Kamerow [13], sleep problems have been 
recognized to increase depression risk. These authors noted that individuals who reported sleep 
disturbances were at a significantly increased risk for developing depression. In another study, 
having 3-4 symptoms of insomnia predicted over 3 times the risk of incident depression [105]; in 
this study, objectively measured sleep latency, continuity, and duration were all significant 
predictors of depression. In the French Three-City Study of older adults, difficulty falling asleep, 
difficulty maintaining sleep, and excessive daytime sleepiness were associated with an increased 
risk of developing depressive symptoms although early morning awakening was not [106].  
The MrOS Sleep Study recently reported that objectively measured sleep disturbances 
were related to future risk for depression among community-dwelling older adults [107]. While 
associations between objectively measured sleep characteristics and depression risk were 
attenuated after adjustments for baseline levels of depressive symptomology, subjectively 
assessed sleep disturbances remained robustly related to depression risk after multiple covariate 
adjustments[107].  
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Mood and sleep disturbance are thought to be bi-directionally related [108]. Our recent 
systematic review of factors associated with incident sleep disturbances among older adults 
found that in 10/13 studies reporting, depression was associated with an increased risk of 
developing sleep disturbances (odds ratios ranged from 1.54 to 9.18 [109, 110]). Of the three 
negative studies reporting on depression, two had marginal (p=0.06) associations with worsening 
sleep [111, 112], and the other was the only to examine a lifetime (as opposed to current) episode 
of depression as a predictor [113]; temporal proximity may be an important determinate of these 
risk relations.  
Sleep disturbances may mediate the relationship between physical health problems and 
mood disturbances. For example pain may lead to sleep problems, subsequently exacerbating 
mood disturbance. Incident disability, health events, or other stressful events may lead to mood 
disturbance by altering the daily pattern of rest and activity. Recently, these rhythmic patterns of 
sleep-wake activity were been examined as a potential correlate [114] and risk factor [115] for 
depression. Older adults with depressive symptoms tend to exhibit less robust daily patterns of 
rest and activity. Among community-dwelling older men, less robust rest-activity rhythms were 
found to independently predict significant increases in depressive symptoms, above and beyond 
numerous relevant covariates including sleep complaints and self-reported physical activity. 
Future research is needed to further understand the nature of sleep-wake rhythms and their 
relation to depression risk. The biological pathways relating sleep, circadian rest-activity 
rhythms, and depression among older adults are unknown. In addition, the hypothesis that 
stressful life-events (i.e. bereavement and incident disability) may lead to depression by 
disrupting sleep-wake rhythms remains currently untested. 
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1.4 TABLES AND FIGURES 
Table 1. DSM-IV-TR Criteria for Major Depressive Disorder (MDD)  
-Depressed mood or a loss of interest or pleasure in daily activities for more than two weeks. 
-Mood represents a change from the person’s baseline. 
-Impaired function: social, occupational, educational.  
-At least 5 of the 9 symptoms below, present nearly every day: 
1. Depressed mood or irritable most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad or empty) or observation made by others (e.g., appears 
tearful). 
2. Decreased interest or pleasure in most activities, most of each day 
3. Significant weight change (5%) or change in appetite  
4. Change in sleep: Insomnia or hypersomnia 
5. Change in activity: Psychomotor agitation or retardation 
6. Fatigue or loss of energy  
7. Guilt/worthlessness: Feelings of worthlessness or excessive or inappropriate guilt  
8. Concentration: diminished ability to think or concentrate, or more indecisiveness  
9. Suicidality: Thoughts of death or suicide, or has suicide plan  
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Table 2. Sensitivity and specificity of self-report depression screens in older adults compared to a diagnosis of 
current MDD 
 
Setting:  Community Primary care/hospital  Nursing home  
Scale (# 
items) 
Cut-
point  
Sensitivity/ 
Specificity 
Cut-
point  
Sensitivity/ 
Specificity 
Cut-
point 
Sensitivity/ 
Specificity 
HAM-D (17)   15/16 87.5/99.1[43]   
CES-D (20) 9/10   
 
15/16 
75/72[42]  
 
100/87.6[44] 
21/22  
 
16/17  
 
21/22  
 
19/20 
75/51 [116]  
 
100/57 [117]**  
 
92/87 [31]  
 
56/91 [33] 
  
CES-D (10)   3/4    
 
11/12   
 
 8/9 
100/92 [118]  
 
76/55 [116]   
 
 91/35 [119] 
  
GDS (30) 11/12  
 
10/11 
75.3/77[120]* 
 
 73/65[121] 
10/11  
 
10/11   
 
9/10   
 
9/10 
85/82 [32]*  
 
91/42 [37]  
 
92/81 [31]  
 
88/64 [33] 
10/11 
 
10/11  
 
10/11 
 
10/11 
96.3/69.1 [122]  
 
89/68 [123]  
 
69/86 [124]  
 
88.89/56.41 [125] 
GDS (15) 5/6 80.5/75[120]* 5/6   
 
5/6   
 
5/6     
 
4/5   
79/77 [32]*  
 
90.9/64.5 [126]  
 
83/69 [37]  
 
92/81 [31] 
5/6   
 
5/6    
 
5/6 
96.3/75.7 [122]  
 
95/83 [127]  
 
88/65 [123] 
MADRS (10)   20/21 72.1/98.9 [43] 
 
82/75 [128] 
 
  
PHQ (9) 4/5 80/78[129] 9/10 80/92 [130] 
 
  
PHQ (2) 0/1 100/77[131] 2/3 83/83 [130]   
* Pooled estimate; **orthopedic patients criterion validity shown - neurological patients  
sensitivity/specificity was 100/36. 
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Table 3. Lifetime Prevalence of MDD by Age Group in National Studies 
 
First Author Study 
Year 
conducted 
Age 
groups 
Prevalence 
(%) 
Weissman [132] ECA 1980-1985 18-24 6.7 
   
25-44 9.5 
   
45-64 5.0 
   
65+ 2.0 
     
Kessler [133] NCS-R 2001-2002 18-29 15.4 
   
30-44 19.8 
   
45-59 18.8 
   
60+ 10.6 
     
Hasin [9] NESARC 2000-2001 18-29 12.02 
   
30-44 14.03 
   
45-59 14.91 
      65+ 8.91 
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Figure 1. Suicide death rates per 100,000 by age and sex 
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2.0  LATENT CLASS ANALYSIS OF SLEEP, CIRCADIAN REST-ACTIVITY, AND 
DEPRESSIVE SYNDROMES AMONG OLDER MEN 
In this chapter we use a data-driven approach to assess the commonly occurring sleep, 
circadian rest-activity rhythm (CAR), and depressive syndromes among older men. Using Latent 
Class Analysis (LCA) we found that only 53.86% of our sample was free from some type of 
probable depressive syndrome, while only 45.17% had no sleep disturbances, and 32.18% had all 
normative CAR parameters. Subjective sleep disturbances were very common, but a dissociation 
with objectively assessed disturbances was observed such that only a sub-set (8.87%) 
experienced both, while 37.46% had only subjective and 8.51% had only objective disturbances. 
Mental health and medication use appeared to correlate with subjective disturbances, whereas 
physical health correlated with objective disturbances. CAR classes were distinguished by 
timing, rhythm height, as well as the length of the active period. Physical health and lifestyle 
factors were among the unique correlates of CAR latent classes. Depressive syndromes 
characterized by somatic/apathy symptoms were very common, whereas psychological/cognitive 
symptoms were relatively rare; emotional impairment was common and distinguished the 
depression classes. Clinical and sub-clinical physical disease were among the unique correlates 
of membership in the identified classes. Overall, our findings demonstrate substantial 
heterogeneity and a high prevalence of sub-diagnostic sleep, CAR, and depressive syndromes 
among older men. Preventing physical health problems may reduce the prevalence of these 
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syndromes. Future work should attempt to replicate these configurations of signs/symptoms in 
other samples.  
2.1 INTRODUCTION 
Despite their high prevalence [12, 134], little is known sub-diagnostic late-life sleep and 
depression syndromes. Especially given that the global population is rapidly aging [8], research 
is required to assess the clinical significance and long-term consequences of these syndromes. 
Thus, assumption-free surveillance of late-life sleep and depressive syndromes is a major public 
health priority.  
In other words, several high priority epidemiologic research questions require detailed 
investigations into the nature, prevalence, and clinical significance of common sign/symptom 
patterns without making a priori assumptions about what constitutes meaningful disease. In 
depression, for example, questions that cannot be answered relying upon MDD criteria alone 
include: Are syndromes which do not meet MDD criteria simply a less severe version of the 
same, single depression phenotype? Do sub-diagnostic syndromes differ in terms of their 
signs/symptoms, physical health correlates, or biological substrates? Are the long-term 
consequences of syndromes similar to those of than MDD?  
Epidemiology is tasked with answering these questions. Specifically, the core purposes of 
epidemiology include: defining syndromes, assessing their prevalence, and understanding their 
causes/consequences [135]. Assessing the potential phenotypic distinctness and consequences of 
common late-life sub-diagnostic syndromes can inform developmental studies of clinical disease 
and also provide evidence to base wide-reaching primary and secondary interventions.   
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Among techniques to examine naturally occurring syndromes without intrinsic 
dependence or reference to known/existing categorization schemes is latent class analysis (LCA). 
LCA is a data-driven method which identifies sub-groups with similar patterns of 
signs/symptoms, thus providing a description of the syndromic states found in a sample. Using 
LCA, one can assess the types of sign/symptom patterns found in a sample, and further, assess 
their prevalence, correlates, and consequences on distal health outcomes. In the current chapter, 
we present all but the latter among a large sample of well-characterized community-dwelling 
older men. In the next chapter we examine the data-derived groups’ association with rates of 
change in overall depressive symptomology over time (Chapter 3).  
2.1.1 Rationale for depression LCA  
LCA has been previously applied with enthusiasm to study depression. In a nationally 
representative sample (the National Epidemiologic Survey on Alcohol and Related Conditions) 
Carragher et al. [45] identified four latent sub-groups characterized by: (1) minimal depressive 
symptoms (18.8%), (2) psychosomatic symptoms (30.6%), (3) cognitive-emotional symptoms 
(10.2%), and (4) severe depression (40.9%). This study was limited by the use of screener or 
“gateway” questions, such that only participants endorsing one of the two core mood disorder 
questions contributed data on depressive symptoms. Therefore, potential depressive syndromes 
which do not include either of these symptoms were entirely excluded.  
Despite this and other prior work, a systematic review of latent models of depression 
(n=10 LCA studies not isolated to older adults) concluded that there is insufficient empirical 
support for depression sub-types beyond severity-based distinctions [19]. Even less research 
using LCA has been conducted among older adults. Hybels and colleagues applied LCA to study 
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symptom profiles of older adults with MDD using the CES-D and HAM-D [136]. Note that 
application of the MDD inclusion criteria ensures, like studies with gateway questions, 
syndromes lacking core features of MDD (the known disease entity characterized by low mood 
and anhedonia) are excluded from studied. Four sub-groups of MDD patients were identified 
based on the CES-D scale.  
These classes varied consistently as a function of symptom severity: one cluster had the 
mildest symptoms (8%), another had generally moderate symptoms (but lacked interpersonal 
symptoms; 36%), and a third generally had less severe symptoms than the moderate group (with 
similar amounts of the psycho- somatic/motor symptoms of restless sleep and reduced talking; 
34%). The final cluster consisted of participants with the most severe symptoms (22%). For the 
HAM-D, a three cluster solution was best, however these clusters appeared to vary as a function 
of symptom severity. Another LCA from this research group in a general sample of community-
dwelling older adults used the MADRS but again found symptom profiles differing mostly in 
terms of severity [137].  
A report from the Cache County Memory Study of older adults identified 3 sub-groups 
differing in terms of overall severity and symptom expression [138]; however this study only 
included participants who endorsed “gateway” questions (n included = 400 out of a total 5092 
participants). The latent classes identified were: (1) symptom levels consonant with major 
depression (61.5%), (2) moderate symptom levels that could indicate either major or minor 
depression without loss of interest in activities (17%), and (3) milder symptomology resembling 
minor depression (21.5%). The moderate and mild symptom groups were distinguished by: a 
complete lack of “loss of interest” in the moderate group, and a lower level of sleep problems 
and neurovegetative symptoms in the mild group.  
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To my knowledge, no prior study has examined the nature, correlates, and consequences 
of data-derived late-life depressive syndromes in a large unselected of community-dwelling older 
adults (not requiring a diagnosis or “gateway questions” as inclusion criteria). It is worth 
highlighting that Hybels et al. [137] previously performed a latent-class analysis of depressive 
symptoms in an unselected sample; these researchers then examined how latent sub-group 
membership was related to future change in depressive symptoms over time. This work provides 
an excellent substantive and methodological precedent, however it did not include a detailed 
examination of the health correlates of being in the identified latent depression subgroups   
2.1.2 Rationale for sleep LCA  
No known prior study has used LCA to assess/describe within-person patterns of specific 
subjective and objective sleep disturbances. We aim to examine the RDOC sleep/arousal domain 
on both self-report and behavioral (actigraph) levels. Subjective sleep reports are easily 
obtainable and are the only source of information regarding perceived sleep quality. However, 
perceived sleep characteristics may not completely concord with objective sleep measures like 
sleep duration or the level of fragmentation. LCA can determine which particular 
subjective/objective sleep disturbances tend to co-occur and how common any distinct 
disturbance patterns are.  
An additional reason to apply LCA to comprehensively characterized sleep is to assess 
the precise nature of long recognized sleep-associated depression risk [13]. Among older adults, 
and indeed, generally, little evidence exists isolating the specific aspects of sleep related to 
depression risk. Recent research among older men suggests that subjective, but not objective 
disturbances are related to future depression [107]. LCA can cut through between-person 
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heterogeneity to determine how various sleep problems commonly co-occur, and this improved 
sleep phenotype categorization can be used in future investigations of depression risk (Chapter 
3).  
2.1.3 Rationale for CAR LCA  
Rest and activity exhibit diurnal variation known as the CAR. Recent research 
demonstrates that specific characteristics of the CAR are relevant to a wide range of health 
outcomes in aging. Aspects of the CAR have been associated with future depression [115], 
cognitive impairment [139], cardiovascular disease [140], and mortality [141]. These studies 
provide important examinations of specific aspects, such as the height, robustness, or timing, of 
the CAR in relation to future disease.  
In reality, however, each person has parameters for all aspects of the CAR. The within-
person configurations of CAR parameters commonly found in the community are unknown. For 
example, do dampened activity patterns often co-occur with phase delays or advanced? 
Application of LCA to study CAR disturbances can determine which patterns of CAR 
disturbances are observed and how often.  
In addition, focusing on each aspect separately may neglect interactions wherein specific 
combinations of parameters synergistically influence health. Given multiple CAR parameters 
including rhythm height, timing, and robustness, traditional testing of interactions based on a 
priori hypotheses can become cumbersome. LCA provides a manageable method for 
understanding which patterns of CAR disturbances are found in a sample (thus which are 
important research targets) and whether/which configurations are related to distal health 
outcomes.  
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2.1.4 Cross-sectional Aims  
Given the above-mentioned rationale, we applied LCA to sleep, CAR, and depression 
domains to accomplish the following specific aims:  
 
Aim 1: Understand the specific patterns (combinations) of signs/symptoms occurring 
within three separate domains (sleep, CAR, and depression) among older men. 
Hypothesis 1(a): Heterogeneity in the overall severity of sign/symptom patterns will be 
observed within each (of three) domains.  
Hypothesis 1(b): Substantial sub-samples within each domain will have mild syndromes: 
In the sleep domain, subjective sleep complaints will be common. 
In the CAR domain, having reduced locomotor activity alone will be common. 
In the depression domain, mild apathy/somatic symptoms will be common.  
Hypothesis 1(c): Within each domain, at least one smaller portion of the sample will have 
additional serious complaints:  
In the sleep domain, a subset of the sample experiencing subjectively poor sleep 
will also have objective measures of insomnia (prolonged sleep onset latency, sleep 
fragmentation, and short sleep). Prolonged sleep onset latency will also co-occur with 
long sleep duration and daytime sleepiness.  
In the CAR domain, a portion of those with overall reductions in locomotor 
activity will also have a dampened rhythm and/or an erratic rest-activity pattern. Late-
timing will often co-occur with this more severe CAR syndrome.  
In the depression domain, a portion of those with somatic symptoms will also 
report psychological symptoms and signs of impairment.  
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Aim 2: Determine the unique physical and mental health correlates of specific sleep, 
CAR, and depression syndromes found in the community.  
Hypothesis 2(a): Anxiety, less physical activity, worse cardiovascular health, and 
instrumental activity of daily living (IADL) impairment will be associated with commonly 
occurring mild syndromes within each domain.  
Hypothesis 2(b): The correlates of mild syndromes within each domain will be similar, 
whereas across domains, the correlates of more severe syndromes will be nuanced.    
2.2 METHODS 
2.2.1 Participants  
The Osteoporotic Fractures in Men (MrOS) Sleep Study was conducted between 
December 2003 and March 2005 and included 3,135 participants recruited at six clinical centers 
in the United States (Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; 
Monongahela Valley, Pennsylvania; Portland, Oregon; and San Diego, California) [142, 143]. 
The parent MrOS study included community-dwelling men ≥65 years who could walk without 
assistance and were without bilateral hip replacements. Men were excluded from the Sleep Study 
if they regularly used overnight nocturnal oxygen therapy, positive pressure or oral appliances 
for treatment of sleep apnea (n=150). Other reasons for non-participation were: death (n=349), 
terminated study participation (n=39), declined sleep study (n=1997), or because MrOS Sleep 
Study recruitment goals had already been met (n=324).  
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Compared with men participating only in the parent MrOS study, the Sleep Study sample 
tended to be healthier (i.e. percent with past myocardial infarction in Sleep Study=12.44% vs. 
excluded=15.53%, p=0.0006), more educated, and younger; no differences in race by Sleep 
Study participation was detected. All men provided written informed consent, and the study was 
approved by the Institutional Review Board at each clinic site. Participants were included in the 
analytic cohort if they had ≥3, 24 hour periods of technically adequate actigraph data (excluded 
n=134). The cross-sectional analysis was therefore initially conducted with 3001 men.  
2.2.2 Measures 
2.2.2.1 Sleep LCA indicators 
Both subjective and objective measures of sleep were considered. Participants were asked 
to rate their past month overall sleep quality, and response were coded as “very bad”/“fairly bad” 
versus “fairly good”/”very good.” Participants were also asked “during the past month, how 
often have you had trouble staying awake while driving, eating meals, or engaging in social 
activity?”; response were coded as “not during the past month”/“less than once a week” versus 
“once or twice a week”/“three or more times a week.” From the GDAS participants answered 
whether: (1) they had been sleeping poorly, (2) they had been waking early, or if (3) they had 
difficulty falling asleep.  
Objective estimates of sleep/wake activity were obtained using the Octagonal Sleep 
Watch actigraphy, or SleepWatch-O, (Ambulatory Monitoring, Inc, Ardsley, NY). Participants 
were asked to wear actigraphs on the non-dominant wrist for a minimum of 5 consecutive 24-
hour periods except when bathing or during water sports; participants were also asked to keep a 
sleep log which was used to edit the actigraphy data. Movement was measured using a 
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piezoelectric biomorph-ceramic cantilevered beam, which generates a voltage each time the 
actigraph is moved. These voltages are gathered continuously and stored in one minute epochs. 
Data collected in digital integration mode were used for this analysis. ActionW-2 software 
(Ambulatory Monitoring, Inc., Ardsley, NY) was used to score the actigraphy data (for scoring 
algorithms details see [144, 145]). This method produces reliable estimate of sleep-wake patterns 
[146, 147], and has been shown to have good concordance with total sleep time (TST) from 
polysomnography [148]. Inter-scorer reliability has been previously found to be high in sleep 
studies performed by the MrOS Sleep Study team (intra-class coefficient=0.95) [144]. 
Actigraphy derived sleep parameters used in the sleep LCA were: total sleep time (TST; 
hours per night spent sleeping in bed after “lights off”), sleep latency (SL; amount of time until 
onset of sleep defined when participant achieved sleep for 20 continuous minutes after getting 
into bed) and wake after sleep onset (WASO; minutes scored awake during the interval after 
sleep onset). Actigraphy measured sleep parameters were dichotomized with the following cut-
offs: (1) short sleep <5 and long sleep >8 hours (contrasted in a single variable with 5-8 hour 
sleepers); (3) SL≥60 minutes, and (4) WASO≥90 minutes.  
2.2.2.2 CAR LCA indicators 
Actigraph identified bedtime, wake-time, mid-sleep time, acrophase [149] and sleep 
period [150, 151] generally correlate with that of urinary 6-sulphatoxymelatonin secretion. 
Diurnal rest and activity variation (the CAR) therefore reflects the central biological pacemaker 
located in the suprachiasmatic nucleus; because voluntary behavior can “mask” endogenous 
signal reflected in rest-activity patterns, the CAR may only indirectly reflect circadian biology 
[146].  
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A five-parameter extended sigmoidally transformed cosine model with an antilogistic 
function was used to model activity data; this model fits CAR data better than a standard cosine 
curve as humans typically exhibits a more “squared” daytime activity rhythm [152]. Modeled 
parameters included measures of rhythm height, timing, and robustness. For all CAR parameters 
except timing variables, the lowest quartile was compared with the others to represent deviations 
the sample’s normative values thus indicating CAR disturbances. For timing parameters, the 
lowest and the highest quartiles were both compared with the others (in a single variable) to 
represent both phase advances and delays. Using quartiles to represent non-normative or 
disturbed CAR parameters is consistent with prior work [115, 139, 141, 153] and, in the context 
of LCA, is designed to identify sub-groups with specific patterns of CAR parameters outside the 
normative range (disturbances).  
Rhythm height parameters were: amplitude (peak-nadir difference) and mesor (estimated 
middle of the fitted curve). To assess whether rhythm height reductions were consequences of 
activity levels overall, rather than relative peak-nadir differences, standardized amplitude was 
computed as amplitude divided by mesor. Lower values of standardized amplitude reflect a 
dampened rhythm.   
Rhythm timing measures were: acrophase (time of day of peak activity level), up-mesor 
(time of day when activity passes up through mesor, also known as left-half detection point 
approximating the time the participant “gets going” in the morning), down-mesor (time of day 
when activity passes down through mesor, also known as right-half detection point, 
approximating the time of day the participant “settles down” for the night).  
The extended cosine model also provides a measure known as the pseudo-F statistic 
which reflects of how well the modeled rhythm fits the observed data [152]. Values indicate how 
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robustly patterned rest-activity is over the assessment period, with lower values indicating poorer 
model fit and suggesting an erratic and/or variable rhythm.  
Finally, a parameter called alpha reflects the relative width of the activity peak compared 
with nadir; higher values indicate a relative narrowness of the active compared with rest period, 
thus the highest quartile was contrasted with the others to reflect a shortened activity period.  
2.2.2.3 Depression LCA indicators 
The Goldberg Depression and Anxiety Scale [154] (GDAS) contains 9 depression and 9 
anxiety oriented items. Responses were binary indicators of whether the symptom was “recently” 
present or absent. The Geriatric Depression Scale-15 [155] (GDS) contains 15 items with binary 
response options indicating whether the symptom was present or absent over the “last week.” 
Three additional depression items were derived from the Short Form-12 [156]. Two of these 
captured impairment attributable to emotional issues leading to: (1) accomplishing “less than you 
would like” or (2) not doing “work or other activities as carefully as usual.” The final item was 
regarding the past 4 weeks, and asked “Have you felt downhearted and blue?” For consistency 
with the other depression items which had binary response options, responses to questions from 
the Short Form-12 were dichotomized (as “all of the time”/”most of the time”/“a good bit of the 
time” verses “some of the time”/“a little of the time”/”none of the time”)  
2.2.2.4 Covariates 
Demographics and lifestyle factors: Age, study site, race, weekly alcohol use, daily 
caffeine intake, educational attainment, smoking status, and BMI were examined as potential 
cross-sectional correlates of latent class group membership. The Physical Activity Scale for the 
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Elderly (PASE; a validated self-report measure of physical activity [157, 158]) was expressed 
continuously.  
Other mental health factors: Cognitive function was measured using the 3MS [159] 
which was expressed as continuous variable. Anxiety symptoms were measured using the 
anxiety portion of the GDAS [154] as a continuous score reflecting symptom counts (range: 0-9). 
In addition, associations of the GDS with LCA-derived sleep and CAR latent classes were 
examined.   
Subjective sleep: The Pittsburgh Sleep Quality Index (PSQI) [160] (range 0-21) was 
expressed continuously to reflect global sleep quality. The Epworth Sleepiness Scale (ESS) was 
also expressed as a continuous measure of excessive daytime sleepiness ranging from 0-24. 
Associations of these factors with sleep latent class were not examined (subjective sleep was a 
part of the LCA group outcome variable). 
Actigraph-derived Circadian Rest-Activity Rhythm (CAR) measures: We examined the 
above mentioned CAR parameters as correlates of only depression latent classes only. 
Relationships between actigraph sleep and CAR parameters were not examined because they are 
derived from the same raw data.  
Polysomnography (PSG) assessed sleep disordered breathing (SDB): In-home sleep 
studies using one night of unattended PSG (Safiro, Compumedics, Inc., Melbourne, Australia) 
were performed with recording of central electroencephalography, bilateral electrooculography, 
chin electromyography, ECG, nasal pressure and thermistry (for airflow measurement), chest and 
thoracic inductance plethysmography, finger pulse oximetry, body position, and leg movements, 
as described previously [161]. Centrally trained and certified staff members performed home 
visits for setup of the sleep study units. Using approaches similar to those in the Sleep Health 
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Heart Study [162], after sensors were placed and calibrated, signal quality and impedance were 
checked, and sensors were repositioned as needed to improve signal quality, replacing electrodes 
if impedances were greater than 5000 ohms. Polysomnography data quality was generally 
excellent, with a failure rate of less than 4% and more than 70% of studies graded as being of 
excellent or outstanding quality. The apnea hypopnea index (AHI) was computed as the average 
number of apneas and hypopneas per hour of recorded sleep. Apneas were defined as a complete 
or almost complete cessation of airflow for more than 10 seconds. Hypopneas were defined as a 
>30% reduction in amplitude of either respiratory effort or airflow for more than 10 seconds 
associated with a ≥3% oxygen desaturation [163]. Rescoring studies over time indicates that 
inter- and intra- scorer reliability (ICC) for the AHI was high (ICC>0.95). The AHI was 
dichotomized at ≥30 to reflect severe sleep disordered breathing. 
Instrumental Activity of Daily Living (IADL) impairment: The number of 5 IADL 
impairments was expressed as a continuous variable; the five IADLs were: heavy housework, 
preparing own meals, shopping for groceries or clothing, walking 2-3 blocks, and climbing ten 
stairs [164, 165].  
Chronic disease: Participants were asked if they had a fall in the past 12 months. They 
also reported whether they had ever received a physician diagnosis of: peripheral vascular 
disease, osteoarthritis (OA), rheumatoid arthritis, hypertension, stroke, angina, congestive heart 
failure (CHF), myocardial infarction, diabetes, chronic obstructive pulmonary disease (COPD), 
Parkinson's disease, renal disease, cataracts, or liver disease. 
Inflammatory markers: Serum was collected during morning clinic visits after an 
overnight fast. A natural log transformation was applied to normalize their distributions which 
were initially skewed. CRP was measured using the ELISA assay kit from ALPCO (CRP 
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sensitive ELISA). This assay utilizes a sandwich Enzyme Immuno Assay, in which plate wells 
are coated with polyclonal antibodies to CRP. The inter-assay CVs ranged from 11.6-13.8%. IL-
6, TNF-α, and IFN-γ were assayed using the Human ProInflammatory I 4-Plex Ultra-Sensitive 
Kit by MSD (catalog #K15009C-4). The sensitivities of the assay were: 0.22 pg/mL for IL-6, 
0.49 pg/mL for TNF-α, and 0.40 pg/mL for IFN-γ. Inter-assay CVs range from: 2.0- 9.9% for IL-
6, 2.1-6.0% for TNF-α, and 1.8-4.5% for IFN-γ. TNF-αsRII was measured with an ELISA from 
R&D Systems (Minneapolis, MN; catalog #DRT200). The normal range for TNF-sRII in serum 
is 1003 – 3170 pg/mL. TNF-αsRII inter-assay CVs range from 3.5-5.1%.  
Medications: Participants were asked to bring all medications used within the last 30 
days to the sleep examination. Medications were entered into an electronic database and matched 
to its ingredient(s) based on the Iowa Drug Information Service (IDIS) Drug Vocabulary 
(College of Pharmacy, University of Iowa, Iowa City, IA)[166]. Psychoactive medications 
(antidepressants, benzodiazepines, and non-benzodiazepine non-barbiturate sedatives/hypnotics) 
were considered based on expected clinical relationships between these drugs and the primary 
predictors and outcomes. Other medications considered were NSAIDs and corticosteroids due to 
their relations with inflammatory markers and potentially the outcomes.  
2.2.3 Statistical methods 
LCA postulates the presence of an unmeasured categorical latent variable that directly 
causes an observed pattern of indicators (single variable items) within a given set. LCA assumes 
local independence, in other words conditional independence of the indicators given latent class 
assignment. All indicators were dichotomous, except in the sleep and CAR domains, 
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duration/timing variables had three categories (i.e. short sleep vs. normative sleep vs. long sleep 
duration).     
The number of latent groups is selected based on both interpretability and model fit 
statistics. We used the Bayesian Information Criterion (BIC) to compare models with a different 
number of latent classes. While a smaller value is favored, BIC may indicate improvements in 
model fit when adding latent classes that do not reflect additional, distinct, or clinically relevant 
entities. Therefore, BIC was used to select the optimal number of latent classes, however the 
number of latent groups was only increased when doing so captured an additional, distinct, and 
clinically relevant entity. An add-in SAS procedure (PROC LCA) was utilized to conduct the 
LCA [167]. Solutions with small latent classes (<5% of the sample) were rejected except when 
the addition of the small group captured expected clinical syndromes (i.e. <5% of older adults 
are expected to have current depression symptoms consistent with MDD).  
Because a large number of depression items were available, we employed a systematic 
method for indicator selection. The goal was to combine depression items to create a fully 
descriptive, parsimonious LCA model that was statistically sound and computationally feasible 
(because we could not include all indicators). Depression indicators were eliminated if they (1) 
did not possess standalone, certain clinical relevance (i.e. by appearing in the Diagnostic and 
Statistical Manual of Mental Disorders – 5 (DSM-5) [168] depression sections) and (2) were not 
influential in separating latent groups. LCA solutions from restricted and inclusive indicator sets 
were compared to determine if the variables exclusion substantively altered the model. The 
variables included in each analysis are listed in Table 14.   
The first analysis was conducted using only GDS items, then in a second model set, GDS 
indicators were eliminated as described above. Items which were removed included life 
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satisfaction, boredom, optimism, anxiety symptoms. These items may generally reflect the 
severity of true depression and therefore entail, at least, contextual clinical relevance; but by 
themselves, these items did not substantively impact the model/sub-groups found in the sample.  
In an initial analysis of the GDAS, only depression items were selected except “…been 
waking early” which was excluded and considered in the sleep LCA. In addition, following 
previous literature suggesting irritability may be an important symptom of depression [169], the 
“…been irritable” item from the GDAS anxiety sub-scale was considered in the depression LCA. 
Two items were found in both the GDS and GDAS and were thus redundant; these items 
assessed (1) hopelessness and (2) loss of energy. The GDS hopelessness item asked “do you feel 
that your situation is hopeless” (italics added) whereas the GDAS item offered improved 
interpretability by simply asking “do you feel hopeless?” The GDAS energy item was selected 
because it was phrased to indicate a deficit in energy (as opposed to feeling full of energy).  
We assessed the age- and site-adjusted associations of all covariates with LCA group 
using multi-nominal logistic regression. The reference group was also set to be the group that 
appeared most healthy (i.e. by not having sleep or depression symptoms). Items included as LCA 
indicators were not eligible predictors of the derived classes (i.e. GDS was not an eligible 
predictor of depression LCA group membership). Otherwise, all significant crude associations 
(p<0.10) were entered into a maximum model, and automated backwards elimination in SAS 
was used to select predictors retaining adjusted significance of at least p<0.15. Multicollinearity 
was assessed using the variance inflation factor (VIF). The selected independent predictors were 
entered into a final multi-nominal logistic model within the PROC LCA framework, thus 
ensuring that no measurement error was introduced. In these final models, we applied a data-
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derived prior to stabilize estimates of item-response probabilities (sleep, CARs, and depression 
models) and regression parameters (only sleep and depression models).  
The final model included cross-sectional predictors which were assessed in only a sub-set 
of the MrOS Sleep Study (inflammatory marker and PSG studies). We therefore re-performed 
LCA model selection among the subset with complete covariate data. In all domains, the 
prevalence and characteristics of identified sub-groups were similar in the reduced models 
(missing covariate data, minimum reduced n=2473) compared with the full sample.  
 
2.3 RESULTS 
2.3.1 Sleep LCA 
2.3.1.1 Description and prevalence of latent sleep classes  
Subjective and objective (actigraph) measured sleep variables were best fit by a five 
group model (Table 4). For consistency with correlates tables, all LCA analyses are shown in 
item-response probability plots corresponding to the final model (participants with complete 
covariate data). Figure 2 shows indicator items across the x-axis with the conditional item 
response probability on the y-axis. Descriptive sleep characteristics (Table 5) indicate that item-
response probabilities corresponded to real, substantial group differences in these sleep 
disturbances.  
The majority of participants (45.17%) had a low probability of endorsing any symptom 
(“healthy sleep”). Substantial portions had high probabilities of endorsing either the single item 
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“Have you been waking early?” (25.57%) or all subjective sleep disturbance items except weekly 
excessive daytime sleepiness (11.89%). One group had objective sleep disturbances (8.51%) as 
indicated by high probabilities of actigraph assessed sleep fragmentation (WASO≥90 minutes) 
and intermediate probabilities of both short (<5 hour) sleep and prolonged SL (≥60 minutes). 
The remaining group (8.87%) had a similar pattern of sleep disturbances as the “subjective only” 
and “objective only” groups, except that this portion of the sample had both sets of elevated 
sleep disturbance probabilities.  
2.3.1.2 Correlates of latent sleep classes  
Age- and site-adjusted odds for all covariates indicated a number of cross-sectional 
associations with LCA-depression groupings (all comparisons are to the reference group of 
apparently healthy sleepers; Table 6).  
In the final model (Table 7), moderate alcohol use was marginally associated with (13%) 
higher odds of being the objective disturbance only group but also with 12% lower odds of being 
in the subjective and objective disturbance group. Moderate alcohol consumption was 
significantly associated with 19% decreased odds of being in the subjective disturbance group. 
Being a current smoker was related to over twice the odds of having objective sleep disturbances 
alone, while being a former smoker was related to 17% higher odds of having both subjective 
and objective sleep disturbances.  
Higher BMI was related to increased odds of being in either group with objective 
disturbances (15% and 26%). Anxiety symptoms were related to about 55% higher odds (per 
standard deviation) of being in the groups with subjective disturbances, and anxiety was related 
to 16% higher odds of being in the early awakening only group.  
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Each additional IADL impairment was related to 20% higher odds of being in the group 
with both subjective and objective disturbances only; higher TNF-α was related to 25% higher 
odds of being in this group (marginally significant finding). On the other hand, higher levels of 
TNF-α were related to modestly (16%) lower odds of being in the “early awakenings” group.  
OA was related to 22% increased odds of being in the objective disturbances alone group. 
CHF was related to 42% and 46% higher odds, respectively, of being in the subjective plus 
objective and objective alone group. Severe SDB were related to about 18% and 36% higher 
respective odds of being the objective plus subjective and objective disturbances alone groups.  
Antidepressant use was marginally associated with 22% higher odds of being in the 
objective disturbance group. Non-benzodiazepine non-barbiturate sedatives/hypnotic use was 
associated with over twice the odds of being in the groups with multiple subjective sleep 
complaints; benzodiazepine use was associated (30% higher odds) with being in the subjective 
disturbances alone group. NSAID use was associated with 22% and 30% higher odds of being in 
the groups with multiple subjective sleep disturbances, and this association with being in the 
early awakening group was marginally significant.  
2.3.2 CAR LCA 
2.3.2.1 Description and prevalence of latent CAR classes  
Circadian rhythm variables were best modeled using eight groups (Table 8; Figure 3). 
Groups were labeled and their characteristics are describe in Table 11. The largest group had 
apparently normal rhythms as indicated by low probabilities of being in any extreme quartile 
(32.18%). A group had a high probability of low mesor and amplitude with an intermediate 
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probability of low robustness (“reduced activity,” 9.79%), but lower probabilities of having 
standardized amplitude and low probabilities of non-normative timing.  
Two groups appeared to have non-normative timing alone: one group had earlier peaks 
and up-mesors plus an intermediate probability of an earlier down-mesor (“early activity’; 
10.7%). Another group had later peaks and down-mesors with an intermediate probability of a 
later up-mesor (“late activity”; 14.36%).  
Two groups had altered timing and active period length. Of these groups, one had an 
earlier peak and down-mesor combined with a high alpha (“early activity with short active 
period”; 10.54%). Another group had a later up-mesor with a short active period (“late rising 
with short active period”; 8.27%).  
The final two groups had similarly advanced or delayed activity as above, except that 
these last groups also had high probabilities of altered rhythm height/robustness. One group had 
high probabilities of having an advanced peak and settling time (down-mesor) with a shorter 
active period, plus high probabilities of having low height, standardized amplitude, and 
robustness period (“early, dampened rhythm with short active period”; 6.48%). The last group 
had delayed CAR activity plus a high probability of low height/robustness (“late with reduced 
activity”; 7.68%).  
Examining continuous characteristics for each CAR parameter by group demonstrates 
substantial mean differences consistent with the conditional item response probabilities (Table 
9). For descriptive purposes, we show also correlations between continuous CAR parameters 
(Table 10).  
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2.3.2.2 Correlates of latent CAR classes  
In the final model (Table 13), older age was independently associated with about 38% 
higher odds of being in the “reduced activity” and “early, dampened rhythm with short active 
period” groups (all comparisons are with being in the “normative rhythm” group). Note that in 
the unadjusted models (Table 12), advanced age was also associated with higher odds of being in 
the “late with reduced activity” group; thus, the relationship between age and this group appears 
to be accounted for by the factors included in the final model.  
Alcohol use was associated with lower odds of being in the “late with reduced activity” 
group (both in unadjusted and adjusted models). The final model also indicated that drinking 14+ 
alcoholic beverages per week (vs.<1 drink/week) was associated with higher odds of being in the 
“early activity with short active period” or “late activity with short active period” groups; 
however, these associations were not detected in the unadjusted models (Table 12).  
Higher education was associated with significantly decreased odds of being in the late 
peak/down mesor group. Being a current smoker was associated with over three times the odds 
of being in the “early activity with short active period” group. Higher BMI was associated with 
higher odds of being in all groups with indication of reduced locomotor activity, as well as 
higher odds of being in the “late rising with short active period” group.  
Higher levels of self-reported physical activity were associated with lower odds of being 
in all groups with indication of reduced locomotor activity, as well as reduced odds of being in 
the “late activity” group. Anxiety symptoms were marginally and modestly associated with being 
in the “late with short active period” group. Higher cognitive functioning scores were associated 
(per standard deviation) with about 20% lower odds of being in the “late rising with short active 
period” and “early, dampened rhythm with short active period” groups.  
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IADL impairments were related to higher odds of being in all of the disturbed (vs. normal 
rhythm) groups except for the “early activity with short active period” group. Hypertension was 
related to higher odds of being only in the “early, dampened rhythm with short active period 
group.” CHF and COPD were related to higher odds of being in the “reduced activity” group 
only, whereas MI was related to higher odds of being in the “late rising with short active period” 
group.   
Levels of CRP were positively related to the odds of being in the “reduced activity,” 
“early activity with short active period,” “late rising with short active period,” and both group 
with altered timing plus activity reductions; note that in the adjusted models, CRP levels were 
also associated with the altered timing only groups.  Levels of TNF-α were positively associated 
with the odds of being in the “early activity” or “late activity” alone groups; in the unadjusted 
models, TNF-α was positively related to all groups except those with altered timing plus a 
shortened period.  
2.3.3 Depression LCA 
2.3.3.1 Description and prevalence of latent depression classes  
When combining GDS data with items selected from the other depression scales (Table 
14), BIC indicated a five group solution fit the data best (Table 15). The final LCA solution in 
the sub-set of participants with complete covariate data is shown graphically (Figure 4). The 
largest group identified appeared to be free of symptoms (53.86%; “not depressed”). The second 
largest group (27.70%; “probable somatic/ apathy”) had low probabilities of most symptoms 
indicating a general lack of depression symptoms; however this group had intermediate to high 
probabilities of endorsing somatic symptoms (especially “feeling slowed”) and had some 
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indication of apathy (i.e. “prefer home”). A parallel group (5.74%; “probable somatic/apathy 
with impairment”) had approximately the same pattern of symptom expression but also had high 
probabilities of endorsing impairment indicators, especially accomplishing ‘less than they would 
like’ due to emotional issues.  
The final two groups, in addition to having the high probabilities of somatic and apathy 
symptoms, had non-zero probabilities across the entire range of cognitive/psychological 
symptoms. One of these groups (“apathy/somatic w/probable impairment”; 8.45%) had a low 
probability of feeling hopeless, worthless, or empty, but had intermediate probabilities of the 
following symptoms: cognitive/memory problems, social withdrawal, irritability, anhedonia, and 
impairment. The last group (4.25%) had intermediate to high probabilities across the entire range 
of cognitive/psychological symptoms; this group also had a high probability of endorsing 
impairment and is accordingly referred to as the “depressed” group. 
Descriptive mental health characteristics indicate that the two groups with probable 
somatic/apathy symptoms were similar in mean number of depression and anxiety symptoms but 
different in terms of the percentage with emotional impairment (Table 16). As expected, the 
depressed group had the highest levels of depressive symptomology, followed by the 
“apathy/somatic with probable impairment” group; the two groups with probable somatic/apathy 
syndromes experienced, on average, about two depression symptoms.  
2.3.3.2 Correlates of latent depression classes  
Age- and site-adjusted odds for all covariates indicated a number of cross-sectional 
associations with LCA-depression groupings (compared to the reference group “not depressed”) 
(Table 17). Significant associations (p<.10) were entered into a maximum model and 
associations which retained independent significance were entered into the final model.  
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In this final model (Table 18), older age and low CAR amplitude had modest, 
independent associations with increased odds of being in both the “apathy/somatic w/ probable 
impairment” and “probable somatic/apathy” groups; early up-mesor was also significantly 
associated with decreased odds of being in these two groups. Late-down mesor was associated 
with 46% higher odds of being in the “depressed” group.  
Higher levels of anxiety symptoms and worse global sleep quality were associated with 
being in all groups (relative to the non-depressed reference); the strength of this association was 
greatest for the “depressed” group (over twice the odds vs. “not depressed”), followed by the 
group with apathy/somatic symptoms (56% higher odds), the group with probable 
apathy/somatic symptoms with impairment (32% higher odds), and anxiety was only modestly 
(10% higher odds) associated with being in the probable somatic/apathy group without 
impairment .  
Higher physical activity scores were modestly related to decreased odds of being in all 
groups except “probable somatic/apathy w/ impairment.” Daytime sleepiness and IADL 
impairment were also associated with modestly increased odds of being in all groups except 
“probable somatic/apathy w/ impairment.” This same pattern (associated with higher odds of 
being all depression groups except “probable somatic/apathy w/ impairment”) was observed for 
past year falls and stroke; however these associations were graded such that the odds were most 
increased for the “depressed” group (also note that the association between stroke being in the 
“apathy/somatic w/probable impairment” group was only marginally significant). 
Peripheral vascular disease was associated with 18-36% increased odds of all groups 
except “depressed.” Rheumatoid arthritis was associated with 28 and 48% increased odds of 
being in the “depressed” and “apathy/somatic w/ probable impairment” groups, respectively. 
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COPD was associated with 57 and 25% higher odds of being in the “depressed” or “probable 
somatic/apathy” groups, respectively. Cataracts were associated with marginally reduced odds of 
being in the “probable somatic/apathy w/ impairment” group.  
Higher CRP levels were significantly associated with 16% higher odds of membership in 
the “probable somatic/apathy w/ impairment” group. TNF-αsRII was significantly associated 
with 26% higher odds of being in the “probable somatic/apathy” group.  
2.4 DISCUSSION 
Findings are summarized and discussed by domain followed by an overall discussion. 
2.4.1.1 Summary of sleep LCA and correlates 
Consistent with our hypothesis, we observed that a substantial portion of older men in the 
MrOS Sleep Study reported subjective sleep disturbances (11.9% reported multiple subjective 
disturbances). We did not, however, anticipate the dramatic dissociation observed between 
subjective and objective disturbances: while almost 20% had evidence of either type of sleep 
disturbance, only about 9% had both.  
This novel finding highlights the importance of measuring both perceived and objectively 
measured sleep quality. About 11% of older men may have objective sleep disturbances which 
would not have been detected using self-report. Since these objective disturbances may be risk 
factors for future disease (i.e. falls [170] or dementia [171]), routine clinical use of actigraph may 
be necessary to identify sleep risk factors among older men. 
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We also found that long sleep duration did not tend to co-occur with greater sleep 
fragmentation or prolonged sleep latency. Instead, short sleep was more often accompanied by 
these objective disturbances. Thus, in our sample, actigraph detected night-time distress is 
typically characterized by sleep fragmentation which is potentially accompanied by short sleep 
and/or prolonged sleep latency. 
Unanticipated, though consistent with known clinical observations, a substantial portion 
of the sample reported early awakening alone. This group did not appear to be distinguished 
from the healthy sleepers (45.17%) by chronic illness. Anxiety symptoms were related to higher 
odds while TNF-α levels were related to lower odds of having early awakenings only (compared 
with the healthy sleeper group). Although future research is required produce definitive 
evidence, our findings suggest that reports of early awakening without other sleep disruption 
may be marked by mild anxiety despite having relatively lower levels of this sub-clinical disease 
marker.  
Moderate alcohol consumption was associated with reduced odds of being in either 
subjective sleep disturbance group, but increased odds of having objective disturbances alone; 
this finding suggests a potential dubious role of moderate alcohol consumption among older 
men. Anxiety symptoms were related to being in either group with subjective disturbances, 
whereas CHF and SDB were related to being in either group with objective disturbances; these 
findings suggest a mental origin to subjective disturbances, and a physical origin to objective 
disturbances.  
Interestingly, sedative/hypnotic use was associated with being in either group with 
multiple subjective complaints. Because this data is both observational and cross-sectional, a 
strong possibility is that sedative/hypnotics were prescribed for the subjective complaints 
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(confounding by indication). Either sedative/hypnotic use actually caused subjective sleep 
disturbances, or they were prescribed for the sleep complaint but were inefficacious. It may be 
that the group with subjective disturbances alone at one point suffered from objective 
disturbances, but by time of study the sedative/hypnotic prescription produced objectively 
measurable improvements in sleep (only in this subset). Even in this case, our findings still 
demonstrates sedative/hypnotics use is related to a higher prevalence of subjective sleep 
complaints, and other treatment strategies are urgently needed for these problems.  
The high prevalence of dissociation between subjective and objective sleep complaints 
calls for cautious interpretation of self-reported sleep. Subjective complaints are still important in 
their own right. Clinical research is needed to test the efficacy of sedative/hypnotics in reducing 
distinct (subjective/objective) types of sleep disturbances, and potentially to establish other (i.e. 
behavioral) interventions to resolve mental suffering related to poor sleep perceptions. Finally, 
future research is required to determine the physical, perhaps electrophysiological underpinnings 
involved in the development of poor perceived sleep, as well as in the characterization of sleep 
phenotypes overall. Given the high prevalence and stark disassociation of subjective and 
objective sleep disturbances, sleep medicine should consider routine use actigraph to 
complement self-report.  
Future studies are needed to determine if a similar dissociation of subjective and 
objective disturbances is observed in other samples. Future longitudinal studies are needed to 
assess the development, stability, and long term consequences of these latent groups. 
2.4.1.2 Summary of CAR LCA and correlates 
Application of LCA to a range of CAR disturbances produced intuitive but novel insights 
into the common CARs patterns occurring among community dwelling older men. Contrary to 
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our hypothesis, rhythm robustness was not a unique factor which distinguished CAR groups; 
instead, a lack of rhythm robustness appeared in the presence of overall reductions in locomotor 
activity (unstandardized rhythm height parameters mesor and amplitude). Therefore, a lack of 
rhythm robustness may directly precede or result from overall locomotion reduction, and future 
longitudinal research is needed to assess these relationships. Because rhythm robustness has 
previously been associated with health outcomes when rhythm height measures themselves were 
not [115], it may still be that low CAR robustness reflects a distinct process that emerges from or 
entails overall locomotor reductions. 
Timing variables distinguished CAR patterns in our sample intuitively, i.e. into “larks” or 
“owls”. After accounting for effects of lifestyle and chronic disease factors, higher levels of 
TNF-α were only uniquely associated with having both advanced or delayed timing only (i.e. 
without altered locomotor levels or periods). TNF-α may be thus particularly related to altered 
activity timing; although this cytokine exhibits diurnal variation [172], morning fasting blood 
samples were drawn and detecting relations to both advances and delays negates potential 
confounding by time of draw. Unadjusted associations between TNF-α with the other sub-groups 
were attenuated after adjustment; therefore, the measured health factors explained these 
associations. But outside from IADL impairment, chronic diseases were not associated with the 
odds of having only an altered phase (timing). Therefore, having altered timing alone may be 
characterized by disability and subclinical disease.  
Having a more narrow active period emerged as a distinguishing characteristic of three 
latent sub-groups. Lifestyle factors may have a particularly important role conferring certain 
combinations of timing and activity alterations. Men with less education were relatively unlikely 
to have late timing without altered activity levels/periods. Current smoking and heavy (14+ 
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drinks per week) alcohol consumption was related to having an early and compressed CAR. 
Current smoking was also associated with having delayed timing plus locomotor reductions, and 
heavier alcohol consumption was also associated with having late timing with a shortened active 
period. Levels of CRP were also positively associated with these group, and indeed, were 
positively associated with being in any groups that had a shortened active period or activity 
reductions. CRP is a downstream product of the liver that does not cross the blood brain barrier 
[173], thus associations between CRP and locomotor compression/reductions likely indicate 
systemic disease processes rather than a direct causal effect from CRP to disruption of the central 
circadian clock.  
Two groups had altered timing plus reductions in locomotor activity. Hypertension was 
associated with higher odds of earlier timing plus dampened rhythm with a shorter activity 
period. Because these are cross-sectional associations, we cannot assess causality and future 
research is necessary to assess the causes and consequences of these CAR configurations. 
However, it is worth highlighting that, overall, physical disease appeared to be highly associated 
with being in the non-normative (disturbed) CAR groups; for example, CHF and COPD were 
strongly associated with having locomotor reductions.  
It is also important to note that IADL impairment was widely related to having a 
disturbed CAR, especially late timing plus altered activity (levels or period). A role of IADL 
impairment in the development of disturbed CARs is both intuitive and suggested by our 
findings. Therefore, studying disability in general is a high priority for future research 
investigating the development of altered CARs.  
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2.4.1.3 Summary of depression LCA and correlates 
Consistent with our hypothesis, psychological/cognitive symptoms were less common 
when compared with the high prevalence of syndromes characterized by somatic/apathy 
symptoms alone. Importantly, we found that impairment (difficulty accomplishing as much as 
they would like due to emotional issues) occurred not only among those with a higher burden of 
psychological, cognitive, and apathy symptoms, but within a sub-set (5.74/33.44%) of those with 
probable somatic/apathy symptoms alone.   
Examining the cross-sectional correlates of latent group membership suggest relevant 
causes or consequences of these depressive symptom configurations that should be examined in 
future longitudinal research. Several correlates of both the “probable somatic/apathy and 
“depressed” group differed in strength of association such that these factors (physical activity, 
anxiety, past year falls, stroke, and COPD) were more robustly associated with the group having 
more general and severe depression symptoms. These, in addition to anxiety symptoms and 
subjective sleep disturbances, appear to be general correlates of the range of depressive 
syndromes identified.  
For example, the following factors increased the odds being in the “depressed” group: 
more anxiety symptoms, subjective sleep disturbances, later evening settling times, more IADL 
impairments, a past year fall, rheumatoid arthritis, stroke, and COPD. The odds of being in the 
group with a near-definite apathy/somatic syndrome that had a substantial probability of 
impairment were increased by: older age, anxiety symptoms, worse subjective sleep quality, 
lower levels of locomotor activity, IADL impairment, past year fall, peripheral vascular disease, 
and rheumatoid arthritis. Differences in the unique correlates of these sub-groups (“depressed” 
vs. “apathy/somatic”) may generate hypotheses regarding the development of specific 
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syndromes. For example is severe peripheral vascular disease uniquely involved in the 
development of apathy symptoms, whereas cerebrovascular and pulmonary disease risk factors 
are more generally related depression? Importantly, eliminating these correlated physical health 
problems may help relieve the major burden of depression found among older men.  
The overall the pattern of covariate association was similar for the probable 
somatic/apathy group without impairment group when compared with the both of the more 
severe syndromes. Some differences should be noted: rheumatoid arthritis, although related to 
both the “depressed” and “apathy/somatic with probable impairment” groups, was not related to 
higher odds of being in the milder “probable somatic/apathy” groups. However, TNF-αsRII was 
uniquely associated with being in the “probable somatic/apathy without impairment” group. 
Significant age- and site- adjusted relationships of TNF-αsRII with higher odds of being in the 
“depressed” and “apathy/somatic with probable impairment” groups were attenuated in the final 
model by covariates adjustments; thus, overt disease may explain associations between TNF-
αsRII and more severe depression, whereas higher levels of subclinical disease marked by TNF-
αsRII may be particularly involved in the experience of mild somatic/apathy depression without 
emotional impairment.  
Interestingly, the “probable somatic/apathy with impairment” group lacked associations 
with almost all of the above discussed other groups’ correlates. Higher levels of anxiety 
symptoms, worse global sleep quality, and peripheral vascular disease were associated with 
higher odds of membership in the “probable somatic/apathy with impairment” group. However, 
levels of physical activity, daytime sleepiness, IADL impairment, past-year falls, stroke and 
COPD (which were noted as correlates of the other syndromes) were not associated with 
membership in this potentially important subgroup.  
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CRP levels, although not associated with any of the other groups in the final model, were 
positively associated with having only probably somatic/apathy symptoms plus impairment. In 
unadjusted models, CRP levels were also associated with higher odds of membership in other 
depressed sub-groups (vs. not depressed); in the final model, it is likely that overt chronic 
diseases (discussed above) explain associations between CRP and these sub-group. However, 
only peripheral vascular disease and CRP levels were uniquely associated with being in the 
group with emotional impairment alongside only a few symptoms; these are likely important 
markers of the physical factors related to this sub-group. Again note that CRP is a downstream 
product of the liver that does not cross the blood brain barrier [173], and thus CRP is likely a 
consequence (not a cause) of factors related to being in the “probable somatic/apathy plus 
impairment” group.   
In sum, a substantial minority experienced at least probable somatic and/or apathy 
symptoms. These symptoms may be caused by complex relations between reduced physical 
activity, poor subjective sleep quality, anxiety, and physical disease. Peripheral vascular disease, 
arthritis, and either overt or subclinical inflammatory-related disease appear to be particularly 
relevant physical health correlates. Patterns of symptoms consistent with a MDD diagnosis were 
relatively rare (about 5%), although emotional impairment was at least twice as common. 
Researchers and clinicians may thus benefit from evaluating emotional impairment even among 
older adults without psychological complaints. Future work should account for the severity of 
individual symptoms rather than their presence or absence explains individual variability in 
emotional impairment.   
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2.4.1.4 Overall conclusions 
Prior epidemiologic sleep and depression research tends to reference known disease 
entities to produce prevalence estimates of: (1) known disorders, (2) symptomatic but sub-
threshold syndromes, and (3) healthy states. Our investigation provides more detail into the 
nature of sub-threshold syndromes. We found that only 53.86% of our sample was free from 
some type of probable depressive syndrome, only 45.17% had no sleep disturbances, and only 
32.18% had all normative CAR parameters. In the case of depression, variability was 
characterized, not just by total symptom count, but also by symptom expression. Specific 
dissociations between sub-groups in the sleep and CAR domains were also dramatic and 
intuitive.  
Future work is needed to investigate the development, stability, and consequences of the 
identified syndromes. A short-term research priority is to investigate the natural history and risk 
relations pertaining to the specific signs/symptoms which appeared valuable in discriminating 
specific sub-groups (i.e. early morning awakening, activity period compression, or emotional 
impairment). It is crucial for future research to assess whether similar sub-groups can be 
identified among other samples. It may be that some of the identified groups are sample specific, 
owing to nuances of our study’s design or age group.   
A major limitation of the current work is the cross-sectional design which excluded 
analysis of the temporal antecedents or consequences of the sub-groups identified. The roles of 
genetic and environmental factors in these relations must also be examined. In addition, the 
sample was mostly white, relatively educated men who were older; these findings should not be 
generalized to the younger adults, women, or some ethic groups. The final models included only 
participants with complete covariate data which required the somewhat more invasive PSG and 
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inflammatory marker measures; nevertheless, the same LCA groupings were identified in this 
sub-set when compared with the groups found among the entire sample. Still, the external 
validity of the study is limited and future studies should attempt to confirm our findings in other 
samples.  
All sign/symptom indicators were coded as binary variables reflecting the presence or 
absence of a specific disturbance, but the severity of each sign/symptom was not accounted for. 
Examining descriptive characteristics in each group (i.e. mean WASO, acrophase, or depressive 
symptom levels) provides assurance the groups were distinct and our examination of pre-defined 
disturbances supported enhanced interpretability. Nonetheless, future latent profile research with 
continuous disease indicators may shed important light on heterogeneity in health/disease states.  
In sum, we found substantial heterogeneity in sleep, CAR, and depressive symptoms. 
Sub-diagnostic syndromes are common and potentially clinically significant. Disability, vascular, 
and pulmonary disease factors appeared to characterize worse disease states across domains. It 
remains true that clinically-derived diagnostic categorizes have an essential roles ensuring 
clinical relevance and fostering improved care for patients with a known disorder; nevertheless, 
we have provided preliminary evidence that data-driven research has the potential to improve our 
understanding of new or under-recognized syndromes. Indeed, this approach of studying 
naturally occurring configurations of signs/symptoms can complement other approaches and 
provide evidence for refining nosology, especially in new areas of study like the CAR. The 
current cross-sectional analysis provides a basis for future longitudinal research on the long-term 
consequences of these sub-diagnostic disease states.  
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2.5 TABLES AND FIGURES 
 
 
 
 
 
 
 
Table 4. BIC for different number of latent classes using all 
sleep indicators 
 
Number of latent 
classes 
Log 
likelihood 
BIC Entropy 
1 -11858.18 3459.51 1.00 
2 -10685.10 1193.42 0.90 
3 -10426.09  755.48 0.83 
4 -10386.21  755.79 0.87 
5 -8552.22  652.90 0.84 
6 -8539.85  711.78 0.78 
BOLD solution selected  
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Table 5. Descriptive sleep characteristics of sleep latent classes (% (n) unless otherwise noted) 
 
Name of latent 
class 
Daytime 
sleepiness 
Early 
Awakening 
Poor sleep Low sleep 
quality 
Difficulty 
falling asleep 
SL, mean 
minutes (sd) 
WASO, mean 
minutes (sd) 
TST, mean 
minutes (sd) 
>8 hours 
TST 
<5 hours 
TST 
Healthy sleep 3.46 (47) 0 (0) 2.88 (39) 1.47 (20) 4.20 (57) 22.99 (16.78) 68.15 (35.45) 407.95 (57.56) 9.71 (132) 1.19 (26) 
Early awakening 6.52 (53) 100 (813) 15.38 (125) 1.72 (14) 5.17 (42) 22.29 (15.07) 67.98 (34.51) 392.33 (55.40) 5.42 (44) 3.82 (31) 
Subjective dist. 11.24 (47) 79.86 (333) 99.52 (415) 73.92 (309) 69.30 (289) 25.13 (16.42) 71.11 (33.95) 397.41 (61.22) 9.35 (39) 4.56 (19) 
Objective dist. 9.45 (24) 37.80 (96) 0 (0) 1.97 (5) 7.48 (19) 79.64 (56.41) 137.33 (47.20) 268..33 (64.34) 0 (0) 77.56 (197) 
Subjective and 
objective dist. 11.95 (19) 57.86 (92) 94.97 (151) 74.84 (119) 67.30 (107) 78.40 (57.74) 146.52 (45.77) 295.04 (90.52) 0.63 (1) 61.64 (98) 
All variables coded as indicated in text on sleep LCA methods; dist. = disturbance; sd = standard deviation 
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Table 6. Age and site adjusted odds of membership in LCA-derived sleep subgroups (vs. healthy sleepers, 45.17%) 
 
Subjective and 
objective 
disturbances 
(8.87%) 
Objective 
disturbances 
(8.51%) 
Subjective 
disturbances 
only (11.89%) 
Early 
awakenings only 
(25.57%) 
Age (per SD) 1.26 (1.07-1.48) 1.08 (0.94-1.24) 1.04 (0.93-1.17) 1.05 (0.96-1.14) 
     
Study Site (vs. PI):     
  BI 0.58 (0.35-0.96) 0.34 (0.21-0.55) 0.89 (0.61-1.29) 0.80 (0.59-1.09) 
  MN 0.40 (0.23-0.67) 0.47 (0.31-0.72) 0.72 (0.49-1.04) 0.76 (0.56-1.02) 
  PA 0.18 (0.10-0.36) 0.33 (0.21-0.53) 0.67 (0.46-0.98) 0.74 (0.54-1.00) 
  PO 0.38 (0.21-0.66) 0.53 (0.34-0.83) 0.70 (0.47-1.04) 0.82 (0.60-1.12) 
  SD 0.44 (0.26-0.73) 0.53 (0.35-0.80) 0.65 (0.44-0.95) 0.78 (0.58-1.05) 
     
Race:     
  Black vs. White 2.28 (1.14-4.60) 1.55 (0.80-3.00) 0.87 (0.47-1.59) 0.81 (0.49-1.33) 
  Other vs. White 2.78 (1.44-5.36) 0.96 (0.49-1.87) 1.39 (0.87-2.21) 1.48 (1.03-2.12) 
     
Alcohol use per week:     
  1-13 drinks vs. <1 drink 0.75 (0.52-1.07) 1.24 (0.93-1.65) 0.65 (0.52-0.83) 0.94 (0.78-1.13) 
  14+ drinks vs. <1 drink 1.31 (0.68-2.54) 1.08 (0.57-2.02) 0.70 (0.42-1.18) 1.05 (0.71-1.54) 
Daily caffeine intake (per SD) 1.16 (0.99-1.35) 1.09 (0.96-1.24) 0.93 (0.83-1.05) 1.08 (0.99-1.18) 
     
Education:     
  Less than high school vs.   
College/graduate school 2.55 (1.42-4.56) 1.36 (0.75-2.48) 1.62 (1.00-2.61) 1.28 (0.83-1.95) 
  High school diploma vs.      
College/graduate school 1.30 (0.83-2.05) 1.19 (0.82-1.74) 1.06 (0.76-1.47) 1.36 (1.06-1.76) 
     
Smoking Status:     
  Former vs. None 2.03 (1.39-2.95) 1.24 (0.93-1.64) 1.08 (0.86-1.36) 1.03 (0.86-1.23) 
  Current vs. None 1.90 (0.54-6.72) 2.79 (1.26-6.17) 1.06 (0.45-2.55) 1.24 (0.64-2.41) 
     
BMI (per SD) 1.63 (1.40-1.91) 1.68 (1.48-1.92) 1.10 (0.98-1.24) 0.98 (0.89-1.08) 
Physical Activity (per SD) 0.74 (0.61-0.89) 0.89 (0.77-1.03) 0.84 (0.74-0.94) 1.09 (1.00-1.19) 
Cognitive function (per SD) 0.78 (0.67-0.90) 0.93 (0.80-1.07) 0.86 (0.77-0.96) 0.92 (0.83-1.00) 
Anxiety symptoms (per SD) 2.82 (2.43-3.26) 1.21 (0.99-1.47) 2.60 (2.31-2.93) 1.56 (1.39-1.76) 
Depressive symptoms (per SD) 2.04 (1.78-2.33) 1.26 (1.08-1.47) 1.81 (1.62-2.02) 1.30 (1.17-1.44) 
     
Chronic Disease History     
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 IADL impairment (per additional) 1.85 (1.59-2.15) 1.31 (1.11-1.53) 1.49 (1.32-1.69) 1.04 (0.91-1.18) 
 Fall in past 12 months 1.99 (1.42-2.79) 1.33 (0.99-1.77) 1.24 (0.98-1.57) 0.96 (0.79-1.17) 
 Peripheral vascular disease 1.61 (0.99-2.60) 1.14 (0.73-1.77) 1.35 (0.95-1.92) 1.01 (0.74-1.37) 
 Osteoarthritis 2.38 (1.67-3.38) 1.86 (1.38-2.51) 1.84 (1.44-2.36) 1.02 (0.82-1.27) 
 Rheumatoid Arthritis 2.16 (1.33-3.52) 1.10 (0.66-1.82) 1.84 (1.29-2.64) 0.93 (0.66-1.32) 
 Hypertension 1.69 (1.21-2.37) 1.24 (0.95-1.62) 1.31 (1.05-1.64) 1.10 (0.93-1.31) 
 Stroke 1.83 (0.92-3.61) 0.64 (0.27-1.51) 0.77 (0.42-1.43) 0.80 (0.50-1.30) 
 Angina 1.79 (1.20-2.66) 1.23 (0.85-1.76) 1.31 (0.97-1.75) 0.87 (0.68-1.13) 
 Congestive Heart Failure 3.33 (1.94-5.72) 3.03 (1.89-4.86) 1.69 (1.06-2.71) 1.41 (0.94-2.10) 
 Myocardial Infarction 1.94 (1.32-2.85) 1.39 (0.98-1.97) 1.57 (1.19-2.07) 1.09 (0.86-1.39) 
 Diabetes 1.57 (1.01-2.43) 1.63 (1.13-2.33) 1.11 (0.80-1.54) 1.16 (0.89-1.50) 
 COPD 2.08 (1.14-3.81) 1.77 (1.03-3.07) 1.54 (0.96-2.48) 1.25 (0.83-1.89) 
 Parkinson's 3.08 (0.99-9.59) 1.37 (0.39-4.83) 1.95 (0.81-4.70) 0.86 (0.35-2.14) 
 Renal disease  1.30 (0.37-4.54) 0.59 (0.14-2.58) 0.89 (0.33-2.41) 0.45 (0.17-1.23) 
 Cataracts 1.34 (0.95-1.89) 1.06 (0.80-1.41) 1.25 (0.99-1.56) 1.18 (0.98-1.41) 
 Liver disease 1.01 (0.30-3.38) 0.57 (0.17-1.90) 1.24 (0.61-2.49) 0.74 (0.38-1.42) 
 Severe SDB (AHI ≥ 30) 2.25 (1.53-3.32) 2.43 (1.76-3.36) 1.03 (0.75-1.41) 1.06 (0.83-1.37) 
     
Medication Use     
 Antidepressant use 2.06 (1.25-3.40) 1.57 (1-2.47) 1.59 (1.10-2.30) 0.74 (0.52-1.08) 
 Non-benzodiazepine non-
barbiturate sedatives/hypnotics 7.03 (2.91-17.00) 1.46 (0.41-5.20) 6.74 (3.40-13.33) 1.32 (0.57-3.02) 
 Benzodiazepines use 3.00 (1.64-5.51) 0.98 (0.45-2.11) 3.35 (2.17-5.17) 0.77 (0.45-1.30) 
 Current NSAID use 1.90 (1.30-2.77) 1.04 (0.73-1.48) 1.87 (1.44-2.41) 1.15 (0.92-1.44) 
 Current corticosteroid use 
(oral/nasal/inhaled) 1.65 (1.02-2.67) 1.02 (0.65-1.61) 0.88 (0.59-1.30) 0.86 (0.63-1.17) 
     
Inflammatory Markers     
 log(IL-6 + 1) 1.37 (0.97-1.94) 1.72 (1.32-2.23) 1.15 (0.88-1.49) 1.01 (0.81-1.26) 
 log(CRP + 1) 1.50 (1.17-1.93) 1.28 (1.02-1.60) 1.14 (0.95-1.37) 0.99 (0.85-1.15) 
 log(TNF-α + 1) 2.36 (1.25-4.48) 1.58 (0.91-2.73) 1.05 (0.67-1.65) 0.72 (0.50-1.03) 
 log(TNF-αsRII + 1) 1.81 (1.09-3.02) 1.36 (0.88-2.10) 1.36 (0.96-1.93) 0.78 (0.58-1.03) 
 log(IFN-γ + 1) 1.08 (0.81-1.45) 0.89 (0.69-1.15) 0.96 (0.79-1.18) 0.87 (0.74-1.02) 
     
*Crude associations adjusted for age and study site 
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Table 7. Final model (n=2515) showing adjusted odds (95% confidence interval) of membership in LCA-derived sleep subgroups 
(vs. healthy sleepers, 43.42%) 
 
Subjective and 
objective 
disturbances 
(8.87%) 
Objective 
disturbances 
(8.51%) 
Subjective 
disturbances 
only (11.89%) 
Early 
awakenings only 
(25.57%) 
Age (per SD) 1.05 (0.98-1.12) 1.06 (0.99-1.12) 0.99 (0.93-1.04) 1.03 (0.98-1.08) 
     
Alcohol use per week:     
  1-13 drinks vs. <1 drink 0.88 (0.76-1.00) 1.13 (1.00-1.27) 0.81 (0.73-0.91) 0.98 (0.90-1.07) 
  14+ drinks vs. <1 drink 0.92 (0.68-1.25) 1.08 (0.82-1.40) 0.85 (0.66-1.08) 0.97 (0.80-1.17) 
     
Smoking Status:     
  Former vs. None 1.17 (1.02-1.34) 1.07 (0.95-1.21) 0.96 (0.86-1.07) 1.01 (0.92-1.10) 
  Current vs. None 1.11 (0.67-1.83) 2.21 (1.55-3.15) 1.17 (0.80-1.73) 0.95 (0.68-1.33) 
     
BMI (per SD) 1.15 (1.08-1.23) 1.26 (1.18-1.33) 1.01 (0.95-1.07) 1.00 (0.95-1.04) 
Anxiety symptoms (per SD) 1.56 (1.47-1.65) 1.04 (0.97-1.11) 1.55 (1.48-1.63) 1.16 (1.10-1.21) 
     
Chronic Disease History     
 IADL impairment (per additional) 1.20 (1.11-1.29) 1.06 (0.98-1.14) 1.03 (0.96-1.10) 1.00 (0.94-1.06) 
 Osteoarthritis 0.98 (0.84-1.14) 1.22 (1.07-1.40) 1.09 (0.96-1.23) 0.90 (0.81-1.00) 
 Congestive Heart Failure 1.42 (1.10-1.82) 1.46 (1.17-1.84) 1.03 (0.81-1.31) 1.14 (0.94-1.38) 
 Severe SDB (AHI ≥ 30) 1.18 (1.00-1.39) 1.36 (1.18-1.57) 0.97 (0.84-1.13) 1.00 (0.89-1.12) 
     
Medication Use     
 Antidepressant use 0.85 (0.67-1.08) 1.22 (0.99-1.51) 0.97 (0.81-1.18) 0.85 (0.72-1.01) 
 Non-benzodiazepine non-
barbiturate sedatives/hypnotics 2.19 (1.48-3.24) 1.29 (0.83-2.02) 2.38 (1.74-3.25) 1.09 (0.79-1.52) 
 Benzodiazepines use 1.22 (0.93-1.60) 0.82 (0.61-1.11) 1.30 (1.04-1.64) 0.83 (0.66-1.04) 
 Current NSAID use 1.30 (1.11-1.52) 0.99 (0.85-1.15) 1.22 (1.07-1.39) 1.11 (1.00-1.24) 
     
Inflammatory Markers     
 log(TNF-α + 1) 1.25 (0.99-1.59) 1.16 (0.94-1.44) 0.90 (0.74-1.09) 0.84 (0.71-0.98) 
     
Estimates also adjusted for study site 
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 Table 8. BIC for different number of latent classes using all 
CAR indicators 
 
Number of latent 
classes 
Log 
likelihood 
BIC Entropy 
1 -17800.07 9674.18 1.00 
2 -16407.27 6984.67 1.00 
3 -15482.09 5230.40 0.93 
4 -15142.20 4646.71 0.94 
5 -14435.54 3329.48 0.98 
6 -14219.98 2994.45 0.95 
7 -13860.36 2371.30 0.95 
8 -13596.55 1939.79 0.95 
 9* -13563.15 1969.07 0.91 
BOLD solution selected ; *=included non-distinct groups 
of <5% of the sample 
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Table 9. Descriptive characteristics of CAR latent classes, mean (SD) 
 Acrophase Up-mesor Down-mesor St. Amp. Mesor Amp. Pseudo-f Alpha 
Name of latent class         
Normal rhythm 14.29 (0.39) 6.71 (0.61) 21.86 (0.68) 1.78 (0.19) 2234.51 (329.52) 3953.75 (658.03) 1282.27 (495.09) -0.40 (0.12) 
Reduced activity 14.19 (0.53) 6.5 (0.8) 21.88 (0.79) 1.53 (0.29) 1688.58 (322.48) 2529.92 (450.64) 628.59 (227.38) -0.42 (0.14) 
Early activity 12.97 (0.55) 5.54 (0.79) 20.4 (0.73) 1.73 (0.23) 2237.79 (368.08) 3839.14 (703.04) 1163.29 (511.24) -0.36 (0.13) 
Late activity 15.66 (0.65) 7.88 (0.85) 23.44 (0.85) 1.75 (0.18) 2213.97 (304.36) 3868.43 (642.66) 1173.9 (411.5) -0.44 (0.14) 
Early activity with 
short active period 12.99 (0.65) 7.08 (0.83) 18.89 (1.16) 1.65 (0.26) 2606.41 (609.99) 4290.21 (1241.03) 1200.96 (501.88) 0.07 (0.29) 
Late rising with short 
active period 14.66 (0.72) 8.83 (1.15) 20.49 (1.12) 1.68 (0.33) 2511.47 (760.59) 4275.28 (1738.7) 1003.51 (515.46) 0.13 (0.34) 
Early, dampened 
rhythm with short 
active period 
12.71 (0.95) 6.82 (1.21) 18.6 (1.54) 1.22 (0.25) 1917.22 (398.34) 2296.71 (466.29) 576.59 (223.78) 0.03 (0.25) 
Late with reduced 
activity 15.99 (1.16) 8.3 (1.47) 23.68 (1.23) 1.46 (0.30) 1682.3 (315.54) 2429.83 (537.53) 584.5 (216.95) -0.41 (0.20) 
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Table 10. Pearson correlations of CAR parameters  
 Amplitude Mesor St. amplitude Pseudo F Up-mesor Acrophase Down-mesor Alpha 
Amplitude - 0.81 -0.16 0.56 0.05 -0.05 -0.10 0.26 
Mesor 0.81 - -0.41 0.44 0.11 -0.14 -0.26 0.43 
St. amplitude -0.16 -0.41 - 0.26 -0.31 0.31 0.62 -0.16 
Pseudo F 0.56 0.44 0.26 - -0.07 -0.04 -0.004* -0.08 
Up-mesor 0.05 0.11 -0.31 -0.07 - 0.68 0.20 0.43 
Acrophase -0.05 -0.14 -0.04 0.68 0.68 - 0.86 -0.31 
Down-mesor -0.10 -0.26 -0.004 -0.004* 0.20 0.86 - -0.71 
Alpha 0.26 0.43 -0.16 -0.08 0.43 -0.31 -0.71 - 
St. = standardized; all p values <0.05 unless noted with a * 
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Table 11. Latent classes of community-dwelling older men based on circadian rest-activity rhythm (CAR) indicators (n=3001) 
 
Group Name Probable Characteristics Prevalence (%) 
Normal rhythm All parameters normative 32.09 
Reduced activity Low height measures 10.06 
Early activity Early up-mesor/peak 10.53 
Late activity Late peak/down-mesor 14.46 
Early activity with short active period Early peak/down-mesor w/ high alpha 9.63 
Late rising with short active period Late up-mesor w/ high alpha 8.23 
Early, dampened rhythm with short active period Early peak/down-mesor, low st. amp and height, high alpha 6.80 
Late with reduced activity Late peak/down-mesor with low height measures 8.20 
Note: Prevalence in entire sample shown; prevalence for final subset with complete covariate data shown elsewhere 
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Table 12. Age and site adjusted odds of membership in LCA-derived CAR subgroups (vs. normal CAR, 32.18%) 
 Altered height Altered timing Altered timing and active period Altered timing and height 
 
Reduced activity 
(9.79%) 
Early activity 
(10.70%) 
Late activity 
(14.36%) 
Early activity 
with short active 
period (10.54%) 
Late rising with 
short active 
period (8.27%) 
Early, dampened 
rhythm with 
short active 
period (6.48%) 
Late with reduced 
activity (7.68%) 
        Age (per SD) 1.60 (1.41-1.82) 0.95 (0.82-1.09) 0.94 (0.83-1.06) 1.05 (0.92-1.21) 1.12 (0.97-1.30) 1.43 (1.23-1.66) 1.52 (1.32-1.75) 
Study Site (vs. PI):        
  BI 1.18 (0.74-1.89) 2.35 (1.41-3.92) 0.33 (0.22-0.50) 1.02 (0.66-1.60) 0.47 (0.28-0.77) 0.92 (0.56-1.52) 0.66 (0.41-1.07) 
  MN 1.03 (0.65-1.63) 1.72 (1.02-2.90) 0.49 (0.33-0.71) 0.91 (0.58-1.41) 0.55 (0.35-0.87) 0.49 (0.28-0.84) 0.61 (0.38-0.96) 
  PA 0.74 (0.46-1.21) 1.57 (0.91-2.71) 0.75 (0.52-1.07) 0.75 (0.47-1.20) 0.64 (0.40-1.01) 0.55 (0.32-0.94) 0.64 (0.40-1.01) 
  PO 1.15 (0.73-1.82) 1.50 (0.87-2.57) 0.46 (0.31-0.68) 0.53 (0.32-0.87) 0.43 (0.26-0.71) 0.45 (0.25-0.79) 0.41 (0.25-0.68) 
  SD 0.86 (0.54-1.38) 2.13 (1.29-3.54) 0.40 (0.27-0.59) 0.76 (0.48-1.19) 0.57 (0.36-0.89) 0.93 (0.58-1.49) 0.47 (0.29-0.76) 
Race:        
  Black vs. White 1.04 (0.46-2.32) 1.14 (0.57-2.29) 1.92 (1.06-3.47) 1.37 (0.68-2.76) 2.50 (1.28-4.90) 1.42 (0.60-3.35) 1.96 (0.95-4.05) 
  Other vs. White 1.50 (0.86-2.61) 1.05 (0.60-1.83) 1.31 (0.82-2.11) 1.13 (0.62-2.04) 1.77 (1.02-3.07) 1.02 (0.50-2.08) 1.59 (0.88-2.87) 
Alcohol use per week:        
  1-13 drinks vs. <1 drink 0.93 (0.71-1.23) 0.81 (0.62-1.06) 0.94 (0.74-1.2) 0.94 (0.71-1.25) 0.83 (0.62-1.13) 0.73 (0.53-1.02) 0.73 (0.55-0.99) 
  14+ drinks vs. <1 drink 0.78 (0.41-1.50) 1.12 (0.66-1.92) 0.86 (0.50-1.48) 1.45 (0.85-2.5) 1.51 (0.87-2.62) 1.10 (0.58-2.09) 0.33 (0.13-0.85) 
Daily caffeine intake (per SD) 0.97 (0.84-1.11) 1.10 (0.98-1.24) 0.97 (0.86-1.08) 1.02 (0.90-1.17) 0.94 (0.81-1.09) 0.81 (0.68-0.97) 0.94 (0.81-1.09) 
Education:        
  Less than high school vs.   
College/graduate school 1.3 (0.73-2.31) 1.35 (0.72-2.52) 0.54 (0.28-1.05) 1.84 (1.05-3.25) 1.88 (1.05-3.38) 1.23 (0.61-2.51) 1.63 (0.92-2.91) 
  High school diploma vs.      
College/graduate school 0.62 (0.40-0.94) 1.10 (0.75-1.59) 0.57 (0.40-0.82) 1.26 (0.87-1.81) 1.1 (0.74-1.63) 1.26 (0.83-1.91) 0.77 (0.50-1.17) 
Smoking Status:        
  Former vs. None 1.07 (0.82-1.40) 0.98 (0.75-1.28) 0.81 (0.64-1.02) 1.23 (0.93-1.62) 1.25 (0.93-1.68) 1.25 (0.91-1.72) 1.20 (0.89-1.61) 
  Current vs. None 1.59 (0.41-6.15) 2.70 (0.95-7.62) 2.87 (1.14-7.20) 4.45 (1.66-1.88) 2.97 (0.94-9.36) 2.48 (0.64-9.64) 7.83 (3.02-0.32) 
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BMI (per SD) 1.39 (1.21-1.59) 1.12 (0.97-1.28) 1.07 (0.94-1.21) 1.22 (1.06-1.41) 1.42 (1.23-1.64) 1.82 (1.57-2.11) 1.47 (1.27-1.70) 
Physical Activity (per SD) 0.60 (0.51-0.70) 1.12 (0.99-1.26) 0.80 (0.71-0.90) 0.96 (0.84-1.09) 0.81 (0.70-0.94) 0.61 (0.51-0.73) 0.44 (0.37-0.52) 
Cognitive function (per SD) 0.87 (0.76-0.99) 0.94 (0.81-1.08) 1.05 (0.91-1.20) 0.89 (0.77-1.02) 0.76 (0.67-0.87) 0.75 (0.66-0.87) 0.88 (0.76-1.02) 
Anxiety symptoms (per SD) 1.10 (0.97-1.26) 0.98 (0.85-1.13) 1.00 (0.88-1.13) 1.08 (0.95-1.24) 1.27 (1.12-1.44) 0.90 (0.76-1.08) 1.29 (1.13-1.46) 
Depressive symptoms (per SD) 1.41 (1.24-1.60) 1.07 (0.93-1.25) 1.10 (0.96-1.25) 1.06 (0.91-1.24) 1.39 (1.21-1.59) 1.31 (1.13-1.52) 1.60 (1.41-1.81) 
Worse global sleep quality (per SD) 1.24 (1.09-1.41) 1.03 (0.90-1.18) 1.08 (0.96-1.22) 1.12 (0.98-1.29) 1.39 (1.21-1.59) 1.24 (1.06-1.44) 1.42 (1.24-1.62) 
Daytime sleepiness (per SD) 1.07 (0.94-1.22) 0.98 (0.86-1.12) 1.01 (0.90-1.13) 0.98 (0.86-1.12) 0.95 (0.83-1.10) 1.10 (0.94-1.27) 1.16 (1.01-1.34) 
        
Chronic Disease History        
 IADL impairment (per additional) 1.72 (1.45-2.04) 1.37 (1.12-1.67) 1.40 (1.17-1.68) 1.16 (0.93-1.45) 1.9 (1.60-2.27) 1.80 (1.49-2.17) 2.22 (1.88-2.62) 
 Fall in past 12 months 1.34 (1.01-1.77) 1.03 (0.77-1.37) 1.37 (1.07-1.75) 0.94 (0.69-1.27) 1.54 (1.15-2.08) 1.16 (0.83-1.62) 1.64 (1.22-2.21) 
 Peripheral vascular disease 1.38 (0.91-2.10) 0.82 (0.49-1.35) 1.11 (0.74-1.67) 1.44 (0.93-2.21) 1.51 (0.96-2.36) 1.27 (0.77-2.09) 1.65 (1.07-2.54) 
 Osteoarthritis 1.14 (0.84-1.55) 1.01 (0.75-1.37) 1.08 (0.83-1.42) 0.79 (0.57-1.10) 1.41 (1.03-1.93) 1.09 (0.76-1.56) 1.39 (1.01-1.91) 
 Rheumatoid Arthritis 1.18 (0.71-1.95) 1.08 (0.64-1.80) 1.60 (1.05-2.43) 1.28 (0.78-2.12) 1.61 (0.98-2.65) 1.65 (0.97-2.78) 2.17 (1.37-3.44) 
 Hypertension 1.25 (0.96-1.62) 1.12 (0.87-1.44) 1.03 (0.82-1.29) 1.35 (1.04-1.76) 1.56 (1.18-2.07) 2.23 (1.62-3.06) 1.53 (1.15-2.04) 
 Stroke 1.15 (0.54-2.45) 1.55 (0.78-3.09) 1.19 (0.59-2.39) 1.18 (0.54-2.57) 2.74 (1.43-5.24) 1.84 (0.86-3.93) 2.31 (1.19-4.49) 
 Angina 1.35 (0.95-1.93) 1.27 (0.89-1.82) 1.10 (0.79-1.54) 0.99 (0.67-1.47) 1.58 (1.09-2.29) 1.49 (1.00-2.23) 1.53 (1.06-2.22) 
 Congestive Heart Failure 2.27 (1.36-3.80) 1.34 (0.73-2.44) 1.15 (0.65-2.02) 1.70 (0.96-3.01) 1.55 (0.83-2.87) 2.38 (1.33-4.25) 2.71 (1.60-4.59) 
 Myocardial Infarction 1.16 (0.83-1.61) 0.95 (0.66-1.35) 0.64 (0.45-0.91) 0.89 (0.62-1.29) 1.76 (1.26-2.46) 1.11 (0.75-1.64) 1.42 (1.01-2.01) 
 Diabetes 1.60 (1.11-2.30) 0.75 (0.48-1.16) 1.05 (0.74-1.48) 1.14 (0.77-1.69) 1.37 (0.92-2.04) 1.73 (1.15-2.61) 1.70 (1.16-2.51) 
 COPD 2.78 (1.63-4.75) 1.92 (1.08-3.42) 1.37 (0.78-2.42) 1.05 (0.52-2.11) 1.84 (0.99-3.42) 1.75 (0.90-3.40) 1.95 (1.06-3.60) 
 Parkinson's 3.40 (1.17-9.88) undefined 0.70 (0.14-3.38) undefined 3.13 (0.98-10.01) 5.33 (1.82-5.56) 5.05 (1.79-4.27) 
 Renal disease  5.30 (1.30-1.50) 4.05 (0.90-8.28) 4.26 (1.01-8.00) 2.22 (0.37-3.41) 8.18 (2.02-33.14) 5.73 (1.26-6.03) 3.5 (0.70-7.64) 
 Cataracts 1.17 (0.90-1.54) 0.96 (0.74-1.26) 1.06 (0.84-1.35) 1.15 (0.88-1.52) 1.17 (0.87-1.56) 1.30 (0.95-1.79) 1.15 (0.86-1.54) 
 Liver disease 0.34 (0.08-1.47) 0.82 (0.33-2.05) 1.20 (0.58-2.46) 1.44 (0.65-3.18) 0.55 (0.16-1.87) 0.74 (0.22-2.51) 0.62 (0.18-2.10) 
 Severe SDB (AHI ≥ 30) 1.65 (1.17-2.33) 0.86 (0.58-1.29) 1.11 (0.80-1.55) 1.16 (0.80-1.68) 1.40 (0.97-2.04) 1.75 (1.19-2.56) 1.86 (1.3-2.67) 
        
Table 12 continued 
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Medication Use        
 Antidepressant use 1.54 (0.93-2.56) 1.21 (0.71-2.04) 1.93 (1.26-2.97) 1.08 (0.61-1.90) 1.79 (1.06-3.01) 1.85 (1.06-3.21) 3.64 (2.33-5.68) 
 Non-benzodiazepine non-
barbiturate sedatives/hypnotics 1.17 (0.5-2.72) 0.85 (0.34-2.15) 1.41 (0.66-2.99) 0.16 (0.02-1.21) 0.63 (0.19-2.16) 0.91 (0.31-2.72) 1.37 (0.56-3.31) 
 Benzodiazepines use 1.19 (0.60-2.36) 0.87 (0.42-1.81) 1.80 (1.03-3.14) 0.78 (0.35-1.71) 2.25 (1.22-4.15) 1.38 (0.66-2.88) 2.90 (1.63-5.15) 
 Current NSAID use 1.03 (0.74-1.43) 1.13 (0.82-1.54) 0.96 (0.72-1.28) 0.93 (0.67-1.30) 0.99 (0.70-1.41) 0.64 (0.42-0.98) 1.01 (0.71-1.44) 
 Current corticosteroid use 
(oral/nasal/inhaled) 1.62 (1.07-2.46) 0.99 (0.62-1.58) 1.36 (0.93-2.00) 0.94 (0.57-1.54) 0.99 (0.59-1.66) 1.06 (0.61-1.84) 1.81 (1.17-2.81) 
        
Inflammatory Markers        
 log(IL-6 + 1) 1.82 (1.33-2.48) 1.16 (0.81-1.67) 1.42 (1.04-1.92) 1.36 (0.96-1.92) 1.76 (1.26-2.46) 2.33 (1.69-3.20) 2.15 (1.58-2.93) 
 log(CRP + 1) 1.64 (1.31-2.04) 1.32 (1.05-1.64) 1.31 (1.07-1.61) 1.50 (1.20-1.87) 1.57 (1.24-1.99) 1.77 (1.38-2.28) 1.96 (1.56-2.47) 
 log(TNF-α + 1) 1.90 (1.11-3.25) 2.13 (1.28-3.56) 1.98 (1.24-3.16) 1.60 (0.93-2.74) 1.39 (0.78-2.49) 2.01 (1.06-3.78) 2.39 (1.35-4.25) 
 log(TNF-αsRII + 1) 2.81 (1.85-4.26) 1.81 (1.20-2.73) 1.74 (1.19-2.53) 1.63 (1.07-2.50) 2.23 (1.42-3.50) 2.17 (1.33-3.55) 2.49 (1.58-3.92) 
 log(IFN-γ + 1) 1.10 (0.87-1.40) 1.05 (0.84-1.33) 1.17 (0.95-1.44) 0.93 (0.72-1.19) 1.10 (0.85-1.42) 0.97 (0.72-1.29) 1.16 (0.90-1.50) 
*Crude associations adjusted for age and study site 
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Table 13. Final model (n=2514) showing adjusted odds (95% confidence interval) of membership in LCA-derived CAR subgroups (vs. normal CAR, 32.18%) 
 Altered height Altered timing Altered timing and active period Altered timing and height 
 
Reduced activity 
(9.79%) 
Early activity 
(10.70%) 
Late activity 
(14.36%) 
Early activity 
with short active 
period (10.54%) 
Late rising with 
short active 
period (8.27%) 
Early, 
dampened 
rhythm with 
short active 
period (6.48%) 
Late with reduced 
activity (7.68%) 
        Age (per SD) 1.39 (1.17-1.66) 0.92 (0.77-1.09) 0.88 (0.76-1.03) 1.07 (0.90-1.26) 1.00 (0.82-1.23) 1.37 (1.12-1.68) 1.17 (0.97-1.42) 
        
Alcohol use per week:        
  1-13 drinks vs. <1 drink 0.84 (0.60-1.17) 0.83 (0.61-1.14) 0.94 (0.71-1.24) 1.03 (0.75-1.41) 0.84 (0.57-1.24) 0.60 (0.47-1.03) 0.72 (0.50-1.03) 
  14+ drinks vs. <1 drink 0.68 (0.28-1.62) 1.52 (0.81-2.85) 1.25 (0.67-2.31) 1.93 (1.03-3.59) 2.38 (1.19-4.75) 1.01 (0.42-2.42) 0.21 (0.05-0.93) 
        
Education:        
  Less than high school vs.   
College/graduate school 0.73 (0.35-1.51) 1.12 (0.53-2.37) 0.33 (0.15-0.75) 1.31 (0.68-2.53) 1.23 (0.60-2.53) 0.73 (0.33-1.62) 0.71 (0.32-1.57) 
  High school diploma vs.      
College/graduate school 0.57 (0.35-0.95) 1.20 (0.78-1.84) 0.49 (0.32-0.74) 1.18 (0.79-1.78) 0.74 (0.44-1.25) 0.92 (0.55-1.51) 0.61 (0.36-1.02) 
        
Smoking Status:        
  Former vs. None 0.92 (0.66-1.28) 0.99 (0.72-1.34) 0.76 (0.58-1.00) 1.20 (0.88-1.63) 1.09 (0.75-1.59) 1.11 (0.76-1.62) 1.21 (0.84-1.75) 
  Current vs. None 0.93 (0.15-5.78) 2.35 (0.74-7.49) 2.59 (0.92-7.29) 3.76 (1.3-10.87) 1.41 (0.28-7.19) 2.02 (0.38-10.4) 5.12 (1.49-17.56) 
        
BMI (per SD) 1.31 (1.10-1.56) 0.98 (0.82-1.16) 1.06 (0.91-1.23) 1.13 (0.96-1.33) 1.29 (1.06-1.56) 1.69 (1.40-2.03) 1.27 (1.05-1.53) 
Physical Activity (per SD) 0.57 (0.47-0.69) 1.18 (1.02-1.37) 0.79 (0.68-0.91) 0.99 (0.85-1.16) 0.89 (0.74-1.07) 0.66 (0.53-0.81) 0.50 (0.40-0.62) 
Cognitive function (per SD) 0.88 (0.74-1.04) 1.01 (0.85-1.20) 1.01 (0.86-1.19) 0.95 (0.80-1.12) 0.80 (0.67-0.95) 0.81 (0.68-0.97) 1.01 (0.83-1.22) 
Anxiety symptoms (per SD) 0.95 (0.80-1.12) 0.95 (0.80-1.11) 0.95 (0.82-1.10) 1.06 (0.91-1.22) 1.15 (0.99-1.35) 0.83 (0.68-1.02) 1.12 (0.96-1.31) 
        
Chronic Disease History        
 IADL impairment (per additional) 1.59 (1.26-1.99) 1.49 (1.16-1.91) 1.35 (1.07-1.70) 1.01 (0.77-1.34) 1.79 (1.41-2.28) 1.40 (1.09-1.81) 1.94 (1.56-2.40) 
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 Hypertension 0.93 (0.68-1.29) 1.09 (0.80-1.47) 0.98 (0.74-1.28) 1.26 (0.94-1.70) 1.30 (0.90-1.88) 1.66 (1.14-2.43) 1.10 (0.77-1.57) 
 CHF 2.03 (1.07-3.85) 1.45 (0.72-2.92) 1.12 (0.55-2.29) 1.52 (0.79-2.91) 0.69 (0.27-1.80) 1.63 (0.76-3.44) 1.41 (0.67-2.95) 
 Myocardial Infarction 0.96 (0.63-1.46) 0.86 (0.57-1.30) 0.62 (0.42-0.93) 0.85 (0.57-1.28) 1.69 (1.11-2.58) 0.82 (0.51-1.34) 1.02 (0.66-1.58) 
 COPD 2.47 (1.30-4.70) 1.56 (0.78-3.10) 1.42 (0.75-2.72) 0.74 (0.33-1.64) 1.31 (0.60-2.84) 1.39 (0.62-3.10) 1.29 (0.60-2.78) 
        
Inflammatory Markers        
 log(CRP + 1) 1.47 (1.13-1.90) 1.17 (0.91-1.51) 1.21 (0.96-1.51) 1.38 (1.09-1.75) 1.42 (1.07-1.88) 1.47 (1.10-1.96) 1.61 (1.23-2.10) 
 log(TNF-α + 1) 1.22 (0.66-2.26) 1.86 (1.07-3.26) 1.79 (1.08-2.95) 1.25 (0.70-2.20) 0.82 (0.40-1.66) 1.22 (0.60-2.48) 1.48 (0.77-2.84) 
Estimates also adjusted for study site 
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Table 14. The item pool selected from to achieve the final depression LCA 
 
 
GDS 
only 
GDS 
reduced 
GDAS 
only 
Combined 
Depression 
Geriatric Depression Scale (GDS) 
    Are you basically satisfied with your life? x 
   Have you dropped many of your activities and interests? x x 
 
x 
Do you feel that your life is empty? x x 
 
x 
Do you often get bored? x 
   Are you in good spirits most of the time? x x 
  Are you afraid that something bad is going to happen to you? x 
   Do you feel happy most of the time? x 
   Do you often feel helpless? x x 
 
x 
Do you prefer to stay at home, rather than going out and doing new 
things? x x 
 
x 
Do you feel you have more problems with memory than most? x x 
 
x 
Do you think it is wonderful to be alive now? x 
   Do you feel pretty worthless the way you are now? x x 
 
x 
Do you feel full of energy? x x 
  Do you feel that your situation is hopeless? x x 
  Do you think that most people are better off than you are? x 
   
     Goldberg Depression and Anxiety Scale (GDAS) 
    Have you been lacking in energy? 
  
x x 
Have you lost interest in things? 
  
x x 
Have you lost confidence in yourself? 
  
x x 
Have you felt hopeless? 
  
x x 
Have you had difficulty concentrating? 
  
x x 
Have you lost weight (due to poor appetite)? 
  
x x 
Have you been waking early? 
    Have you felt slowed up? 
  
x x 
Have you tended to feel worse in the morning? 
  
x x 
Have you felt keyed up or on edge? 
    Have you been worrying a lot? 
    Have you been irritable? 
  
x x 
Have you had difficulty relaxing? 
    Have you been sleeping poorly? 
    Have you had headaches or neckaches? 
    Have you had any of the following: trembling, tingling, dizzy spells, 
sweating, diarrhoea, or needing to pass water more often than usual? 
    Have you been worrying about your health? 
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Have you had difficulty falling asleep? 
    
     Additional Depression Items 
    
How much of the time during the past 4 weeks have you felt 
downhearted and blue? (A good bit of the time/most of the time/all of 
the time vs. some of the time/a little of the time/none of the time) 
   
x 
During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities because of any 
emotional problems (such as feeling depressed or anxious) 
    ... Accomplished less than you would like? 
   
x 
… Didn't do work or other activities as carefully as usual?       x 
Table 14 continued 
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Table 15. BIC for different number of latent classes using 
all depression indicators 
Number of latent 
classes 
Log 
likelihood 
BIC Entropy 
1 -19814.24 12503.40 1.00 
2 -16944.18  6915.41 0.86 
3 -16274.09  5727.36 0.83 
4 -16141.24  5613.80 0.85 
5 -16059.53  5602.52 0.83 
6 -15999.99  5635.57 0.85 
BOLD solution selected  
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Table 16. Descriptive mood characteristics of depression latent classes 
Name of latent class Mean GDS (SD) Mean GAS (SD) Percent with impairment* 
Not depressed 0.62 (0.81) 0.32 (0.91) 1.37 (22) 
Probable somatic/apathy 2.18 (1.30) 1.00 (1.78) 2.03 (17) 
Probable somatic/apathy 
with impairment 2.25 (1.56) 1.78 (2.20) 100 (215) 
Apathy/somatic with 
probable impairment  4.23 (1.78) 3.00 (2.73) 63.68 (128) 
Depressed 8.40 (2.38) 4.40 (2.74) 87.23 (123) 
* Accomplished less than you would like due to emotional issue at least “a good 
bit of the time” over the past two weeks 
82 
Table 17. Age and site adjusted odds of membership in LCA-derived depression subgroups (vs. non-depressed, 53.86%) 
 
Depressed 
 
 
(4.25%) 
Apathy/somatic 
w/ probable 
impairment 
 (8.45%) 
Probable 
somatic/apathy 
w/ impairment 
(5.74%) 
Probable 
somatic/apathy  
 
(27.70%) 
Age (per SD) 1.55 (1.30-1.84) 1.63 (1.4-1.89) 1.45 (1.25-1.67) 1.53 (1.41-1.68) 
     
Study Site (vs. PI):     
  BI 0.73 (0.41-1.30) 1.58 (1.00-2.51) 0.99 (0.61-1.63) 0.93 (0.70-1.25) 
  MN 0.52 (0.29-0.91) 0.54 (0.32-0.91) 0.55 (0.33-0.93) 0.61 (0.46-0.81) 
  PA 0.37 (0.20-0.69) 0.48 (0.28-0.82) 0.85 (0.53-1.37) 0.58 (0.43-0.77) 
  PO 0.66 (0.38-1.16) 0.87 (0.53-1.43) 0.93 (0.57-1.51) 0.54 (0.40-0.74) 
  SD 0.62 (0.36-1.07) 0.43 (0.24-0.75) 0.64 (0.39-1.06) 0.69 (0.52-0.91) 
     
Race:     
  Black vs. White 1.84 (0.81-4.21) 1.99 (1.04-3.80) 1.26 (0.58-2.72) 1.25 (0.79-1.99) 
  Other vs. White 0.99 (0.44-2.23) 1.37 (0.71-2.61) 1.03 (0.57-1.88) 1.01 (0.70-1.47) 
     
Alcohol use per week:     
  1-13 drinks vs. <1 drink 0.91 (0.63-1.32) 0.62 (0.45-0.85) 0.74 (0.54-1.00) 0.77 (0.64-0.92) 
  14+ drinks vs. <1 drink 0.86 (0.40-1.87) 0.57 (0.28-1.17) 0.60 (0.30-1.19) 0.64 (0.43-0.95) 
Daily caffeine intake (per SD) 0.91 (0.75-1.10) 0.96 (0.82-1.13) 1.11 (0.96-1.27) 1.01 (0.93-1.11) 
     
Education:     
  Less than high school vs.   
College/graduate school 2.77 (1.50-5.12) 1.56 (0.82-2.97) 1.67 (0.89-3.11) 1.75 (1.18-2.58) 
  High school diploma vs.      
College/graduate school 1.08 (0.65-1.79) 1.51 (1.02-2.25) 1.12 (0.73-1.71) 1.23 (0.96-1.57) 
     
Smoking Status:     
  Former vs. None 1.39 (0.96-2.01) 1.5 (1.09-2.06) 1.02 (0.76-1.37) 1.18 (0.99-1.41) 
  Current vs. None 4.15 (1.70-10.15) 1.69 (0.57-5.03) 1.55 (0.58-4.14) 1.14 (0.58-2.24) 
     
BMI (per SD) 1.16 (0.97-1.38) 1.19 (1.03-1.39) 1.28 (1.11-1.48) 1.20 (1.10-1.32) 
Physical Activity (per SD) 0.45 (0.37-0.56) 0.6 (0.50-0.71) 0.79 (0.68-0.92) 0.72 (0.66-0.79) 
Cognitive function (per SD) 0.67 (0.58-0.77) 0.79 (0.68-0.90) 0.9 (0.77-1.05) 0.85 (0.77-0.93) 
Anxiety symptoms (per SD) 6.86 (5.69-8.28) 4.74 (4.01-5.62) 3.38 (2.85-4.00) 2.38 (2.06-2.75) 
Worse global sleep quality (per SD) 3.59 (3.04-4.25) 2.99 (2.58-3.48) 2.36 (2.03-2.74) 1.97 (1.78-2.18) 
Daytime sleepiness (per SD) 1.87 (1.59-2.21) 2.11 (1.83-2.43) 1.25 (1.08-1.45) 1.39 (1.27-1.52) 
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WASO ≥ 90 minutes 1.28 (0.88-1.85) 2.08 (1.54-2.82) 1.66 (1.23-2.24) 1.48 (1.23-1.77) 
SL ≥ 60 minutes 2.54 (1.59-4.05) 2.60 (1.72-3.92) 1.47 (0.92-2.34) 1.54 (1.16-2.05) 
     
Sleep duration     
  <5 vs. 5-8 hours 1.43 (0.86-2.38) 2.18 (1.47-3.25) 1.34 (0.86-2.10) 1.62 (1.25-2.09) 
  >8 vs. 5-8 hours 1.08 (0.56-2.09) 1.11 (0.64-1.95) 1.11 (0.65-1.88) 0.91 (0.65-1.28) 
     
Circadian Activity Rhythms     
 Low amplitude (Q1 vs. Q2-4) 2.22 (1.53-3.23) 2.40 (1.75-3.31) 1.52 (1.09-2.11) 1.92 (1.57-2.34) 
 Low mesor (Q1 vs. Q2-4) 2.17 (1.50-3.15) 1.76 (1.27-2.44) 1.28 (0.92-1.79) 1.62 (1.33-1.97) 
 Low st. amplitude (Q1 vs. Q2-4) 1.36 (0.93-2.00) 1.23 (0.88-1.72) 1.21 (0.87-1.68) 1.29 (1.06-1.57) 
 Low psuedo-F (Q1 vs. Q2-4) 2.83 (1.96-4.07) 2.31 (1.68-3.20) 1.88 (1.37-2.60) 1.70 (1.39-2.08) 
 Acrophase      
   Early (Q1 vs. Q2/3) 0.81 (0.51-1.30) 0.66 (0.45-0.98) 0.77 (0.53-1.12) 0.84 (0.68-1.03) 
   Late (Q4 vs. Q2/3) 2.12 (1.43-3.14) 1.53 (1.08-2.16) 1.59 (1.13-2.22) 1.21 (0.98-1.50) 
 Up-mesor     
   Early (Q1 vs. Q2/3) 0.71 (0.44-1.14) 0.81 (0.56-1.19) 0.86 (0.59-1.24) 0.75 (0.61-0.93) 
   Late (Q4 vs. Q2/3) 1.81 (1.21-2.68) 1.60 (1.12-2.27) 1.75 (1.25-2.45) 1.25 (1.02-1.55) 
 Down-mesor     
   Early (Q1 vs. Q2/3) 1.23 (0.79-1.92) 0.66 (0.44-0.98) 1.00 (0.70-1.43) 0.99 (0.81-1.22) 
   Late (Q4 vs. Q2/3) 2.06 (1.37-3.09) 1.16 (0.81-1.65) 1.36 (0.97-1.92) 1.16 (0.94-1.43) 
     
Chronic Disease History     
 IADL impairment (per additional) 3.21 (2.69-3.84) 2.75 (2.32-3.26) 2.09 (1.73-2.53) 2.12 (1.84-2.44) 
 Fall in past 12 months 3.64 (2.56-5.19) 2.51 (1.85-3.41) 1.50 (1.10-2.04) 1.71 (1.42-2.06) 
 Peripheral vascular disease 2.43 (1.47-4.01) 2.88 (1.88-4.40) 2.55 (1.66-3.91) 1.91 (1.43-2.56) 
 Osteoarthritis 3.23 (2.25-4.65) 2.83 (2.06-3.89) 1.88 (1.36-2.60) 1.60 (1.31-1.97) 
 Rheumatoid Arthritis 3.63 (2.23-5.92) 2.97 (1.90-4.65) 1.38 (0.79-2.41) 1.98 (1.44-2.72) 
 Hypertension 1.50 (1.06-2.13) 1.62 (1.20-2.19) 1.01 (0.76-1.34) 1.45 (1.22-1.73) 
 Stroke 3.62 (1.73-7.59) 3.24 (1.68-6.24) 2.72 (1.37-5.38) 2.34 (1.46-3.77) 
 Angina 2.49 (1.65-3.74) 2.06 (1.43-2.97) 1.45 (0.99-2.14) 1.51 (1.19-1.92) 
 Congestive Heart Failure 2.29 (1.26-4.14) 2.48 (1.49-4.14) 1.78 (1.02-3.10) 1.36 (0.94-1.97) 
 Myocardial Infarction 1.75 (1.15-2.66) 1.72 (1.20-2.47) 1.16 (0.78-1.71) 1.64 (1.31-2.05) 
 Diabetes 1.69 (1.06-2.68) 1.39 (0.91-2.12) 1.16 (0.75-1.79) 1.56 (1.22-1.99) 
 COPD 4.17 (2.35-7.43) 2.67 (1.51-4.72) 1.59 (0.81-3.11) 2.19 (1.48-3.24) 
 Parkinson's 9.03 (2.49-2.76) 11.95 (4.02-5.62) 6.43 (1.92-1.47) 4.55 (1.71-2.15) 
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 Renal disease  2.67 (0.73-9.81) 1.15 (0.25-5.32) 1.78 (0.49-6.50) 2.11 (0.94-4.74) 
 Cataracts 1.79 (1.24-2.57) 1.32 (0.97-1.79) 1.02 (0.76-1.37) 1.39 (1.17-1.66) 
 Liver disease 1.80 (0.62-5.22) 0.61 (0.14-2.59) 1.88 (0.81-4.35) 1.17 (0.63-2.16) 
 Severe SDB (AHI ≥ 30) 1.61 (1.03-2.52) 1.68 (1.14-2.47) 1.54 (1.06-2.25) 1.55 (1.23-1.95) 
     
Medication Use     
 Antidepressant use 7.49 (4.72-1.88) 4.76 (3.05-7.44) 3.37 (2.10-5.42) 2.09 (1.47-2.96) 
 Non-benzodiazepine non-barbiturate 
sedatives /hypnotics 2.91 (0.95-8.85) 4.87 (2.20-0.78) 3.01 (1.22-7.40) 2.41 (1.25-4.64) 
 Benzodiazepines use 4.03 (2.17-7.51) 3.36 (1.92-5.91) 2.57 (1.39-4.72) 1.55 (0.99-2.43) 
 Current NSAID use 1.72 (1.15-2.57) 1.76 (1.25-2.47) 1.11 (0.77-1.60) 1.21 (0.97-1.50) 
 Current corticosteroid use 
(oral/nasal/inhaled) 2.14 (1.29-3.53) 1.21 (0.72-2.04) 1.38 (0.86-2.21) 1.41 (1.06-1.89) 
     
Inflammatory Markers     
 log(IL-6 + 1) 1.56 (1.08-2.24) 1.63 (1.20-2.22) 1.59 (1.17-2.15) 1.28 (1.04-1.57) 
 log(CRP + 1) 1.54 (1.16-2.03) 1.24 (0.97-1.60) 1.44 (1.14-1.82) 1.24 (1.07-1.43) 
 log(TNF-α + 1) 1.94 (0.96-3.93) 1.48 (0.80-2.74) 1.09 (0.60-1.99) 1.43 (1.01-2.02) 
 log(TNF-αsRII + 1) 2.49 (1.44-4.33) 1.62 (1.00-2.62) 1.42 (0.88-2.28) 2.16 (1.64-2.84) 
 log(IFN-γ + 1) 0.85 (0.60-1.20) 0.99 (0.75-1.32) 1.20 (0.94-1.55) 0.95 (0.81-1.11) 
     
*Crude associations adjusted for age and study site 
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Table 18. Final model (n=2473) showing adjusted odds (95% confidence interval) of membership in LCA-derived depression 
subgroups (vs. non-depressed reference group, 53.86%) 
 
Depressed 
 
 
(4.25%) 
Apathy/somatic 
w/ probable 
impairment 
 (8.45%) 
Probable 
somatic/apathy 
w/ impairment 
(5.74%) 
Probable 
somatic/apathy  
 
(27.70%) 
Age (per SD) 1.08 (0.97-1.20) 1.18 (1.10-1.27) 1.08 (0.97-1.20) 1.14 (1.09-1.19) 
Physical Activity (per SD) 0.77 (0.69-0.86) 0.91 (0.85-0.98) 0.99 (0.92-1.08) 0.94 (0.90-0.98) 
Anxiety symptoms (per SD) 2.13 (1.97-2.30) 1.56 (1.47-1.66) 1.32 (1.22-1.42) 1.10 (1.05-1.15) 
Worse global sleep quality (per SD) 1.18 (1.07-1.30) 1.31 (1.22-1.40) 1.21 (1.11-1.31) 1.22 (1.17-1.27) 
Daytime sleepiness (per SD) 1.16 (1.06-1.28) 1.30 (1.22-1.39) 1.04 (0.96-1.12) 1.10 (1.06-1.15) 
     
Circadian Activity Rhythms     
 Low amplitude (Q1 vs. Q2-4) 1.16 (0.92-1.44) 1.32 (1.13-1.53) 1.14 (0.95-1.37) 1.19 (1.08-1.31) 
 Up-mesor     
   Early (Q1 vs. Q2/3) 0.92 (0.72-1.18) 0.82 (0.69-0.96) 0.92 (0.77-1.11) 0.88 (0.80-0.97) 
   Late (Q4 vs. Q2/3) 0.93 (0.74-1.18) 0.99 (0.85-1.17) 1.18 (0.98-1.42) 0.96 (0.87-1.06) 
 Down-mesor     
   Early (Q1 vs. Q2/3) 1.25 (0.99-1.59) 0.76 (0.65-0.90) 0.92 (0.77-1.11) 0.94 (0.86-1.04) 
   Late (Q4 vs. Q2/3) 1.46 (1.15-1.84) 0.94 (0.79-1.11) 1.08 (0.90-1.30) 1.01 (0.91-1.11) 
     
Chronic Disease History     
 IADL impairment (per additional) 1.12 (1.00-1.24) 1.12 (1.03-1.21) 1.05 (0.95-1.16) 1.09 (1.04-1.16) 
 Fall in past 12 months 1.33 (1.09-1.63) 1.18 (1.02-1.35) 1.06 (0.90-1.25) 1.12 (1.03-1.22) 
 Peripheral vascular disease 1.07 (0.80-1.43) 1.36 (1.11-1.65) 1.39 (1.10-1.76) 1.18 (1.04-1.35) 
 Rheumatoid Arthritis 1.48 (1.12-1.97) 1.28 (1.03-1.60) 0.82 (0.60-1.11) 1.13 (0.98-1.31) 
 Stroke 1.57 (1.03-2.39) 1.30 (0.95-1.78) 1.11 (0.74-1.65) 1.28 (1.04-1.57) 
 COPD 1.57 (1.11-2.21) 0.95 (0.71-1.27) 1.06 (0.75-1.48) 1.25 (1.05-1.48) 
 Cataracts 1.06 (0.87-1.29) 0.93 (0.81-1.06) 0.86 (0.73-1.00) 1.07 (0.99-1.16) 
     
Inflammatory Markers     
 log(CRP + 1) 1.10 (0.95-1.27) 1.01 (0.91-1.12) 1.16 (1.03-1.31) 0.97 (0.94-1.06) 
 log(TNF-αsRII + 1) 1.07 (0.81-1.43) 1.03 (0.84-1.25) 0.92 (0.73-1.16) 1.26 (1.12-1.42) 
     
Estimates also adjusted for study site 
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Figure 2. Final LCA model of sleep variables 
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 Figure 3. Final LCA model with CAR parameters 
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 Figure 4. Final LCA model with combined depression items 
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3.0  LATENT PREDICTORS OF FUTURE CHANGE IN DEPRESSIVE SYMPTOMS 
AMONG OLDER MEN 
In this chapter we examine the relationships between the sleep, CAR, and depressive 
syndromes (identified in Chapter Two) with future change in overall depression severity. We 
found that sleep and depressive syndromes were not associated with future levels or change in 
depressive syndromes. CAR latent classes were independently related to faster rates of change in 
depressive symptoms overall. Having reduced activity alone was related to faster increases in 
depressive symptoms, but this relationship was attenuated after covariate adjustment. CAR 
configurations with later activity, or early activity combined with dampened rhythm and a 
shortened activity period, were independently related to future increases in depressive symptoms. 
These associations were independent of, but similar in magnitude to known risk factors, which 
were also identified in our analysis and included diabetes, a past year fall, and Parkinson’s 
disease. Future research is needed to understand the biological, psychological, and social 
rhythms and mechanisms related to these novel CAR markers of depression risk.    
3.1 INTRODUCTION 
Sleep problems have been empirically linked to depression incidence for about 25 years 
[13]. Arguably one of the most physiologically central of all normal human behaviors, sleep may 
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be linked to depression development through a wide range of related, multifaceted processes. 
Problems with sleep are included one of nine symptoms of major depressive disorder (MDD) 
[15]. Potentially relevant characteristics include the patterning, timing, latency, duration, 
fragmentation, quality, and electrophysiology of sleep. Because sleep can be a part of and risk 
factor for depression, understanding the specific aspects involved is both an important scientific 
and public health priority that can lead to targeted prevention interventions.  
These fundamental issues could have the greatest impact among older adults, not only 
because older adults are a fast growing segment of the population [8], but because they 
experience sleep problems more often than younger adults [174, 175]. Several studies have 
demonstrated that among older adults, subjective sleep problems are correlated with incident 
depressive syndromes ([106, 107, 176-178]). While these studies reliably demonstrate 
associations between subjectively assessed (self-reported) sleep disturbances and future 
depression, few reports on the contribution of objectively measured sleep characteristics are 
available. 
In the MrOS Sleep Study, Paudel et al. [107] found that subjective, but not objective, 
sleep disturbances were associated with future increases in depressive symptoms. In the prior 
chapter, we determined that subjective and objective disturbances often co-segregate, and we 
now assess whether these groupings are associated with future changes in depressive symptoms. 
Based on prior evidence, we hypothesize that subjective, but not objective disturbances will be 
associated with a faster increases in overall depression severity (reflected as the total scores on 
the GDS).   
We recently found that above and beyond the influence of subjective sleep disturbances, 
the robustness of daily rest-activity patterns (the CAR) is associated with future increases in 
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depressive symptoms among MrOS Sleep Study men. This prior analysis, however, was limited 
by a relatively short (1.2 year) average follow-up period [179]. Furthermore, in our previous 
work we simply examined the association of individual CAR disturbances with future 
depression, and we did not assess how specific within-person combinations of CAR 
characteristics might relate to depression development. We therefore now utilized the CAR 
groupings from the prior chapter to assess how configurations of CAR disturbances relate to 
future change in depression severity.  
Finally, the question of how pre-existing syndromes or configurations of symptomology 
relate to depression development spans beyond the sleep health domain. Contemporary MDD 
criteria reserves diagnoses for severe cases of depression, but does not directly classify clinically 
meaningful within disorder heterogeneity. The previous chapter demonstrates that, although 
depressive syndromes clearly vary by symptom burden, individuals with the same symptom 
count may have different syndromes characterized by distinct symptom patterns (including the 
presence or absence of psychological symptoms and impairment). Whether these syndromes are 
linked to future worsening depression severity is unknown. We therefore assess whether 
commonly occurring depression syndromes are associated with a faster rate of future increases in 
depression symptoms overall. This may help determine whether mild syndromes characterized 
by somatic/apathy symptoms are developmental intermediates along the pathway to severe 
depression.  
To assess whether any associations between sleep, CAR, and depression syndromes with 
future depression are independent of known risk factors, we include a range of covariates 
previously implicated in the pathogenesis of late-life depression (LLD) spanning from biological 
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to the social, including chronic diseases, inflammatory markers, disability, stressful life events, 
and social support. 
3.2 METHODS 
3.2.1 Participants 
The analytic sample is restricted to the MrOS Sleep Study (2003-2005) men described 
via LCA in Chapter 2 (n=3001). Three follow-up questionnaires were administered in: March 
2005-May 2006, March 2007-March 2009, and March 2009-April 2011. Retention was high and 
complete outcome (GDS) data was available from 99.9%, 97.3%, 88.90%, and 79.37% of 
baseline participants, respectively. We required participants to have at least complete outcome 
data at baseline and one other time-point; n=68 failed to meet this criteria and the total 
unadjusted model therefore included 2933 men. Excluded men tended to be in a latent sleep sub-
group characterized by subjective sleep disturbances (Chi-square value = 14.26, df = 4, 
p=0.007), and they also differed by CAR group (Chi-square value = 17.98, df = 7, p=0.01), and 
drop-outs appeared to more often have low height or a compressed active period. Men with 
insufficient longitudinal outcome data did not differ on the basis of their initial LCA depression 
sub-group (Chi-square value = 5.51 df = 4, p=0.24). Men excluded due to insufficient outcome 
data also tended to have higher prevalence of certain chronic diseases (i.e. diabetes: Chi-square 
value=4.81, df=1, p=0.03), past year falls (Chi-square value=8.47, df=1, p=0.004) and were 
older (mean age 79.54 (6.38 sd) vs. 76.28 (5.48 sd), p<0.0001). No differences in drop-out by 
race or education were detected.  
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3.2.2 Measures 
3.2.2.1 Primary predictors expressed as individual variables:  
When LCA-derived sub-groups were not associated with depression over time, the 
relevant indicators were modeled as individual variables. Subjective sleep was expressed 
continuous variable reflecting global sleep quality measured with the Pittsburgh Sleep Quality 
Index (PSQI) [160] (range 0-21). The self-reported Epworth Sleepiness Scale (ESS) was 
expressed as a continuous measure of excessive daytime sleepiness ranging from 0 – 24. 
Objectively assessed variables (including CARs) were expressed exactly as the indicators 
described in Section 2.2.2.2. 
Sleep architecture and sleep disordered breathing (SDB) variables were assessed using 
polysomnography (PSG) as described in Section 2.2.2.4. Sleep stages (rapid eye movement 
(REM), stages 1, 2, and slow wave sleep (SWS)) were scored using standard criteria [180] and 
were expressed as the percentage of sleep time spent in these states. Also included was REM 
latency, which was defined as the number of minutes from sleep onset to the first REM period. 
These measures were not included in any LCA and were therefore considered as predictors in all 
models.  
3.2.2.2 Covariates 
Age, study site, race, weekly alcohol use, daily caffeine intake, educational attainment, 
and smoking status were entered as predictors in models of depression levels and change over 
time. Physical activity, cognitive function, and anxiety symptoms were measured as defined in 
Section 2.2.2.4.  
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Psychosocial factors: At MrOS Visit 2, participants were asked whether, over the past 12 
months, they had experienced any stressful event included in Table 19. At this time, participants 
were also administered a questionnaire [181] providing measures of their social networks size 
and levels of social participation. This including questions regarding if they have living children 
(yes/no), a special person they feel close to (yes/no), as well as how many relative and friends 
they have and how many they see at least once per month (response options were 0, 1-2, 3-5, 6-9, 
or 10+; this variable was entered as a continuous measure reflecting these levels of ranges of 
increasing social contact). Participants were also asked how many hours per week they 
participate in groups, and how often they attend religious services (categorical response options 
were used, see Table 19).  
Instrumental Activity of Daily Living (IADL) impairment, chronic diseases, inflammatory 
markers, and medications were defined as in Section 2.2.2.4.  
3.2.3 Statistical methods 
The outcome was raw GDS score (including all items) reflecting overall levels of 
depressive symptoms over time (expressed in years). The GDS is a reliable and valid measure of 
depression among older adults [155]. Growth curve modeling was implemented using SAS 
PROC MIXED, an unstructured correlation matrix, and random slopes and intercepts. Separate 
base models (adjusted for age and study site) assessed crude relationships between latent groups, 
primary predictors expressed individually, and covariates with the level of depressive symptoms 
over time; interactions between all predictors/covariates with time (per year) were also included 
in these base models to assess whether which variables were associated with the rate of change in 
overall symptomology.  
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From these separate models, a maximum multivariable was constructed including all 
associations that achieved at least p<0.10 with the level (intercept) or rate of change (slope) in 
depression symptoms over time. To achieve a parsimonious final model, variables which were 
not significantly associated with the outcome in the maximum model (p<0.10) were removed. 
Accordingly, only when a latent group predicted change in depression symptoms was it retained 
in subsequent modeling; otherwise, latent groups were dropped. When a latent group was 
dropped, the individual measures of the domain were entered if related to depression in crude 
models. 
3.3 RESULTS 
The final follow-up assessment was conducted an average of 5.5 years (0.52 SD) after 
baseline.  
Unadjusted associations of covariates with depressive symptoms 
Base models indicated that a range of expected factors were significantly associated with 
the rate of change in depression over follow-up (Table 19). Age was positively associated with 
both levels and rates of change in depression. Higher educational attainment and levels of self-
reported physical activity (PASE) were inversely related to depression levels. Higher BMI, 
current smoking, and consuming less than one alcoholic beverage per week were all associated 
with higher levels of depression.  
Other mental health factors: Higher levels of cognitive performance (on the 3MS) were 
related to lower levels of depression and a decreased rate of change over time. Anxiety 
symptoms were positively associated with levels of depressive symptoms, and were also 
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associated with a lower rate of change; this finding is likely due to the positive correlation 
between anxiety and depressive symptoms and a potential ceiling effect on change over time 
(regression to the mean).  
Sleep variables: Higher scores on the PSQI and ESS were related to higher levels of 
depression. Short sleep duration was associated with higher symptom levels. Long sleep duration 
and prolong SL were associated with a greater rate of change. 
Sleep architecture: Spending a greater percentage of TST in REM sleep was associated 
with both lower levels of depression and lower rates of change over time. Longer REM latency 
was associated with higher depression levels. Percentages of time spent in stage 1, stage 2, or 
SWS were not significantly associated with depression levels of the rate of change. 
Stressful events: Separation from someone they depend on, loss of a pet, moved/residence 
change, serious financial trouble, or any other stressful event were related to higher levels of 
depression.  Spousal/partner serious illness was related to higher rates of change.  
Social factors: Having a problem interfere with social activities was related to higher 
levels but lower rates of change in depressive symptoms. Attending religious meetings and 
participating in groups more often were both related to lower depression symptom levels; 
participating in groups ≥16 hours per week was related to lower rates of change. Having living 
children, a close friend or relatives, and having greater monthly contact with friends/relatives 
were related to lower levels of depressive symptoms.  
Chronic disease: IADL impairment and all chronic diseases (except liver disease), were 
related to higher levels of depression. The following were additionally related to greater rates of 
change in depression: falls in the past 12 months, hypertension, diabetes, and Parkinson’s 
disease; severe SDB was associated with higher levels but lower rates of change over time. 
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 Medication use: All medications examined were related to higher levels of depressive 
symptoms. Antidepressant use was related to higher rates of change in depression, whereas non-
benzodiazepine non-barbiturate sedatives/hypnotics were related to lower rates of change in 
depression.  
Inflammatory markers: Except for IFN-γ, all inflammatory markers examined were 
related to higher levels of depression. In addition, higher levels of TNF-α and TNF-αsRII were 
associated with higher rates of change in depressive symptoms.  
Main analysis: Crude and adjusted associations of latent classes with depression over 
time 
The first unadjusted model (Table 20) included the latent groupings in depression, sleep, 
and CAR domains (derived in Chapter 2). The depression latent groups were related to levels of 
symptoms as expected, however there were no meaningful relationships with the rate of change. 
While the “depressed” group had significantly lower rates of change, this effect reflects a likely 
ceiling effect or regression towards the mean (patients with depression at baseline had “more 
room” to improve). The sleep latent sub-groups were also not related to levels or rates of change 
over time. Therefore these LCA groups were excluded from further analyses.  
CAR disturbance sub-groups were all related to faster rates of change in depression over 
time (compared with the “normal rhythm” group) except for the “early activity” and “early 
activity with short active period” groups. The “reduced activity” and “early, dampened rhythm 
with short active period,” and “late with reduced activity” groups had higher levels of symptoms 
over time compared with the “normal rhythm” group.  
We assessed whether associations with CAR groups were altered when adjusting for 
individual sleep and depression variables instead of the representative LCA groups (Table 21); 
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associations of CAR groups with the rate of change in depression over time were consistent, 
although associations with the depression intercept were all attenuated to non-significance (this 
model adjusted for baseline GDS symptoms). Higher levels of baseline depression were related 
to higher symptom levels and lower rates of change over time. Higher PSQI scores (reflecting 
worse global sleep quality) were associated with higher symptom levels, and both PSQI scores 
and long sleep duration were associated with higher rates of change over time.   
Further adjustments were added to assess whether the association between depression 
severity, individual sleep variables, and CAR grouping were independent of covariate 
associations detected in crude models. The final model (Table 22) included all covariate 
associations with the level or rate of change that retained significance in the maximum model. 
Compared with participants included in the final model (n=2700), men excluded appeared to 
more frequently often to come from CAR groups with delayed or reduced activity, more often 
had certain chronic diseases (i.e. percentage excluded with Parkinson’s = 2.68% compared with 
included 1.04%, p=0.01), or a past year fall (percentage excluded that fell = 35.43% compared 
with included 29.58%, p=0.04). Men excluded from the model also tended to be older (age 
included = 76.99 (6.01 sd) vs. included = 76.28 (5.46 sd), p=0.03) and had higher levels of 
depressive symptoms at baseline (GDS excluded = 2.07 (2.28 sd) vs. included = 1.74 (2.15 sd), 
p=0.02).  
Covariate adjustment attenuated the association of the “reduced activity” CAR sub-group 
with higher rates of increase to non-significance. However, the other associations between CAR 
sub-groups retained significance; specifically, being in any group with late activity (“late activity 
[only],” “late rising with short active period” and “late with reduced activity”) was associated 
with significantly higher annual increases in depressive symptom load. Being in the “early, 
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dampened rhythm with short active period” sub-group also remained significantly associated 
with faster rates of change over time.  
Associations between covariates and the levels/rates of change in depressive symptoms 
over time are shown in Table 22. Note that in the final model, levels of symptoms increased over 
time and this effect was greater among men who were older. More anxiety symptoms, 
antidepressant use, having a past year fall, diabetes, and Parkinson’s were also associated with 
faster rates of change. Higher scores on the 3MS (reflecting cognitive function), spending a 
greater percentage of TST in REM sleep, severe SDB, and benzodiazepine use were related to 
slower rates of change in depressive symptoms over time.  
3.4 DISCUSSION 
In our sample, specific configurations of CARs were related to future increases in 
depressive symptoms independent of physical activity, chronic diseases, and other sleep factors. 
This finding complements and extends our prior work [179], in part due to the extended follow-
up of over 5 years and explicit examination of the overall rate of change symptoms. The primary 
novel aspect of our analysis is the use of a person-centered, data-driven clustering approach that 
specified within-person configurations of CAR disturbances related to the development of 
depressive symptoms.  
Although replication in other samples is necessary, we identified CAR configurations 
which are novel behavioral markers of depression risk. In our study, men with delayed timing or 
combined early timing with a dampened rhythm and short active period had faster increases in 
depressive symptoms over time. Having early activity timing alone or in combination with a 
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compressed active period was not related to future levels of depressive symptoms. Associations 
between delayed timing and future increases in depressive symptoms were stronger when 
accompanied by a compressed active period or overall activity reductions. While having reduced 
activity alone was related to faster increases in depressive symptoms, this association could be 
explained by covariate adjustments including lifestyle and chronic disease factors.  
Although the magnitude of these associations may appear small, comparison with 
previously established depression risk factors gives context for interpreting the relevance of these 
novel behavioral markers. The increase in the rate of change associated with CAR sub-groups 
was equivalent to or greater than the addition risk confirmed by a fall or by diabetes. Therefore, 
in our study, the depression risk associated with these particular CAR configurations is not only 
independent of, but it is at least as substantial as known risk factors.  
On the other hand, specific sleep or depression syndromes did not predict changes in 
depression over time. Future research in other samples across different age groups is required to 
understand whether the impact of sleep factors on depression risk differs across the life course. 
Our findings also suggest that men with mild depressive syndromes are not at increased risk for 
faster symptom increases overall. However, these results do not imply that the identified 
syndromes have wholly similar long term outcomes; we only examined overall changes in 
depression severity. It is possible that the identified depression syndromes have different 
outcomes in terms of, for example, risk of physical illness or suicide. Our analysis also did not 
test whether certain symptoms precede others. Neither did we employ generalized growth 
mixture modeling which would have enabled us to examine whether LCA group related to 
distinct patterns of depressive symptom trajectories over time; it is possible that although sleep 
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and depression symptoms were not related to the overall rate of change, they may relate to 
specific patterns of change (configurations of symptom intercepts and slopes) over time.  
Several limitations should be noted. Although the CAR reflects the activity of the master 
biological keeper in the suprachiasmic nucleus, it is not a direct indicator of circadian biology. In 
addition, the CAR is indifferent to psychological and social qualities of rest and activity which 
may moderate relations to depression over time.  The derivation of sub-groups via LCA and 
subsequent use of these sub-groups to predict change in a longitudinal mixed model introduces 
measurement error. However, any such bias would potentially reduce the available signal 
(potency of the true CAR configurations) and bias our results to the null. Our sample consisted 
of older men who were mostly white and highly educated; therefore these findings cannot 
necessarily be generalized to other populations.  
Other threats to internal and external validity should be considered. The longitudinal 
analysis method assumes data is missing at random. Our analysis included men who were 
generally healthier than their counter-parts who did not have complete covariate or adequate 
outcome data. Participants excluded from the longitudinal models were more likely to be from 
the CAR groups identified to be at risk; however, if some men who were most at risk for 
symptom increases were excluded, this could bias/dilute our estimates of the effects of true risk 
factors towards the null hypothesis. Regarding missing covariate data, we found consistent 
results in crude (which did not exclude men with missing covariate data) and adjusted models 
thus suggesting that covariate missing data did not substantively bias or lead to spurious 
findings. In sum, considering the wide-range of relevant covariate adjustments, our findings 
appear internally valid. However, these association estimates may not generalize and should be 
examined in other samples.   
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In conclusion, specific patterns of CAR disturbance are related to the development of 
depressive symptoms among older men. Because the CAR is potentially modifiable, future 
research should test whether interventions targeting the CAR can curtail the burden late-life 
depression. Future research is required to assess how CAR configurations exert their influence 
and relate to variability in biological, psychological, and social processes over time. In addition, 
research investigating the role of circadian rhythms in treatment response is needed to expand 
our understanding of circadian-depression relations throughout the entire spectrum and course of 
depressive illness. Finally, given the relevance of CARs to the pathogenesis of depression, future 
research is needed to understand the developmental history and stability these configurations of 
CAR disturbances.    
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 3.5 TABLES AND FIGURES 
 
Table 19. Crude associations of covariates with the intercept and slope of depressive symptoms over time 
 
  Predictor * Time 
 
β SE p β SE p 
Age (per SD) 0.33 0.04 <0.0001 0.06 0.01 <0.0001 
Study Site:       
  BI 0.42 0.13 0.0012 0.02 0.03 0.54 
  MN -0.11 0.13 0.37 0.04 0.03 0.16 
  PA -0.32 0.13 0.01 0.06 0.03 0.04 
  PI 0.28 0.13 0.03 0.07 0.03 0.01 
  PO 0.03 0.13 0.80 0.02 0.03 0.58 
  SD Reference    
Race:       
  White -0.27 0.16 0.10 0.01 0.03 0.83 
  Black  0.23 0.25 0.36 -0.07 0.05 0.19 
  Other Reference Reference 
Alcohol use per week:       
  <1 drink 0.35 0.17 0.04 -0.04 0.03 0.20 
  1-13 drinks 0.08 0.17 0.65 -0.04 0.03 0.21 
  14+ drinks Reference Reference 
Daily caffeine intake (per SD) -0.03 0.04 0.47 -0.005 0.01 0.53 
Education:       
  Less than high school 0.64 0.17 0.0003 0.03 0.04 0.34 
  High school diploma 0.19 0.11 0.09 0.05 0.02 0.02 
  College/Graduate school Reference Reference 
Smoking Status:       
  None -1.15 0.28 <0.0001 -0.05 0.06 0.34 
  Former -0.97 0.28 0.001 -0.02 0.06 0.67 
  Current Reference Reference 
BMI (per SD) 0.15 0.04 0.0001 -0.003 0.01 0.72 
Physical Activity (per SD) -0.40 0.04 <0.0001 0.004 0.01 0.58 
Cognitive function (per SD) -0.24 0.04 <0.0001 -0.04 0.01 <0.0001 
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Anxiety symptoms 0.52 0.02 <0.0001 -0.02 0.004 0.0002 
PSQI (continuous) 0.22 0.01 <0.0001 -0.004 0.002 0.07 
Epworth (continuous) 0.10 0.01 <0.0001 -0.001 0.002 0.69 
WASO 0.33 0.08 <0.0001 0.01 0.02 0.55 
SL -0.01 0.03 0.58 0.64 0.13 <0.0001 
Sleep duration       
  <5 0.31 0.12 0.008 0.03 0.02 0.26 
  5-8 Reference Reference 
  >8 0.06 0.15 0.68 0.07 0.03 0.03 
Sleep architecture       
% TST in Stage 1 0.007 0.01 0.477 0.003 0.002 0.153 
% TST in Stage 2 0.007 0.004 0.094 0.00001 0.001 0.99 
% TST in Stage 3/4 0.002 0.004 0.623 0.001 0.001 0.31 
% TST in REM -0.02 0.01 0.0003 -0.003 0.001 0.03 
REM Latency (minutes) 0.003 0.001 <.0001 0.00004 0.00011 0.68 
 
      
Recent Stressful events       
Serious illness or accident of wife or partner 0.18 0.10 0.07 0.04 0.02 0.05 
Death of other close relative or close friend 0.08 0.08 0.29 0.01 0.02 0.38 
Separation from child, close friend, or other 
relative who participant depends on 1.09 0.24 <0.0001 0.03 0.05 0.60 
Loss of a pet 0.45 0.16 0.01 -0.05 0.03 0.13 
Moved or changed in residence 0.83 0.17 <0.0001 -0.06 0.04 0.09 
Serious financial trouble 1.61 0.22 <0.0001 -0.07 0.05 0.13 
Anything else important happen 0.47 0.08 <0.0001 0.01 0.02 0.50 
 
      
Social Factors       Physical or emotional problem interfered 
more with social activities 1.36 0.05 <0.0001 -0.03 0.11 0.003 
How often go to religious meetings?       
  More than once per week  -0.66 0.11 <0.0001 -0.02 0.02 0.27 
  Once per week  -0.47 0.10 <0.0001 0.01 0.02 0.56 
  1-3 times per month -0.30 0.14 0.04 0.04 0.03 0.21 
  Less than once per month -0.11 0.15 0.48 -0.04 0.03 0.16 
  Never or almost never Reference Reference 
 
How many hrs/wk participate groups?       
  16 or more -0.98 0.19 <0.0001 -0.08 0.04 0.04 
  11-15 -0.90 0.21 <0.0001 -0.004 0.04 0.93 
Table 19 continued 
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  6-10 -0.85 0.12 <0.0001 -0.02 0.03 0.46 
  3-5 -0.61 0.11 <0.0001 -0.02 0.02 0.26 
  1-2 -0.39 0.10 0.0001 -0.001 0.02 0.97 
  None Reference Reference 
Has living children -0.41 0.15 0.01 0.01 0.03 0.87 
Has special person feels close to -0.81 0.12 <0.0001 -0.01 0.02 0.62 
Number of close relatives -0.18 0.03 <0.0001 -0.01 0.01 0.28 
How many relatives participants sees once 
per month -0.12 0.04 0.002 0.001 0.01 0.81 
Number of close friends -0.35 0.03 <0.0001 0.01 0.01 0.07 
How many close friends participant sees 
once per month -0.33 0.03 <.0001 0.003 0.01 0.61 
       Chronic Disease History       
 IADL Impairment (per additional 
impairment) 0.81 0.04 <0.0001 0.01 0.01 0.21 
 Fall in past 12 months 0.68 0.08 <0.0001 0.03 0.02 0.07 
 Peripheral vascular disease 0.77 0.13 <0.0001 -0.01 0.03 0.70 
 Osteoarthritis 0.68 0.09 <0.0001 -0.01 0.02 0.59 
 Rheumatoid Arthritis 0.91 0.14 <0.0001 0.04 0.03 0.17 
 Hypertension 0.29 0.76 0.0001 0.03 0.02 0.08 
 Stroke 1.02 0.20 <0.0001 0.05 0.04 0.27 
 Angina 0.61 0.11 <0.0001 0.01 0.02 0.67 
 Congestive Heart Failure 0.58 0.16 0.0004 0.03 0.04 0.42 
 Myocardial Infarction 0.41 0.10 <0.0001 0.03 0.02 0.15 
 Diabetes 0.29 0.11 0.01 0.06 0.02 0.01 
 COPD 1.01 0.17 <0.0001 0.02 0.04 0.57 
 Parkinson's 1.91 0.34 <0.0001 0.25 0.07 0.0006 
 Renal disease  0.86 0.39 0.03 0.04 0.09 0.64 
 Cataracts 0.22 0.08 0.005 0.01 0.02 0.48 
 Liver disease 0.20 0.27 0.46 -0.06 0.05 0.26 
 Severe sleep disordered breathing (AHI ≥ 
30) 0.28 0.10 0.01 -0.04 0.02 0.05 
Medication Use       
 Antidepressant use 1.69 0.14 <0.0001 0.05 0.03 0.10 
 Non-benzodiazepine non-barbiturate 
sedatives /hypnotics 
0.89 0.27 0.001 -0.15 0.05 0.01 
 Benzodiazepines use 1.22 0.18 <0.0001 0.01 0.04 0.73 
 Current NSAID use 0.34 0.95 0.0003 -0.001 0.02 0.69 
       
Table 19 continued 
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Curr
ent 
corticosteroid use (oral/nasal/inhaled) 
0.34 0.13 0.01 0.04 0.03 0.15 
 
      
Inflammatory Markers       
 log(IL-6 + 1) 0.26 0.09 0.0033 0.03 0.02 0.18 
 log(CRP + 1) 0.22 0.06 0.0004 -0.01 0.01 0.45 
 log(TNF-α + 1) 0.40 0.15 0.01 0.06 0.03 0.06 
 log(TNF-αsRII + 1) 0.54 0.12 <0.0001 0.08 0.02 0.0006 
 log(IFN-γ + 1) -0.04 0.07 0.58 0.02 0.01 0.24 
              
*Base model includes age and study site 
Table 19 continued 
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Table 20. Crude associations of combined sleep/depression and CAR latent class membership with the intercept and slope of 
change in depressive symptoms (n=2933) 
 
  
 
Predictor * Time 
 
β SE p 
 
β SE p 
Depression Latent Class 
        Depressed 6.96 0.12 <0.0001 -0.45 0.04 <0.0001
 Apathy/somatic with probable impairment 3.23 0.10 <0.0001  -0.02 0.03 0.52 
 Probable somatic/apathy with impairment  1.48 0.10 <0.0001  -0.004 0.03 0.90 
 Probable apathy/somatic  1.41 0.06 <0.0001  0.01 0.02 0.45 
 Not depressed Reference  Reference 
        
Sleep Latent Class        
 Subjective and objective disturbances 0.17 0.11 0.13  -0.02 0.04 0.55 
 Objective disturbances 0.005 0.09 0.96  0.03 0.03 0.37 
 Subjective disturbances 0.08 0.08 0.33  0.01 0.02 0.76 
 Early awakening -0.06 0.06 0.34  0.02 0.02 0.29 
 Healthy sleep Reference  Reference 
    
Circadian Activity Rhythm Latent Class        
 Normal rhythm Reference  Reference 
 Reduced activity 0.28 0.09 0.001  0.06 0.03 0.03 
 Early activity 0.13 0.08 0.11  -0.02 0.03 0.47 
 Late activity -0.04 0.08 0.63  0.05 0.02 0.04 
 Early activity with short active period 0.16 0.09 0.06  0.02 0.03 0.47 
 Late rising with short active period 0.07 0.09 0.42  0.10 0.03 0.001 
 Early, dampened rhythm with short active period 0.26 0.10 0.01  0.11 0.03 0.002 
 Late with reduced activity 0.23 0.10 0.02  0.10 0.03 0.002 
                
*Crude model includes age and site 
108 
  
Table 21. Crude associations of CAR latent class membership plus individual parameters with the intercept and slope of change 
in depressive symptoms (n=2929) 
 
  
 
Predictor * Time 
 
β SE p 
 
β SE p 
        Baseline symptom level 0.89 0.01 <0.0001  -0.06 0.004 <0.0001 
PSQI (continuous) 0.01 0.01 0.01  0.01 0.003 0.01 
WASO≥90 0.05 0.04 0.23  0.02 0.02 0.38 
SL≥60 -0.001 0.06 0.93  -0.02 0.03 0.55 
        
Sleep duration (hours)        
  <5  -0.02 0.06 0.71  0.02 0.03 0.47 
  5-8 Reference  Reference 
  >8 -0.02 0.06 0.77  0.06 0.03 0.05 
 
       
Circadian Activity Rhythm Latent Class        
 Normal rhythm Reference  Reference 
 Reduced activity 0.01 0.06 0.85  0.10 0.03 0.0008 
 Early activity 0.01 0.06 0.81  -0.02 0.03 0.52 
 Late activity -0.01 0.05 0.86  0.05 0.02 0.04 
 Early activity with short active period 0.06 0.06 0.29  0.02 0.03 0.51 
 Late rising with short active period 0.04 0.06 0.51  0.10 0.03 0.0016 
 Early, dampened rhythm with short active period 0.05 0.07 0.48  0.13 0.03 0.0002 
 Late with reduced activity 0.02 0.07 0.79  0.13 0.03 <0.0001 
               
*Crude model includes age and site 
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 Table 22. Adjusted associations of individual predictors with the intercept and slope of change in depressive symptoms from the 
final model (n=2700) 
 
  
 
Predictor * Time 
 
β SE p 
 
β SE p 
Intercept 1.06 0.20 <0.0001    
Time (per year) 0.50 0.10 <0.0001     
Baseline symptom level 0.87 0.01 <0.0001  -0.07 0.004 <0.0001 
Circadian Activity Rhythm Latent Class        
 Normal rhythm   Reference 
 Reduced activity     0.04 0.03 0.21 
 Early activity     -0.02 0.03 0.47 
 Late activity     0.05 0.02 0.03 
 Early activity with short active period     0.01 0.03 0.65 
 Late rising with short active period     0.06 0.03 0.03 
 Early, dampened rhythm with short active period     0.09 0.03 0.01 
 Late with reduced activity     0.07 0.03 0.02 
Demographic and Lifestyle        
 Age (per SD) 0.04 0.02 0.05  0.06 0.01 <0.0001 
 BMI (per SD) 0.03 0.02 0.06     
 Physical activity (per SD) 0.03 0.02 0.07     
Other mental health        
 Cognitive function (per SD in 3MS score)     -0.04 0.008 <0.0001 
 Anxiety symptoms      0.02 0.005 0.0006 
 PSQI (continuous) 0.01 0.01 0.03     
 % time REM      -0.003 0.002 0.02 
Stressful events        
 Loss of a pet -0.15 0.07 0.03     
 Separated from child who is depended on 0.19 0.10 0.06     
 Serious financial trouble 0.21 0.10 0.03     
 Anything else important happen 0.16 0.03 <0.0001     
Social Factors        
How many hrs/wk participate groups?        
16 or more -0.24 0.09 0.01  -0.10 0.04 0.01 
11-15 -0.26 0.09 0.01  -0.05 0.04 0.21 
6-10 -0.19 0.05 0.0005  -0.04 0.03 0.14 
3-5 -0.16 0.05 0.0008  -0.04 0.02 0.04 
1-2 -0.08 0.04 0.08  -0.01 0.02 0.49 
0 Reference  Reference 
Number of relatives -0.05 0.01 0.0012     
Chronic Disease        
 IADL Impairment (per additional impairment) 0.08 0.02 0.0009     
 COPD 0.11 0.07 0.15     
 Fall in past 12 months     0.05 0.02 0.003 
 Diabetes     0.07 0.02 0.004 
 Parkinson's     0.26 0.08 0.0008 
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 Severe SDB     -0.06 0.02 0.01 
Medication Use        
 Antidepressant use 0.17 0.07 0.01  0.10 0.03 0.0011 
 Benzodiazepine use     -0.13 0.05 0.01 
 Non-benzodiazepine non-barbiturate sedatives/hypnotics 0.16 0.08 0.06     
                
Table 22 continued 
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4.0  PHARMACOLOGICAL RESPONSE IN LATE-LIFE MAJOR DEPRESSIVE 
DISORDER AND ASSOCIATED PROGNOSTIC FACTORS 
Depression severity may be causally related to treatment resistance among the over 50% 
of older adults who fail to recover after an antidepressant trial. However, no current evidence 
demonstrates whether high levels of baseline symptoms are a necessary component of poor 
treatment response. In addition, limited prior research examines whether differential symptom 
expression or specific aspects of cognitive function are related to treatment outcomes. We 
examined these prognostic factors in an open-label pharmacological (venlafaxine XR) treatment 
study conducted among adults aged ≥60 years who had major depressive disorder (n=453). 
Group-based trajectory analysis was used to derive sub-groups exhibiting similar patterns of 
symptom change over 12 weeks. Distinctly remitting groups were detected across lower 
(15.23%), moderate (23.84%), and higher (5.52%) baseline symptom levels. Persistent 
trajectories were most common among patients with higher baseline symptom levels (totaling 
35.98%), however, a group with relatively moderate symptoms at baseline also followed 
mixed/non-responsive trajectory (19.43%).  The prognostic factors significantly associated with 
less favorable trajectories included greater overall symptom burden, longer episode duration, 
past adequate antidepressant treatment, less reduced sleep, more guilt and work/activity 
impairment. Higher scores on a list-recognition test were associated with a more rapid response.  
Although not necessarily generalizable to younger adults or other treatments/settings, these 
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findings show that treatment response is heterogeneous across a range of baseline symptoms 
levels. Future research is needed to understand the biological basis of the identified prognostic 
factors and to develop predictive algorithms for early detection of treatment resistance in clinical 
settings. 
4.1 INTRODUCTION 
The epidemiologic study of prognostic factors in geriatric mental health is important, not 
only to improve detection and targeted prevention approaches, but also to support clinical 
treatment allocation strategies for late-life major depressive disorder (LLD). Depression is most 
often treated in primary care [49, 182], however over 50% of older adults fail to respond to first-
line antidepressant treatment [183, 184]. In part due to substantial pre-treatment co-morbidity 
[185] and polypharmacy [186], pharmacological treatment can be particularly complex and time 
consuming among older adults [187-189]. Initial antidepressant treatment success rates (i.e. 28% 
in the STAR*D trial) may improve to up to 70% after multiple drug trials by one year, but as 
described by National Institute of Mental Health director Thomas Insel, M.D., current 
expectations for antidepressant success may have been set “far too low” [190]. Improving our 
understanding of the patterns of pharmacological treatment response and associated prognostic 
factors can guide clinical approaches to accurately anticipate treatment response variability and 
decrease the time before recovery.  
Early detection of treatment resistant LLD can save time, money, and suffering by 
informing when clinicians should “stay the course” and when first-line treatment will inevitably 
fail (and a new treatment strategy will need to be employed) [189, 191]. Treatment failure 
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mechanisms are not understood although a range of clinical and neurobiological factors have 
been linked to treatment failure. Research has not yet arrived upon a clinically actionable 
description of the measureable aspects of resistance as it appears at treatment intake. Such 
description would give hints towards the determinants of treatment response variability and 
could lead to early detection strategies.  
Prior research demonstrates that certain clinical characteristics and early change in 
certain factors predict overall treatment response and stability [189, 192]. In recent evidence 
from a prospective evaluation of treatment resistance in the Incomplete Response in Late-Life 
Depression (IRLGREY) Study, several prognostic factors were identified, including: total 
symptom burden and its early change, episode duration, and prior history of adequate 
antidepressant treatment [183]. In this analysis of IRLGREY, the most powerful prognostic 
predictors were overall baseline and early changes to overall symptom severity.  
These findings suggest a role of baseline symptom load in the etiology of treatment 
resistance, however this may be an artifact of outcome definition. Often studies define remission 
as achievement of a pre-specified total symptom level after a certain time period (i.e. a 
Montgomery Asberg Depression Rating Scale [28] (MADRS) score of ≤10 after 12 weeks of 
treatment). The etiological interpretation afforded by this outcome definition is limited, because, 
depending on initial symptom level, two patients recovering at the exact same rate may or may 
not reach the remission threshold within a timeframe. Therefore, while pre-specified remission 
criteria are essential to secure a clinically valid response definition, they alone may obscure the 
causal picture regarding whether a high symptom burden is a component or a necessary 
component of treatment non-response. 
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An alternative technique to study treatment response is to identify distinct sub-groups of 
individuals based on their pattern of change in symptom level over time. Despite widespread use 
including investigations of late-life depression’s course among community-dwelling older adults 
[193-197], less research has applied group-based clustering techniques to understand patterns of 
change in pharmacological treatment for LLD. Longitudinal clustering techniques have been 
applied to examine patient trajectories in primary care [198], in heart failure patients [199], after 
combined psychotherapy and pharmacotherapy [200-202], and in relation to pharmacogenomics 
markers of response to either nortriptyline or escitalopram [203]. Other studies have utilized 
longitudinal clustering techniques to examine heterogeneity in response to solo pharmacological 
treatment [203-205]. These studies often conclude that such methods capture heterogeneity 
across the course of treatment that could be neglected using pre-specified response thresholds or 
other methods which assume the patient population follows a single response trajectory. 
To my knowledge, this is the first application of group-based trajectory modeling to a 
large (several hundred) sample of older adults undergoing solo pharmacological treatment. We 
aim to add detail to descriptions of expected [183, 184] heterogeneity in treatment response 
patterns. Depending on whether heterogeneity in response is detected across a range of baseline 
symptom levels, this may suggest if a high burden of baseline symptoms is a necessary or 
sufficient condition for treatment resistance. 
We also aim to provide a comprehensive description of the prognostic factors associated 
with treatment response trajectories. Specific domains of cognition have been implicated in the 
etiology of treatment resistance. Some have suggested that executive function in particular 
predicts treatment response [206-208]; and a recent study reported that even complaints of 
executive function were predictive [209]. Information processing speed, which may be the core 
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cognitive process on which other cognitive domains (including executive function) depend [210], 
has also been associated with treatment response [211, 212].  
In addition to overall severity and cognitive performance, disproportionate expression of 
depression symptoms may have a role determining treatment resistance. Early change in core 
symptoms have recently been associated with treatment response [213]. Sparse evidence 
demonstrates that sleep symptoms may be an important determinant/proxy measure of response 
[202].  
In current analysis we examine the patterns of treatment response observed among a large 
sample of older adults undergoing open label Venlafaxine XR (Effexor) treatment for LLD. We 
estimate the prevalence of distinct patterns of longitudinal change, and also extend prior work 
[183] by examining whether specific depressive symptoms, domains of cognitive functioning, 
and other clinical variables are associated with treatment response variability. 
4.2 METHODS 
4.2.1 Participants 
Details of recruitment have been described previously [183]. Recruitment sources 
included primary and specialty care referrals, advertisement responses, research registry based 
solicitation. Participants were aged ≥60 (n=466) and had current nonpsychotic major depressive 
disorder as diagnosed by the Structured Clinical Interview for DSM-IV [23] plus a Montgomery-
Asberg Depression Rating Scale (MADRS) score ≥15. Exclusions were: lifetime diagnosis of 
bipolar disorder, schizophrenia, schizoaffective, other psychotic disorders or current psychotic 
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symptoms; clinical history of dementia or cognitive impairment as indicated by a score of <20 on 
the Mini Mental Status Exam [214]; alcohol or substance abuse in the past 3 months; high 
suicide risk; unstable medical illness; or contraindication to venlafaxine XR or aripiprazole. For 
this analysis, participants were included if they had complete outcome data from baseline and at 
least one follow-up visit (n=453).  All participants provided informed consent and ethical 
approval was obtained from institutional review boards across participating sites.  
4.2.2 Intervention 
The open-label trial being examined was conducted to prospectively establish treatment 
resistance for a subsequent randomized trial of an adjunctive therapy for treatment resistant LLD.  
Participants in the open-label trial were treated with Venlafaxine XR for 12 weeks, stating at 
37.5 mg/day and titrated in increments (of 37.5 mg) at least every 3 days. By the end of week 6, 
patients with MADRS scores >10 had their dose increased further in 37.5-75 mg increments 
every 3 days to a target of 300 mg/day dose. Further details regarding use of other medications 
has been published previously [183]. Pharmacological treatment was delivered within a model of 
depression management including supportive clinical care focused on psychoeducation about 
depression, its symptoms and treatment, suicidal ideation, countermeasures for adverse 
medication effects, and treatment adherence. Depression-specific psychotherapy was not 
provided.  
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4.2.3 Outcome measures 
Depression symptom burden was measured over time as the total MADRS score assessed 
at study baseline, week 1, week 2, and every two weeks thereafter until the completion of the 
open-label study at 12 weeks.  
4.2.4 Potential prognostic factors 
Baseline assessments also included the 17 item Hamilton Rating Scale for Depression 
(HRSD-17) [215]. Both the MADRS and HRSD-17 were examined as scored totals as well as 
individual items in order to assess potential prognostic roles of both overall symptom burden and 
individual symptoms.  
Adequacy of prior antidepressant treatment was measured with the Anti-depressant 
Treatment History Form (ATHF) [216] where scores ≥3 indicate a prior adequate trial. Age at 
onset of first depressive episode, duration of current episode (natural-log transformed), single vs. 
recurrent episodes, and any outside psychotherapy during participation were also considered. 
The Scale for Suicidal Ideation (SSI) [217] was used to measure suicidal ideation. The Brief 
Symptom Inventory (BSI) [218] were used to assess general anxiety symptoms. Medical 
comorbidity was assessed using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) 
[219] examined as a total score, count, and individual items (coded as ≥2 to reflect the presence 
of organ system dysfunction). The physical function sub-section of the 36-item Medical 
Outcomes Study Short-From Health Survey (SF-36 Physical) was expressed as a total score 
[220]. Alcohol use was assessed as the self-reported number of drinks per week. 
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Neuropsychological measures administered at baseline included the Repeatable Battery 
for the Assessment of Neuropsychological Status (RBANS) [221]. We initially examined 
RBANS Index Scores; when potential prognostic differences were detected, we investigated the 
component subtests to assess associations of domain-specific neuropsychological performance 
with response. Analyses of RBANS subtest scores were conducted after computing age normed 
Z-scores. Two tasks from the Delis-Kaplan Executive Function System (D-KEFS) [222] were 
examined in a similar manner.  
4.2.5 Statistical methods 
A semiparametric, group-based modeling strategy was used to classify the cohort into 
sub-cohorts based on identifying heterogeneous longitudinal polynomial trajectories [223, 224]. 
The sub-groups are sometimes referred to as latent classes or trajectories. We implemented this 
technique using PROC TRAJ [224] in SAS version 9.3 (SAS Institute Inc., Cary, NC). Our 
implementation employed a censored normal distribution and the number and degree of 
trajectory groups was determined using the Bayesian information criterion (BIC).  
The BIC measures improvement in model fit gained by adding additional groups or shape 
parameters incorporating a penalty for added complexity. BIC log Bayes factor approximation, 
defined as 2 times ΔBIC (subtracting a less complex from a more complex model), was used to 
base selection of the number of trajectory groups which fit the data; BIC log Bayes factor 
approximation of >10 is considered strong evidence in favor of the more complex model [224]. 
Solutions that identified small (<5% of the sample) trajectory groups were rejected. When 
initially assigning all groups linear, quadratic, and cubic trajectories, BIC consistently indicated 
the same optimal number of groups. The degree of the fitted polynomials was determined by 
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examining BIC for all possible permutations of group exponents. We also used a step-down 
model fitting strategy, that is, we started with all trajectories being cubic polynomials and 
sequentially decreased the polynomial degree until all parameters associated with the highest 
degree of polynomial were statistically significant. The two strategies yield the same solution for 
the curve fits. We then examined the average posterior probability (>70% recommended) and 
odds of correct classification (OCC; >5 considered adequate) as model fit heuristics.  
Trajectory groups were compared outside of the PROC TRAJ framework to select 
predictors using weighted multi-nominal logistic regression; these regressions were down-
weighted by the probability of group membership to account for measurement error introduced 
by the probabilistic nature of group assignment. To determine whether trajectory group 
membership was associated with the severity of individual depression symptoms independent of 
overall symptom severity (which was investigated in its own right) we examined associations of 
individual symptoms with trajectory group after adjusting for total baseline depression severity 
as measured using the item’s scale’s total score (MADRS or HRSD-17). Associations of group 
membership with prognostic factors that achieved statistical significance (defined as p<0.05) 
were selected as predictors in a maximum model. We applied automated backwards elimination 
(elimination threshold p>.20) to select uniquely predictive prognostic factors which were then 
entered as baseline risk factors within the PROC TRAJ framework. The reference group was 
chosen to represent the largest group with a distinct response. 
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4.3 RESULTS 
4.3.1 Model selection and trajectory groups 
Model fit indicated with BIC continuously improved with additional trajectory groups 
(Table 23), however a seven-group solution included a small (<5%) group. BIC log Bayes factor 
approximation indicated strong evidence that a six-group solution fit the data better than a five-
group solution. The data was best fit by a combination of linear and quadratic trajectory groups 
(see below).  
This model detected heterogeneity in response trajectories across all levels of baseline 
depressive symptoms (Figure 5). Average posterior probabilities were high for all six groups 
(range: 0.84-0.90; Table 24), and the OCC were all well above 5 (minimum OCC=20.18). 
Spaghetti plots by trajectory group are shown in Figure 6. Groups were labeled according to their 
relative starting position and trajectory over time. Two groups with quadratic trajectories of 
change started at relatively lower and moderate levels before remitting (15.23% (n=68) “rapid 
response”; 23.84% (n=108) “moderate, response”); an additional group with a higher level of 
symptoms followed a linear trajectory of change and remitted (5.52% (n=25) “high, response”). 
A second group starting with moderate symptom levels followed a linear trajectory, but 
maintained the majority of their symptoms (19.43% (n=88) “moderate, mixed/non-response”). 
One group started high and followed a linear trajectory of change which ended with still high 
depression severity (24.28% (n=110) “high, non-response 1”), whereas the last group started 
high and followed a persistent pattern with a linear slope (11.7% (n=53) “high, non-response 2”).  
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4.3.2 Predictor selection 
Age was related to trajectory group membership (p<0.0001), and it appeared that 
generally groups with higher baseline symptom levels were younger (Table 25). The following 
were also related to trajectory group membership: age at first episode, episode duration, prior 
adequate antidepressant trial, SF-36 physical health, and BSI anxiety scores. No significant 
relations were detected between count, total, or individual CIRS-G items with trajectory group. 
All individual depression symptoms were significantly related to trajectory group before 
adjusting for total symptom level (all p<0.05). These differences individual symptom severity 
levels appeared to be a function of overall symptom load and did not clearly differ by whether 
the trajectory group remitted. We therefore examined associations adjusted for total baseline 
symptom severity. After this adjustment, the only MARDS item significantly associated with 
trajectory group was the baseline symptom “reduced sleep” (p=0.0085). From the HDRS-17 
items, trajectory group membership was significantly associated with two items: “depressed 
mood” (p=0.0059), “feelings of guilt” (p=0.0077), “work and activities” (p=0.0096), and 
“agitation” (p=0.0026).   
Neuropsychological characteristics were not associated with group membership except 
for performance in the delayed memory and language domains of the RBANS (Table 26). Higher 
performance in the language domain was related to lower odds of membership in all three of the 
less favorable trajectories; higher performance in the delayed memory domain was related to 
higher odds of being in the “rapid response” group. 
122 
4.3.3 Adjusted associations of prognostic factors with group membership 
The above mentioned factors were entered into a maximum, weighted multinomial 
logistic regression model. Associations that retained significance were entered into the PROC 
TRAJ framework as baseline risk factors. In the final model (Table 27), higher baseline 
depression severity was related to 44% lower the odds of being in the “rapid response” compared 
with the “moderate, response” group. Each standard deviation higher in list recognition 
performance (a sub-test from the delayed memory domain of the RBANS) was associated with 
2.22 times the odds of being a “rapid responder” (all comparisons are with the “moderate, 
response” group). Baseline MADRS were positively associated with being in the “high, 
response” group, but no other prognostic factors correlated with membership in this group.  
Higher depression severity overall (total MADRS) and for the MADRS “reduced sleep” 
item were associated with lower odds of being in the “moderate, mixed/non-response” group. 
Baseline MADRS scores were positively associated with the odds of membership in both “high, 
non-response” groups; however, baseline levels of “reduced sleep” were negatively associated 
with being in these non-responsive groups.  
Longer episode duration was related to 54% higher odds of being in the “high, non-
response 1” group, while greater education was related to 17% decreased odds of being in this 
group; greater levels of guilt were marginally (p=0.0554) associated with higher odds of 
membership in this treatment resistant group. Higher levels of work/activity impairment and 
guilt were both associated with substantially greater odds of being in the other treatment resistant 
group (“high, non-response 2” group).  Each standard deviation higher list-recognition 
performance was also associated with 33% lower odds of being in the second non-responding 
group (although this association failed to achieve statistical significance; p=0.0795).  
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4.4 DISCUSSION 
Using group-based trajectory modeling, our analysis illustrates the specific treatment 
response patterns found across the entire range of baseline symptom severity. We detected a 
group of patients who clearly remitted following Venlafaxine XR treatment. These responders 
(44.59% across the range of baseline symptom load) were in similar proportion to prior research 
[183], and this convergence adds validity to our data-driven endeavor.  
Patients with higher baseline depression severity generally experienced a lack of 
symptom relief, and this finding suggests that high symptom severity is associated with treatment 
resistance. However, we also noted a group (“high, response”) with severe baseline symptoms 
that appeared to remit, thus, severity alone may be an insufficient cause of treatment resistance. 
Additionally, we found symptom persistence among the “mixed, non-response” group, 
suggesting that beginning treatment in the upper symptom range is not a necessary (though 
perhaps a common) causal component of treatment resistance.   
In the final multivariable model, self-report of more severely reduced sleep was 
associated with favorable response patterns. We also found that higher levels of guilt were 
associated with increased odds of having persisting symptoms, as were greater levels of 
work/activity impairment (for the second treatment resistant group).  Venlafaxine XR may be 
particularly efficacious for patients with relatively high levels of subjective sleep deficits and 
low levels of guilt and work/activity impairment.  It is important to also note that the three sleep 
items on the HRDS-17 indicating early, middle, and late insomnias were not associated with 
trajectory group (other than as a function of overall symptom severity). To clarify the meaning of 
these results, future examinations should include comprehensive/objective sleep assessments.  
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Prolonged episode duration was associated with being in a non-responding trajectory 
group. Our analysis cannot clarify whether a longer course of illness is a marker of or causative 
factor involved in treatment resistance. We also found that better list recognition performance (a 
sensitive measure of learning among older adults) was associated with having a rapid response.   
Patients with more chronic and severe LLD are likely burdened with a greater level of 
specific cerebral vascular abnormalities [225].  These markers of brain pathology have been 
previously linked to treatment resistance [226-228]. Perhaps emerging through prolonged 
episodes or other underlying resistance factors, atrophy and/or demyelination of specific neural 
circuits may cause treatment resistance. Our finding that higher list recognition scores were 
associated with a rapid response may indicate that relative preservation of hippocampal 
structures and functions, despite older age and depression, may facilitate recovery.  On the other 
hand, brain pathology disrupting the neural circuits involved in guilt may mark difficult to treat 
depression.  The specific neural circuits underlying variability and interconnections between 
symptom expression, cognitive function, and treatment response have not yet been isolated.  
Strengths of our study include the novel data-driven profiling of pharmacological 
treatment response in the largest open-label trial for LLD conducted to date. Additional strengths 
include the comprehensive examination of previously established prognostic response factors 
including specific neuropsychological test performance plus the novel inclusion of individual 
depressive symptoms. We found that heterogeneity in symptom expression and cognitive co-
morbidity might reflect differences in MDD phenotype, rooted in to-be-determined 
neurobiological substrates relevant to pharmacological response. The substantial possibility of 
confounding due to a lack of adequate pharmacological care was excluded by providing 
treatment appropriately (including sufficient monitoring, depression management support, as 
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well as careful dose titration). Even in this specialty care setting, patients with severe symptoms 
at baseline often failed to recover, and this finding highlights the importance of establishing a 
mechanistic understanding of treatment resistance. 
Several limitations should be noted. The sample consisted of older adult out-patients and 
cannot necessarily be generalized to middle-aged/younger patients or older in-patients. Although 
providing adequate care minimized potential confounding (for example due to insufficient 
dosing), rates and patterns of response cannot necessarily be generalized to primary care settings 
where specialist monitoring may be minimal or absent. Reduced sleep was associated with 
trajectory grouping, however our reliance on self-report limits the specificity of this finding. 
Distinct patterns of overall response were examined, but influence of early change in specific 
symptoms was not. Analyses were prognostic and could not determine factors which, if any, 
moderate intervention efficacy. We did not account for unmeasured confounding potentially 
including genetic and social contextual factors. Our approach illustrates the important difference 
between “response rates” and “rates of response,” however we did not directly assess 
associations of prognostic factors with the rate of symptom change over time.  
The biological mechanisms underlying the identified prognostic associations remain 
unknown and, in addition, our analysis cannot distinguish treatment resistance factors from 
downstream insults accumulated through a chronic depression course. Consistent associations of 
episode duration with resistance highlights the potential importance of treating depression early 
on; further, this consistent finding highlights challenge of isolating causal factors from 
downstream consequences. Mounting evidence of associations between specific cognitive 
deficits and treatment resistance calls for integrative studies of clinical/neuropsychological and 
brain structural factors in relation to LLD treatment response.  
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In sum, we found that longer episode duration, greater symptom burden with a relative 
lack of sleep deficits, great feelings of guilt, and lower list recognition scores were related to 
slower or absent treatment responses. When faced with a patient presenting with severe, 
longstanding depression with these co-morbidities, alternative treatment strategies or intensive 
short term-monitoring should be implemented. Although this recommendation is supported by 
the prognostic factors associated with distinct response patterns, mechanisms linking high levels 
of depression severity plus these clinical markers to treatment response are still unclear. 
Associations and interactions between clinical prognostic factors and biological markers have 
not yet been examined in the context of LLD treatment.  
Future research integrating clinical and biological prognostic factors will increase our 
understanding of the mechanisms which determine treatment response trajectories. Such 
integration can support predictive analyses aimed at creating clinically accessible treatment 
allocation strategies. A major research priority is isolating the psychological and neurobiological 
circuits whose dysfunction causes treatment resistance. Such research can improve early 
detection strategies, decrease time to remission, and inform targeted prevention strategies to 
reduce the incidence of treatment resistant depression.   
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4.5 TABLES AND FIGURES 
 
Table 23. BIC by number of groups for models with all linear exponents, 
and associated BIC log Bayes factor approximation 
 
Number of Groups BIC 2*∆BIC (Evidence against Ho) 
1 -11971.12 
 2 -11243.70 1454.84 
3 -11058.70 370 
4 -10978.19 161.02 
5 -10931.47 93.44 
6 -10888.79 85.36 
7* -10883.20 11.18 
*=included a small (<5%) trajectory group  
  
128 
  
Table 24. Posterior probabilities and odds of correct classification per trajectory group 
 
  % (n) Mean SD Min Max OCC 
Rapid Response 15.23 (69) 0.90 0.14 0.51 0.99 57.67 
Mod., Response 23.84 (108) 0.86 0.16 0.39 0.99 18.93 
High, Response 5.52 (25) 0.88 0.16 0.51 0.99 128.47 
Mod., Mixed/Non-
response 19.43 (88) 0.84 0.17 0.35 0.99 20.49 
High, Non-response 1 24.28 (110) 0.87 0.17 0.42 0.99 20.18 
High, Non-response 2 11.70 (53) 0.90 0.16 0.40 1.00 70.65 
Abbreviation: Mod.=Moderate 
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 Table 25. Descriptive Patient Characteristics by Trajectory Group 
 
  
 
Rapid 
Response 
Mod., 
Response 
High, 
Response 
Mod., 
Mixed/Non-
response 
High, Non-
response 1 
High, Non-
response 2 p 
Demographic factors        
White, % (n) 88.41 (61) 88.89 (96) 84 (21) 89.77 (79) 82.73 (91) 96.23 (51) 0.9902 
Female % (n) 69.57 (48) 67.59 (73) 76 (19) 65.91 (58) 60.91 (67) 58.49 (31) 0.5046 
Age 70.13 (8.37) 70.81 (8.04) 67.73 (5.40) 69.45 (7.09) 67.44 (5.92) 67.41 (6.43) 0.0079 
BMI 29.76 (6.54) 29.48 (7.02) 29.17 (6.34) 29.78 (5.92) 30.94 (7.38) 29.86 (7.61) 0.6666 
Education (years) 14.49 (3.16) 14.71 (2.88) 13.88 (2.85) 14.82 (2.91) 13.91 (2.33) 14.26 (2.97) 0.1826 
Potential Prognostic Factors        
Age at first episode 47.48 (20.67) 45.02 (22.15) 35.28 (20.57) 42.97 (21.63) 38.88 (21.02) 37.13 (21.39) 0.0183 
Episode duration (weeks)* 239.55 (538.94) 224.66 (504.58) 130.84 (118.64) 327.28 (614.73) 410 (794.55) 292.5 (625.18) 0.0288 
Recurrent depression, % (n) 72.46 (50) 70.37 (76) 84 (21) 68.18 (60) 68.18 (75) 79.25 (42) 0.4751 
Adequate prior treatment 
(ATHF=> 3), % (n) 60.87 (42) 52.78 (57) 48 (12) 59.77 (52) 66.67 (72) 81.13 (43) 0.0164 
Number of drinks/week* 1.19 (2.96) 0.70 (1.58) 0.20 (0.65) 0.85 (1.80) 0.93 (2.67) 1.23 (3.23) 0.6912 
SF-36 Physical Health 45.40 (10.84) 43.18 (10.9) 43.53 (10.57) 43.57 (12.09) 40.98 (12.14) 38.67 (11.69) 0.0526 
CIRS Count** 5.62 (2.23) 6.44 (2.54) 6.04 (2.01) 6.13 (2.21) 6.26 (2.44) 5.94 (2.37) 0.4721 
CIRS Total** 8.94 (4.68) 10.13 (4.58) 9.56 (3.85) 9.93 (3.96) 10.09 (4.62) 9.62 (4.65) 0.7146 
SIS Total 1.83 (4.24) 1.76 (3.74) 1.28 (2.64) 2.38 (4.63) 2.38 (4.32) 3.94 (5.68) 0.0965 
BSI Anxiety 1.18 (0.85) 1.36 (0.89) 1.97 (0.92) 1.26 (0.82) 1.59 (0.94) 2.07 (0.91) <0.0001 
Total Depression Scores        
Total baseline MADRS  21.09 (4.12) 25.87 (4.84) 32.16 (4.06) 24.09 (4.22) 28.86 (4.64) 32.96 (4.11) <0.0001 
Total 12 week MADRS 3.92 (5.59) 5.63 (4.26) 6.35 (4.05) 13.49 (6.63) 23.05 (4.67) 30.84 (4.86) <0.0001 
Mean (SD) shown unless otherwise noted; *p value shown after log transformation (mean and SD are not transformed); BOLD indicates 
selected prognostic factors; Abbreviation: Mod.=Moderate 
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Table 26. Bivariate associations between neuropsychological predictors and trajectory group  
 
Rapid Response Mod., Response High, Response 
Mod., 
Mixed/Non-
response 
High, Non-
response 1 
High, Non-
response 2 
RBNAS       
Total 1.03 (1.00-1.05) Ref 1.02 (0.98-1.05) 1.00 (0.98-1.02) 1.00 (0.98-1.03) 1.00 (0.98-1.03) 
Visuospatial 1.02 (1.00-1.04) Ref 1.01 (0.98-1.04) 1.01 (0.99-1.03) 1.01 (0.99-1.03) 1.02 (1.00-1.04) 
Attention 1.02 (1.00-1.04) Ref 1.00 (0.97-1.03) 1.01 (0.99-1.03) 1.01 (0.99-1.03) 1.00 (0.97-1.02) 
Delayed 1.03 (1.01-1.06) Ref 1.01 (0.98-1.04) 1.00 (0.98-1.03) 1.00 (0.98-1.02) 0.99 (0.97-1.01) 
Immediate 1.02 (1.00-1.04) Ref 1.02 (0.99-1.05) 1.00 (0.98-1.02) 1.00 (0.98-1.01) 1.01 (0.98-1.03) 
Language 1.00 (0.97-1.03) Ref 0.99 (0.95-1.03) 0.97 (0.94-0.99) 0.97 (0.95-1.00) 0.96 (0.93-0.99) 
D-KEFS       
Stroop C-W 
(CWI3CSSFinal) 1.05 (0.94-1.17) Ref 1.15 (0.98-1.36) 1.04 (0.94-1.16) 1.04 (0.94-1.16) 1.02 (0.90-1.15) 
Trails 4 v 5 1.01 (0.92-1.10) Ref 0.96 (0.84-1.10) 0.98 (0.89-1.07) 0.97 (0.89-1.06) 0.97 (0.87-1.08) 
Bold indicates significant (p<0.05) association 
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Table 27. Multivariable model predicting trajectory group 
 
Rapid Response Mod., Response High, Response 
Mod., 
Mixed/Non-
response 
High, Non-
response 1 
High, Non-response 
2 
 
      Age 1.01 (0.95-1.09) Ref 0.96 (0.88-1.04) 1.02 (0.96-1.08) 0.96 (0.91-1.02) 0.98 (0.90-1.07) 
Education 0.83 (0.68-1.01) Ref 0.89 (0.73-1.08) 0.91 (0.78-1.07) 0.87 (0.76-0.99) 0.93 (0.77-1.12) 
Baseline MADRS 0.56 (0.46-0.69) Ref 1.43 (1.21-1.69) 0.76 (0.65-0.88) 1.13 (1.00-1.27) 1.54 (1.30-1.83) 
Reduced Sleep 0.83 (0.59-1.17) Ref 0.99 (0.62-1.59) 0.72 (0.54-0.96) 0.69 (0.53-0.91) 0.62 (0.42-0.91) 
Work/activity impairment 1.29 (0.63-2.65) Ref 1.68 (0.57-4.95) 1.51 (0.75-3.02) 0.97 (0.55-1.70) 3.65 (1.22-10.99) 
Feelings of Guilt 0.62 (0.32-1.19)  1.47 (0.81-2.69) 1.13 (0.67-1.90) 1.49 (0.99-2.25) 2.16 (1.23-3.79) 
List Recognition 2.22 (1.18-4.20) Ref 1.05 (0.62-1.77) 1.02 (0.68-1.53) 0.99 (0.70-1.42) 0.67 (0.43-1.05) 
Adequate prior Rx 2.12 (0.73-6.16) Ref 0.34 (0.11-1.07) 2.06 (0.84-5.04) 1.84 (0.86-3.90) 2.81 (0.89-8.90) 
Episode duration (log) 1.11 (0.78-1.60) Ref 1.25 (0.84-1.86) 1.40 (1.04-1.87) 1.54 (1.20-1.96) 1.32 (0.93-1.88) 
Estimates were also adjusted for study site; Bold indicates p<0.05 
132 
Time from Beginning of Study (in weeks)
0 2 4 6 8 10 12 14
M
AD
R
S
0
5
10
15
20
25
30
35
Average
Predicted
Rapid Response 15.23%
Moderate Reponse 23.84%
High, Moderate Response 5.52%
Mixed, Non-response 19.43%
High, Non-reponse one 24.28%
High, Non-response two 11.70%
 
Figure 5. Data-derived trajectories of depressive symptom severity over 12-weeks of open-label treatment 
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Figure 6. Spaghetti plots by trajectory group 
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5.0  PUBLIC HEALTH SIGNIFICANCE 
Sub-diagnostic sleep and depressive syndromes are common among older adults. 
Specifically, we found a high prevalence of subjective sleep complaints (37.46% of the sample) 
and depressive syndromes characterized by somatic/apathy symptoms (32.44% of the sample). 
An important novel contribution of this work is the finding that a portion (5.74% of the sample) 
of men experiencing only somatic/apathy symptoms also reported impairment due to their 
emotional state; this finding highlights the importance of investigating the burden of sub-
diagnostic syndromes among older adults. Since the important correlates of these syndromes 
were medication use and aspects of physical health, chronic disease prevention may reduce the 
overall burden of these syndromes on the aging population. Future longitudinal research is 
needed to understand the development and long term consequences of sub-diagnostic syndromes.  
We found that baseline sleep or depressive syndromes were not related to future change 
in overall depression severity. However, we identified a novel behavioral marker of risk for 
future increases in depressive symptoms: having a delay in activity timing or having combined 
advanced/dampened/compressed activity rhythms were independently related to the development 
of depressive symptoms. Although we did not investigate the longitudinal determinants of these 
patterns of rest-activity rhythm disturbances, IADL impairment was related to being in these 
groups. Avoiding disability and maintaining appropriately timed activity may therefore prevent 
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the accumulation of depression symptoms in late-life. Intervention research should assess 
whether modifying these behavioral rhythms can prevent late-life depression.  
Presently, however, prevention alone will not suffice to relieve the burden of depression 
for many older adults. Indeed, over 4% of the men in the MrOS Sleep Study appeared depressed 
and were characterized by a high probability of endorsing a range of psychological, cognitive, 
somatic, and apathy symptoms along with impairment. For individuals with this or similar 
symptom patterns and severity, tertiary intervention (treatment) is needed. But in a large sample 
of older adults treated with first-line pharmacological care in a specialty setting, we found that 
55% experienced a poor treatment response trajectory. Having more severe depression at 
treatment baseline was often associated with treatment resistance; however, we also found that 
high baseline severity was neither necessary nor sufficient in conferring treatment resistance. 
Specific cognitive performance deficits (list recognition/learning) and symptom expression may 
contribute to treatment resistance; future work is needed to assimilate these findings with 
biological data. Valid clinical tools which detect treatment resistance at patient intake can 
decrease the time to remission, save clinical effort, and eliminate patient suffering.  
In conclusion, the burden of late-life depression is both substantial and heterogeneous. 
But opportunities for prevention and treatment innovation abound. Specific physical health and 
behavioral factors are linked to depression development; reducing the prevalence of these factors 
(i.e. diabetes, IADL impairments, falls, and specific patterns of rest and activity) may attenuate 
the burden of late-life depression. Prolonged episode duration is related to a less favorable 
treatment response trajectory, suggesting that when prevention fails, intervening early may be 
crucial. In a rapidly aging world, understanding the mechanisms involved in the pathogenesis 
and resolution of late-life depression is a major public health priority.  
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